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ABSTRACT 
 
 
INTRODUCTION 
Brain tumours are the most common solid tumour in childhood, while Magnetic 
Resonance Spectroscopy (MRS) studies have been performed on brain tumours 
previously, the majority have been performed on the adult patient population and at 
long echo times.  The work presented in this thesis outlines work performed in the 
usage of short echo time MRS in the characterisation of childhood brain tumours.   
 
METHODS 
Short echo time MRS was performed on children with brain tumours at the time of 
diagnostic imaging.  In addition, follow up data was accrued for some patients.  
Resulting spectra were assessed for characteristics either of diagnosis, prognosis or 
treatment response. 
 
RESULTS 
Spectra collected were used in assessing characteristics of an array of childhood brain 
tumours.  Initially the technique was tested on a well understood dataset of cerebellar 
tumours, and was later expanded to provide diagnostic aids for both brain stem 
tumours and pineal region tumours.  A group of pilocytic astrocytomas were assessed 
for differences by location within the brain, for prognosis and for response to 
treatment.  
 
CONCLUSIONS 
The additional information given by short echo time MRS was useful in the 
characterisation of childhood brain tumours. 
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CHAPTER 1: INTRODUCTION  
1.1 BRAIN TUMOURS IN CHILDREN 
Although cancer is very rare in childhood, with less than 1% of all cancers 
registered in 2005 being from children [1], it is the most common cause of 
death from disease in children over one year of age (figure 1).   
 
 
Figure 1: Pie chart depicting cause of death in children under the age of 15 years in the 
year 2007 [1] 
 
 
Figure 2: Pie Chart depicting the distribution of deaths from cancers in children under the 
age of 15 years, in the year 2007 [1] 
 
Of all cancers that can occur in childhood, brain tumours are the commonest 
type of solid tumour (figure 2),  with 24% of registered cancer being in the 
CNS [2]. The only cancer more prevalent in childhood is leukaemia, with a 
reported 31% of registered cancers being attributed to this in 2000. In the year 
2000, 340 new CNS tumours were diagnosed in the UK [2], out of an overall 
1426 reported.  Survival rates of childhood cancer in the UK have improved 
overall over time, with an overall survival of 33% in the period 1962-1971 
increasing to 73% in the period 1992-1996 [2].  The survival in CNS tumours 
has increased from 38% to 66% in the same period.  Improved and earlier 
diagnosis and characterisation is vital in the continuation of this trend.  
 
1.2 METHODS FOR DIAGNOSING CHILDHOOD BRAIN 
TUMOURS  
When a child has a suspected brain tumour, one of the first and most 
important procedures performed is either a CT or MRI scan.  This then 
confirms the presence, or absence, of a tumour.  A CT examination is quicker 
and cheaper to perform and many types of brain tumours will appear on these 
images.  MRI is often preferred as it has much more detail present and most 
brain tumours will be apparent on these scans.  It can essentially be used to 
confirm or remove the likelihood of a brain tumour being present in a child 
exhibiting symptoms indicating the presence.  Conventional MRI can be used 
to detect the presence of abnormalities in the brain, but it is usually not 
enough to determine the type of tumour present.  This is achieved by 
performing a biopsy and histopathology. 
 
1.2.1 HISTOPATHOLOGY 
Histopathology is a microscopic examination of a biopsy sample in order to 
assess the presence and type of disease.  It is the current ‘gold standard’ for 
the diagnosis of brain tumour type and grade.    
 
Once the tissue has been removed, it needs to be stabilised by fixing it in 
formalin.  It is then embedded into paraffin, which allows for very thin slices to 
be cut and these can then be processed and assessed through staining.  To 
assess the tissue sample, the slices are stained with a variety of stains, which 
reveal cellular components and allow contrast.  A combination of hematoxylin 
and eosin is used to stain the nuclei blue and the cytoplasm pink, which 
allows the cellular structure to be assessed [3].   
 
There are many other stains, which allow highlighting of different features and 
categories of cells under the microscope using the technique of 
immunohistochemistry.  Immunohistochemistry allows for the staining of 
proteins and lipids using antibodies of specific types.   One example of this is 
the presence of glial fibrillary acidic protein (GFAP); this is found in glial cells 
such as astrocytes.  A common stain used is for the Ki-67 protein, this is a 
marker of cell proliferation.  As such, this is highly elevated in cells which have 
a fast turnover, and thus elevated in tumour tissue.  This is one of the 
methods used to grade tumours, and in the assessment for aggressiveness 
and invasion.  The stain MIB-1 is most commonly used to stain for this protein 
and is used to determine the Ki-67 labelling index of a sample, which is higher 
in more aggressive tumours [4].   
 
The use of histopathology and immunohistochemistry allows for a definitive 
diagnosis of the tumour.  This is not always achievable in cases of small 
specimens that may be lacking in viable tumour tissue [5], but we can 
normally obtain a diagnosis using this method.  This is further complicated 
when there is not complete concordance between histopathologists, and in 
some cases an agreement between histopathologists is difficult.   
 
There are risks associated with the surgery necessary for obtaining the 
tumour tissue sample [5-7].  This is not always required as part of a treatment 
plan for a patient.  Some of these tumours do not require surgical intervention 
because of their benign nature, meaning that watching these tumours would 
be preferable.  Other tumours are less amenable to surgery, but do respond 
to other treatments available.  An example of the latter would be a 
germinoma; these grow back rapidly post-operatively, but are exquisitely 
sensitive to radiotherapy [8, 9].  These tumours are located in the midline of 
the brain, for example in the pineal region, which is a highly delicate area to 
biopsy, and would therefore benefit from surgery not being performed 
unnecessarily.   
 
Characterising tumours, which are within a set group, creates further 
limitations concerning histopathological diagnosis.  Two particular tumours 
may be given an identical diagnosis due to an identical histopathological 
appearance, but each may respond differently to certain treatments or, 
alternatively, one may be significantly more aggressive that the other. It may 
not be possible to detect these subtle differences using standard 
histopathology and immunohistochemistry [10].  Much interest have been 
generated into the discovery of novel biomarkers which have the ability to 
give additional information about the tumour’s behaviour and, in particular, 
prognosis 
 
In addition, to obtain the best resection, it would benefit the surgeon to know a 
diagnosis prior to surgery.  This information could be used to plan the 
resection extent.   
 
1.2.2 BLOOD MARKERS OF DIAGNOSIS 
There are a small number of tumours which secrete substances into the blood 
which, if detected, can be used for diagnosis. The main example of tumours 
where this is present is germ cell tumours, which may secrete alpha-
fetoprotein and Beta HCG. 
 
1.2.3 MRI  
MRI has been used in the assessment of brain tumours for many years.  It is 
often the first imaging procedure performed when a brain tumour is 
suspected.  It is non-invasive and may offer a means to determine a diagnosis 
pre-surgically.  In tumours where surgery is very high risk, for example those 
located within the brain stem, it forms a major part of the final diagnosis [11].     
 
Diagnosis using MRI is achieved using certain features such as the location of 
the tumour with a high accuracy [12, 13], whether it has metastasised and 
whether there is a cyst present. Other features such as being iso-dense or 
hypo-dense are also considered, as is the apparent invasion of surrounding 
tissue [14]. 
 
1.2.4 NEW IMAGING TECHNIQUES 
Newer imaging techniques often used in the assessment of a suspected brain 
tumour include diffusion weighted imaging (DWI), diffusion tensor imaging 
(DTI) AND magnetic resonance spectroscopy (MRS). 
 
 
DIFFUSION WEIGHTED IMAGING 
DWI is a modification of standard MRI techniques, and allows for the 
measurement of random motion of molecules.  From this, images can be 
weighted with characteristics of water diffusion.  This has been shown to be 
useful for the differentiation between brain abscesses, cystic and non-cystic 
tumours [15-17]. 
 
DIFFUSION TENSOR IMAGING 
DTI is an MR technique that enables the measurement of the restricted 
diffusion of water in tissues.  This allows for the imaging of neural tracts.  DTI 
can be used to perform tractography within white matter, where fibres can be 
tracked along their entire length [18-26].  This is a useful tool for measuring 
deficits in the white matter, and has been used in the assessment of white 
matter lesions, such as those caused by trauma ([19, 21, 23].  DTI has also 
been used in the assessment of tumours [18, 20, 22, 24-26], including in 
surgical planning [18, 22, 25, 26] and determining recurrence [20, 24].     
 
MAGNETIC RESONANCE SPECTROSCOPY 
MRS is a technique that allows for the non-invasive assessment of the 
metabolites present in a given volume of tissue using an MR scanner.  A 
region of interest is selected either in the tumour or in a region of suspicion.  A 
cubic region is selected, called a voxel, and this is the region which the 
spectrum is depicting.  This can either be performed using one region of 
interest (single voxel spectroscopy – SVS) or a grid of many voxels (magnetic 
resonance spectroscopic imaging – MRSI or chemical shift imaging – CSI).  
This has been shown to be useful in the assessment of a variety of conditions, 
including brain tumours [27-30], brain injury [31-34], and a variety of 
neurological conditions [35]. 
 
1.3 TUMOUR TYPES 
Tumours that occur in children are mainly different to those occurring in the 
adult population, with some tumour types being unique to the paediatric 
population.  These are usually classified by the WHO classification system of 
2007 [36]. 
 
1.3.1 GLIAL TUMOURS 
The glial group of tumours is a diverse group, derived from astrocytes, 
oligodendroglial cells, and ependyma [37]: astrocytomas, ependymomas and, 
in rare instances, oligodendrogliomas.  Each of these has a very different 
prognosis and requires different treatment plans.   
 
ASTROCYTOMAS 
Astrocytomas are one of the subgroups of gliomas, unbiopsied astrocytomas 
are usually referred to as gliomas.  Astrocytomas can vary in aggression and 
prognosis, ranging from slow growing (WHO grade 1; pilocytic astrocytoma 
(PA)) to very fast growing, highly invasive (WHO grade 4; glioblastoma 
multiforme (GBM)).   
 
In the adult patient population higher grade astrocytomas are common, but 
these are rare in children.  The majority of astrocytomas diagnosed in children 
are PAs [38], which have a Ki67 usually <5% [39, 40], with a 10 year survival 
rate greater than 85% [41].   
 
Diffuse gliomas do not carry such a good outlook; these are common in the 
brain stem.  Diffuse intrinsic brainstem gliomas comprise 15-20% of all CNS 
tumours in children [42].  These are one of the main causes of death in 
children with brain tumours, with more than 90% of those diagnosed dying 
within 2 years of diagnosis [42].  Since biopsy carries a significant risk they 
are commonly diagnosed on clinical and imaging grounds alone, restricting 
the opportunity for biological studies.   
 
Higher grade gliomas can also occur in children, but these are less common, 
comprising approximately 5% of childhood brain tumours.  These are more 
common in the adult population, where they carry an extremely poor 
prognosis. However, in children, although the prognosis is still poor, even 
patients with grade IV lesions can become long term survivors implying that 
these lesions are different biologically than those found in adults. 
 
EPENDYMOMA 
Ependymomas are the third most common brain tumour in children [41, 43], 
and are especially common in younger children, with the average age of 
diagnosis being less than 6 years [43, 44].  As with astrocytomas, these 
tumours can have a spectrum of grades from WHO grade 1 to 3 [45, 46].  
Grade 1 ependymomas occur predominantly in the spine.  Grades 2 and 3 
can occur both infratentorially and supratentorially, these form a continuum 
and the distinction between these is controversial.  However, they are more 
common in the posterior fossa [45]  and this percentage is increased in 
childhood ependymomas.   
 
1.3.2 PRIMITIVE NEUROECTODERMAL TUMOURS (PNET) 
PNETs are aggressive tumours, corresponding to WHO grade 4; these 
tumours have a tendency towards metastasising.  They can occur both infra- 
and supra-tentorially, those occurring supratentorially are referred to as 
supratentorial PNETs (SPNETs), or pineoblastomas when located in the 
pineal region.  Those occurring infratentorially are referred to as 
medulloblastomas.  PNETs in the posterior fossa are the most common, with 
medulloblastomas comprising 20-25% of all childhood brain tumours reported 
[47].  SPNETs are much less common, comprising <3% [47]. 
 
These tumours have similar appearances on histology, but SPNETs have 
been shown to carry a worse prognosis than medulloblastomas [47, 48], with 
a markedly lower 5 year recurrence free survival [47].  Another important 
prognostic factor with these tumours is the presence of metastases.  These 
have a huge impact on the 5 year overall free survival rates, with 1 study 
quoting a drop from 87.2% to 25.0% in the presence of metastatic spread 
[47]. 
 
1.3.3 GERM CELL TUMOURS (GCTs) 
These tumours are thought to arise from primordial germ cells and account for 
about 3% of cancers in children.  They most commonly occur in the testes or 
ovaries, but can occur intracrainially. Intracranial GCTs are more common in 
children than in adults [49].  They occur in the midline, mainly in the pineal or 
suprasellar regions of the brain.  Intracranial GCTs comprise <5% of all brain 
tumours [9], although this is higher in Japan and the Far east.  They are a 
highly diverse group, ranging from the benign to the highly malignant.  There 
are 3 main subgroups of GCT: germinomas; secretory GCTs (SGCTs); and 
teratomas.  Germinomas are the most common [9], despite being highly 
aggressive tumours they are highly radiosensitive [9, 50] and, hence, carry a 
good prognosis with quoted 5 year progression free survival rates often in 
excess of 90% [8, 9, 51-53].  Around 25% of intracranial GCTs are secretory 
[8, 9, 49, 50, 52]; these are diagnosed on the basis of serum markers [9, 49].  
These are highly malignant and less sensitive to radiotherapy than 
germinomas [9, 52].  This leads to a worse prognosis, with an event free 
survival of 5-years being approximately 50% [9, 52, 53].  The remaining 10% 
of intracranial GCTs are variants of teratoma.  These can be either benign 
(mature teratoma) or malignant (immature teratoma) [54]. There is a good 
prognostic outcome for patients with a mature teratoma, with a 5 year survival 
of around 86% [53]. This is worse for a patient with an immature teratoma, 
with a survival rate of about 50-70% [9, 53].  There is a benefit from 
aggressive resection in these tumours [53, 54]. 
 
1.3.4 OTHER TUMOURS 
In addition to the tumours listed, there are many other histological types.  The 
list provided above covers all the major tumour types.  Rare tumours provide 
a particular challenge in both diagnosis and management. 
1.4 TUMOUR LOCATIONS 
Different tumours can occur in different regions of the brain, and this affects 
diagnosis and prognosis.   
 
 
Figure 3: Brain diagram showing all major regions [55] 
 
The following is a list and description of the major regions of the brain, 
relevant to this thesis: 
o Supratentorial regions: 
o The cerebrum – this is the largest area of the brain and is made 
up of 2 hemispheres.  Each hemisphere is subdivided into lobes: 
frontal, temporal, occipital and parietal.  The cerebrum is largely 
concerned with mental functions such as thinking and memory, 
along with motor function and sensation.   
o Pineal gland – this is a small endocrine gland that produces 
melatonin, which affects the sleep/wake cycle. 
o Pituitary gland – this is a small endocrine gland that secretes 
hormones that regulate homeostasis. 
o Thalamus – amongst other functions, the thalamus plays an 
important part in the regulation of the sleep/wake cycle and is 
involved in level of awareness.  
o Hypothalamus – this acts as a link between the nervous system 
and the endocrine systems.  This is performed via the pituitary 
gland. 
o Optic pathway – information about an image is transmitted via 
the optic nerves, these meet and cross at the optic chiasm.  The 
chiasm is at the base of the hypothalamus; at this point the 
information coming from each eye is combined, split and, later, 
processed. 
 
o Infratentorial: 
o The cerebellum - this is concerned with coordination and with 
balance. 
o The brain stem – this is at the base of the brain and connects it 
to the spine.  It controls the functions that are essential for 
maintaining life: blood pressure, breathing and heart beat. 
 
1.4.1 DISTRIBUTION 
The location of a lesion affects the type of tumour considered in diagnosis.  In 
the adult population most brain tumours occur in the cerebral hemispheres.  
This, however, is not the case in the paediatric population.  Tumours in 
children commonly occur infratentorially, in the brain stem or cerebellum, with 
around 50% of reported brain tumours being reported in these locations.  
Around 20% are in the suprasellar/sellar region; this refers to tumours above 
the sella turcica (a saddle shaped decompression in the sphenoid bone).  The 
remaining 30% occur in other supratentorial locations. 
 
1.4.2 CEREBELLAR TUMOURS   
Tumours that occur in the cerebellum are usually confined to 1 of 3 types: 
o Pilocytic Astrocytoma 
o Medulloblastoma 
o Ependymoma 
Although, other tumours, such as ATRTs [56] and high grade gliomas, can 
also occurs here, amongst other rarer tumours. 
1.4.3 BRAIN STEM TUMOURS 
Most commonly types of astrocytoma occur in this region of the brain.  There 
are either high or low grade: 
o Diffuse Pontine Glioma (DPG) 
o Tectal Plate Glioma (TPG) – assumed to be focal low grade glioma 
o Focal astrocytoma of various grades 
 
1.4.4 PINEAL REGION TUMOURS  
3-8% of childhood brain tumours occur in the pineal region.  This is a complex 
area to biopsy, with surgery carrying a risk of morbidity and mortality.  This 
diverse group of tumours varies from the benign to the highly malignant, with 
highly different treatment requirements.    
The most common pineal region tumours are germ cell tumours (GCTs): 
o Germinoma  
o Teratoma (mature and immature)  
o SGCT 
The other major group of pineal tumours arise from pineocytes: 
o Pineoblastoma  
o Pineal parenchymal tumour of intermediate differentiation (PPTID)  
o Pineocytoma  
Astrocytomas can also occur around the pineal gland. 
 
1.4.5 OPTIC PATHWAY TUMOURS and NEUROFIBROMATOSIS TYPE 1 
3-5% of childhood brain tumours are optic pathway gliomas [57].  Of these, 
approximately 25% are confined to the optic disc and nerve and 40-75% 
involved the chiasm.  These are most common in the first decade of life, with 
approximately 75% being diagnosed at this age [58]. 
 
Neurofibromatosis Type 1 (NF1) is a familial condition which predisposes the 
carrier to developing low grade gliomas.  These tend to be present in the optic 
pathways or chiasm and are more indolent than other low grade gliomas 
occurring in these locations [59-63].  If a diagnosis has been made using 
general diagnostic criteria for NF1 [59-61, 63] and a slow growing lesion is 
seen in the optic pathways/chiasm a biopsy is not usually performed as this is 
enough for a diagnosis [62, 64].  These tumours tend to be observed rather 
than treated aggressively [62].   
 
1.5 CURRENT STATE OF MRS 
To date there have been several studies published relating to the use of MRS 
in the assessment of brain tumours, and these have shown the promise of this 
technique in this area [29, 65].  MRS has been used to improve diagnostic 
accuracy [27, 65], grading tumours [66-68], assessing for the presence of 
prognostic markers [69], and offer guidance for surgical intervention [70].   
 
A much more limited number of studies have been performed in the paediatric 
population, which have also shown the benefit of using MRS to aid in the 
characterisation of tumours [71-73].   The number of studies achievable in the 
paediatric population has been hindered by small numbers of cases.  Brain 
tumours are not common in children and thus only small groups are available 
for study.  Much of the work published is in the form of case reports or a small 
series of cases.  This leads to the need for larger multicentre studies, which 
introduces new problems.  Multicentre studies need to be subject to strict 
protocols that are followed rigorously in order to allow for the data between 
institutions to be analysed together.  
 
Much of the published data is also from MRS collected at a longer echo time 
(chapter 2.5); this leads to a loss of information from certain metabolites, lipids 
and macromolecules.  The signals lost at longer echo times have been shown 
to be useful in the characterisation of tumours in studies collected at shorter 
echo times [66, 67, 71, 72, 74-76] .  
 
 
1.6 CURRENT USES OF MRS IN BRAIN TUMOUR RESEARCH 
When a patient has a suspected brain tumour they traditionally have an 
imaging evaluation. This is performed either by CT or MRI scan.  Contrast-
enhanced MRI has been shown to offer a higher diagnostic accuracy than CT 
[77-79].  However, while MRI is very good at detecting the presence of 
lesions, it does not have a high diagnostic accuracy, with problems in the 
diagnosis of many tumours [80].  An improvement in accuracy has been 
shown to be possible by the addition of MRS to the standard MRI study [81].  
One study using a mixed age group quotes an increase in diagnostic 
accuracy of indeterminate brain lesions from 55% to 71% when comparing 
MRS with MRI [27]. In another study, 104 out of 105 spectra were correctly 
identified by using ‘leave-one-out’ discriminant analysis on MRS data.  This 
can be compared with conventional preoperative diagnosis methods, which 
misclassified 20 out 91 tumours that were analysed [69].  In addition to this, 
conventional MRI offers us little information on the prognosis of tumours [82], 
little information about the grade of the tumour [74] and no information with 
regards to the biology of the tumour [83].   Conventionally, this is achieved by 
taking a biopsy sample and processing it using histopathology.  This can lead 
to a sampling error in heterogeneous tumours, which may be reduced by 
using techniques such as MRS to target active tumour tissue [29, 70, 84].  
Also, since all tumours do not require surgery as part of their curative 
treatment [9, 85], it would be better to remove unnecessary risks associated 
with surgery for these patients. 
 
To date, many studies have been performed to assess the utility of MRS in 
adult patients in the diagnosis of both tumours and neurological disorders [27, 
29, 30, 65-68, 84, 86-97].  There are a more limited number in the paediatric 
population [28, 71, 73, 75, 76, 86, 98-107]. Adult studies have shown the 
considerable promise of MRS as a method to diagnose and characterise 
tumours and also as an aid to assist in the understanding of the biology of 
these tumours.   
 
Most studies using MRS use ratios between NAA, Cr and Cho as their major 
discriminating factors, as these appear to be the metabolites that alter by the 
greatest measureable amount in tumours compared with ‘normal’ brain, and 
these also vary strongly between tumour types.  A common finding described 
is an elevated signal arising from Cho, either relative to water [87, 90, 94, 
108-111] or in ratio to Cr or NAA [66, 70, 84, 87, 97].   
 
Cho is a marker of cell turnover and is therefore elevated in tumour tissue.  It 
has frequently been used to differentiate between tumour types that look 
similar using conventional MRI [90].  Cho/Cr is elevated in nearly all tumours 
[84].  This has also been used to grade tumours, with higher levels being 
reported in more aggressive tumours [68, 87, 97].  The ratio between Cho/Cr 
is such a strong indicator of cancerous tissue, that it has been used in one 
study to guide biopsies, leading to a success rate of 100% in obtaining tissue 
useful for histopathological processing [70]. NAA/Cho is also altered in glioma 
tissue [84, 87], and this can also be used to differentiate between high and 
low grade gliomas [66, 84].  Cho ratios have also been used in monitoring 
treatment response [108, 110, 111] and in determining the difference between 
recurrence and radiation changes post radiotherapy [109]. 
NAA is another metabolite closely linked with tumour characterisation.  It is a 
marker of neurons and is, therefore, usually higher in healthy brain tissue 
when compared with tumour tissue [87, 90, 94, 96, 97, 112].  This is lower in 
high grade tumours compared with low grade tumours, and this can be used 
to differentiate these either referenced to internal water [90, 94, 96] or in ratio 
to Cr [84, 97].  NAA and Cho can be used in combination as a ratio to target 
areas of active tumours tissue, the area where this is highest has been shown 
to be the densest area of infiltration of tumour cells [84], this ratio has also 
been shown to alter prior to progression [110].        
 
Creatine is often used as an internal concentration reference as it is usually 
present in brain tissue.  This is not always the case in glioma tissue though 
[94], where it is decreased.  It is often absent entirely in high grade gliomas 
[94], and can therefore be used as a method of grading these tumours.  This 
can mean that it is more useful to use Cho or internal water as a reference 
rather than Cr.    
 
Signals arising from Lipids and Macromolecules are not usually seen in 
healthy brain tissue, but are elevated in tumour tissue [66, 68, 84, 94, 110, 
113].  These are higher in aggressive tumours than benign and are often 
linked with malignancy [66, 68, 84, 94], and have also been shown to 
increase before progression [110]. LMM have also been confirmed using ex 
vivo sampling as a method to grade tumours [113].   
One of the most prominent peaks associated with LMM signals is at 
1.3/1.4ppm and 0.9ppm.  This peak often overlaps with the doublet assigned 
to Lac, leading to some mis-assignment and inaccurate quantitation.  This can 
be resolved by using an intermediate echo time of ~135ms, at this point Lac is 
inverted and the LMM signals have decayed.  This inversion has been seen in 
glioma tissue [68].  Lac has been repeatedly seen in glioma tissue [68, 84, 89, 
93, 94, 110].  As with LMM concentrations, Lac has been used in the grading 
of tumours, in particular in the grading of gliomas [68, 84, 93, 94].  One study 
saw only Lac in LGGs, whereas LMM signals were strong in higher grade 
tumours [94].  When performed on the cysts that are associated with a 
tumour, it has been shown that Lac is of use in the grading of tumours.  
Higher levels of lactate within a cyst pertain to higher level of aggression of 
the lesion [89]. 
 
Another metabolite present at short echo times, but not long, is mIns.  This 
has been shown to be very important in the analysis of glioma tissue [67, 87, 
90].  Lower grade gliomas show an elevated mIns signal [67, 90], whereas 
this is decreased in higher grade gliomas [67]. 
 
Other smaller metabolites not seen at long echo times include Glu, Gln, sIns 
and Tau.  These have all been seen in tumour tissue [66, 87, 108], and have 
been useful in determining prognosis [108] and in grading tumours [66, 87].    
 
 
 
PAEDIATRIC STUDIES 
These findings have been echoed in studies performed on a paediatric cohort.  
Cho is repeatedly elevated in higher grade tumours and is useful for grading 
purposes [74]. NAA can also be used for grading, being higher in controls [72, 
105] and in lower grade tumours [98] compared with more malignant lesions.  
Both of these metabolites have also been used to predict response to 
treatment [101, 114].  Percentage change in Cho concentration can be used 
to predict progression [101, 114], as can the maximum Cho/NAA ratio at 
diagnosis to predict survival time [107].  Creatine has again been shown to be 
significantly lower in tumour tissue when compared with normal surrounding 
brain tissue [86], this is especially low in glioma tissue [71, 98].   
 
Again, LMM signals have been shown to be elevated in tumour tissue [72, 74, 
75, 115, 116] and have been used in both diagnosis [72, 74, 115] and 
monitoring treatment response and progression [75, 116].  A conjunction with 
the signal arising from Cho, the best diagnostic accuracy [74] and 
independent predictor of survival [75] was achieved. 
 
Not all tumours arising in adults occur in children and vice versa, and as such 
there are some findings that can only be detected in a paediatric cohort.   
Approximately one half of childhood brain tumours occur in the posterior fossa 
[41].  The three most common histopathological tumour types in the 
cerebellum are PA, medulloblastoma and ependymoma.  
 
Cr concentration is especially low [71] in PAs and they usually have a 
prominent NAA peaks present at 2.0ppm and a high Cho concentration [73] . 
  
The NAA peak is decreased in ependymoma and medulloblastoma spectra 
compared with PA spectra [71, 73, 100].  The presence of a large 
concentration of Cho in medulloblastoma spectra leads to the ratio NAA/Cho 
being able to be used to distinguish medulloblastoma from other posterior 
fossa tumours [73, 100].    
 
Ependymoma spectra exhibit a very strong peak assigned to mIns [98, 99].  
This can be used as a major distinguishing feature of the spectra associated 
with these tumours.  The ratios mIns/Cho and mIns/NAA are lowest in 
medulloblastoma spectra [72, 99]. 
 
The presence of Tau in the medulloblastoma spectra is another distinctive 
characteristic of these tumours [71, 96, 98, 100].  This resonance is not seen 
in a large concentration of any other posterior fossa tumour, although it has 
been seen in germinoma spectra [71]. 
 
Other features seen in these 3 tumour types include PAs having a higher 
Lac/Cho ratio compared with the other 2 tumours types [73].  This echoes 
observations made with gliomas showing a high Lac concentration [68, 84, 
89, 93, 94, 110].  Glx has also been reported as being elevated in PAs 
compared with other tumour types [72].    
 
Another, less studied tumour type, more common in children, is the diffuse 
pontine glioma.  This is a tumour with a particularly dismal prognosis [42] and 
little is understood about their biology due to lack of biopsy tissue.  MRS has 
shown a strong resonance due to mIns and less pronounced increase in Cho 
compared with other tumours, leading to an elevated ratio mIns/Cho [72].  
They also show a low ratio for Glx/Cho [72].  It is tumours such as these, 
where biopsy carries too large a risk that MRS can be of the most use. 
 
AIM AND OBJECTIVES 
AIM 
The aim of this body of work is to improve the non-invasive characterisation of 
childhood brain tumours 
 
OBJECTIVES 
1. To assess short echo time (TE=30ms) MRS for the characterisation of 
childhood brain tumours, in particular the metabolites not easily 
quantitated in long echo time (TE=135ms) MRS 
2. To compare MRS peak height ratios with metabolite concentrations for 
the diagnosis and characterisation of childhood cerebellar tumours 
3. To apply these analysis methods to brain tumours of the pineal gland 
and brain stem, for which non-invasive diagnosis would be particularly 
useful  
4. To explore the ability of MRS to predict the clinical and biological 
behaviour of pilocytic astrocytomas 
 
MAJOR CONTRIBUTIONS 
1. A simple classifier for childhood cerebellar tumours based on 
differences between peak height ratios [99] (chapters 4.2) 
2. A comparison of methods between a simple peak height classifier and 
a more sophisticated method based upon metabolite and LMM 
concentrations as given by LCModel™ (chapters 4.3 and 4.4) 
3. An analysis of the differences in spectra between childhood germ cell 
tumours of the pineal region and other tumours occurring in this area 
[117] (chapter 5) 
4.  An analysis of childhood brain stem tumours with an emphasis on 
diffuse tumours of the pons [118] (chapter 6) 
5. An analysis of the variation between spectra of pilocytic astrocytoma 
occurring supratentorially and infratentorially [119] (chapter 7) 
6. Determining preliminary prognostic markers for supratentorial pilocytic 
astrocytomas [119] (chapter 7). 
 
OVERVIEW OF RESULTS  
In chapters 5, 6 and 7, short echo time MRS is studied in a series of important 
clinical scenarios involving children with brain tumours. The ability of the 
technique to aid non-invasive diagnosis, provide prognostic biomarkers and 
improve treatment monitoring of childhood brain tumours is investigated. In 
particular, the role of metabolites which are not well quantified at long echo 
times is determined. The emphasis of the work is on providing guidance to 
clinicians in the use of MRS. 
 
The strategy starts with the development and evaluation of simple 
classification schemes for cerebellar tumours at diagnosis, chapter 4.  The 
aim of this chapter is to determine the ability of short echo time MRS to 
characterise a specified set of childhood brain tumours and determine the 
feasibility of providing a diagnostic scheme for clinicians. Cerebellar tumours 
were selected as the test-bed for this part of the work, since they have a 
relatively high incidence and surgery usually forms part of the treatment 
making a definitive histopathological diagnosis available. Previous MRS 
studies have also been reported for this tumour group allowing important 
comparisons to be made. 
 
Two approaches to MRS analysis are used in chapter 4. The first approach 
was designed to be used entirely in a clinical setting, where sophisticated 
MRS processing and analysis tools are not readily available (chapter 4.2).  
The method relies on measuring MRS peak heights of major metabolites from 
spectra produced by software available on the MR scanner.  This scheme 
was developed using data collected using a single MR scanner (chapter 
4.2.1) then evaluated prospectively using data collected from more that one 
centre (chapter 4.2.2). The classification scheme was also re-optimised using 
the entire data available (chapter 4.2.3). The second approach used a more 
sophisticated MRS analysis in which  a commercially available software 
package (LCModel™ [120]) was used to quantify the concentrations of a 
larger number of metabolites and these were used to provide a simple 
classifier for diagnosis (chapter 4.3.1). This scheme was also evaluated 
prospectively on the same dataset that was used to evaluate the classifier 
based on peak heights (chapters 4.3.2). 
 
Having investigated short echo time MRS on a group of tumours with a 
histopathological diagnosis, the technique was applied to brain tumours in the 
pineal gland (chapter 5) and brain stem (chapter 6). Developing non-invasive 
diagnostic techniques for tumours in these locations is of particular 
importance, since surgery poses significant risks. Furthermore, the lack of 
tumour tissue for research makes non-invasive techniques for providing 
information on the biology of these tumours particularly valuable. This is 
illustrated in chapter 6 where the ability of two distinct types of diffuse pontine 
glioma a particularly poor prognosis and poorly understood tumour, is 
investigated and two distinct types may be defined by their MRS profiles. 
 
The final clinical study of the thesis concentrates on one specific diagnostic 
type, pilocytic astrocytomas (chapter 7).  A number of important biological and 
clinical problems exist for this tumour group beyond non-invasive diagnosis 
for which MRS could be an important tool. The non-invasive detection of 
variations between tumours in different locations of the brain; the 
measurement of prognostic biomarkers and the detection of early markers of 
treatment failure are investigated. 
 
CHAPTER 2: MAGNETIC RESONANCE 
SPECTROSCOPY 
The NMR phenomenon was first described in 1946 by both Felix Bloch [121] 
and Edward Mills Purcell [122], who later shared the Nobel prize in physics in 
1952 for the discovery.  Since then, NMR techniques have been increasingly 
used in both research and clinical settings. 
 
Two important applications of the NMR phenomenon are now in both clinical 
and research use:  Magnetic Resonance Imaging (MRI) and Magnetic 
Resonance Spectroscopy (MRS).  In MRI, the protons present in tissue water 
are detected and these are used to generate a structural image.  In MRS, it is 
the protons present in metabolites and macro-molecules other than water that 
are of particular importance.  
 
A basic understanding of the fundamental principles of magnetic resonance 
(MR) is vital for understanding the role of MRS in a clinical setting.  The 
following section outlines the basic principles of MR, equipment used and how 
it is applied in a clinical and research setting [123].  A full account of NMR 
physics and instrumentation is beyond the scope of this thesis, there are 
many standard texts which cover this in more detail [123, 124]. 
 
2.1 THEORY OF THE NMR PHENOMENON 
Cells in the human body contain up to 90% water, this leads to a large 
prevalence of hydrogen atoms in the human body.  The hydrogen nucleus is a 
single proton, which has a positive charge and possesses a magnetic quality 
called nuclear spin.  Other atomic nuclei, including carbon-13 and phosphorus 
also possess nuclear spin and can be used in an MR experiment, but 
hydrogen is usually the preferred choice.  Hydrogen is the most abundant 
nuclei in the human body that possess a nuclear spin.   
 
In the absence of an external magnetic field, the directions of nuclear spin 
vectors, usually known as magnetic dipole moments, are oriented randomly. 
However, when a body is exposed to a strong static external magnetic field 
(B0), the magnetic dipole moments will align with this external field and they 
will begin to precess about the main direction of the field.  An oscillating 
magnetic field is generated by the precessing net magnetisation.  The 
frequency of this precession, the Larmor frequency, can be calculated via the 
Larmor equation: 
 
ω0 = γB0 
Equation 1: The Larmor Equations 
ω = frequency; γ = gyromagnetic ratio; B = magnetic field strength 
 
Under these conditions, known as the ground or equilibrium state, there exist 
marginally more spins aligned parallel to the field, in a low-energy state, than 
anti-parallel, in a high-energy state.   
 
This excess number of magnetic dipole moments aligning parallel with the 
field produces a potentially observable bulk magnetization for a sample of 
spins when placed in an external magnetic field and it is known as the 
macroscopic or equilibrium magnetization.  Using a second electromagnetic 
field, oscillating at radiofrequencies perpendicular to the main field, these 
nuclei are pushed out of alignment, moving the net magnetization to a 
different angle.  As these nuclei drift back to align with the main field they emit 
a detectable radiofrequency.  Protons in different environments, i.e. in 
different tissue types, will realign at different speeds, and thus they will have a 
differing T1 relaxation time.  When the spins precess in the transverse plane 
they induce an oscillating current that can be detected by the receiver coil.  
This signal corresponds to an exponentially decaying sinusoid in the time 
domain, and is called the Free Induction Decay (FID).   
 
The energy difference between the two spin states is proportional to the 
frequency.  This frequency is proportional to both B0 and the gyromagnetic 
ratio, equation 1.  The gyromagnetic ratio is characteristic of a given nuclei, 
and is relatively high for hydrogen.  Thus, a nuclei with a high gyromagnetic 
ratio will lead to a larger energy difference between spin states.  Hydrogen 
has a relatively large gyromagnetic ratio, leading to a larger energy difference 
and therefore improving the sensitivity of the technique.  This, in addition to 
the relatively high abundance in the human body, is why 1H-MRS is the most 
commonly used for of MRS. 
 
One factor affecting the strength of this signal is the number of nuclei that give 
rise to it, in order to increase the signal-to-noise ratio (SNR) several data 
acquisitions are recorded and the resulting signal is averaged over all of 
these. 
The relaxation rate can be characterised by two time constants known as T1 
and T2.   
T1 (longitudinal) relaxation time describes the recovery of the z-component on 
the net magnetisation vector, while the T2 (transverse) relaxation time 
describes the decay of the xy component.  
 
T1 (longitudinal) relaxation time is the time it takes to recover 63% of the 
equilibrium magnetisation [123]. It is related to the transfer of energy from a 
nuclear spin to the surrounding environment, this is usually referred to as a 
lattice and hence this can sometimes be referred to as spin-lattice 
interactions. At equilibrium point, all the magnetisation is aligned with the 
external field.  
 
The T2 relaxation time is related to the effect that nuclear spins have on each 
other; these are often referred to as spin-spin interactions.  This refers to the 
loss of phase coherence of the spins as they interact via their oscillating 
magnetic fields.  The slight change in B experienced by the proton cause its 
Larmor frequency to change (Equation 1).  The result of this is that the 
precession of spins moves out of phase and this loss of phase coherence 
results in a reduction in the transverse magnetisation. In general, T2 is 
greater than or equal to T1.     
 
In an ideal model, the FID will decay exponentially with T2.  Spins will 
dephase due to molecular interactions as well as an inhomogeneous 
magnetic field.  These inhomogeneities in the external field cause the field to 
have slightly different strengths at different locations in a sample.  This 
causes the Larmor frequency to vary across the body, which leads to 
destructive interference.  This interference, in turn, shortens the FID.  The 
observed decay of the FID is described by a time constant known as T2*.  T2* 
is always shorter than T2.  Additional coils can be used to compensate for 
these inhomogeneities.  These are referred to as shim coils and the current in 
these coils can be altered to improve the magnetic field distribution.  This 
process is known as shimming. 
 
2.2 MAGNETIC RESONANCE SPECTROSCOPY (MRS) 
Metabolites, and other resonances, can be distinguished in a spectrum due to 
a feature known as chemical shift.  The chemical environment of a given 
nucleus will effect the resonance frequency, the chemical shift is a measure of 
this dependence [123].   
 
A synthesised proton MR spectrum is shown Figure 4, this spectrum was 
produced using software that uses the density matrix formulation of NMR 
[125].  Each of these peaks is ‘fixed’ at a given frequency [123].  This is 
shown as a fixed position on the x-axis, which shows the chemical shift.  The 
chemical shift on this axis is parts per million (ppm) of B0.  Some of the signal 
is seen as being inverted, this is due to not all of the signal being refocused at 
an echo time of 30ms.   
 
This can be explained using an example, such as lactate which has a J-
coupling of 14Hz.  To fully refocus something with a J-coupling of 14Hz you 
need an echo time of 1/14.  For lactate this will be a TE = 0.270s or 270ms or 
multiples of this, i.e. TE = 0, 270, 540ms etc.  If a TE of half of this is use, i.e. 
135ms for lactate, then the peak/s will be inverted. TE of 30ms is close to 
0ms, thus a majority of the signal from lactate will be refocused, but a small 
component will appear inverted about the x-axis.   
 
 
Figure 4: Synthesised in vivo 1H-MRS spectrum, the region is limited to 0ppm – 5ppm.  
Each metabolite’s individual spectrum is shown in a different colour. 
 
Simple metabolites may just give a single peak.  Other metabolites lead to a 
combination of singlets and multiplets.   
 
Nuclei that are connected with covalent bonds will experience some effect 
from each other’s effective magnetic field.  This effect can be detected in the 
MR spectrum between non-equivalent nuclei.  This effect is known as J-
coupling, or spin-spin coupling, and is seen in the MR spectrum as a splitting 
of peaks [123].  An example of this effect can be depicted by the doublet 
shown by lactate (Figure 5)    
 
Lactate has three magnetically equivalent methyl protons coupled to a single 
methine proton.  Since the methyl protons are magnetically equivalent they do 
not produce any splitting between themselves, but they do experience an 
effect from the methine proton, this results in the doublet seen at 1.31ppm.  
The methine proton experiences three spins, all of which have the same 
coupling constant.  The result of this is the line at 4.10ppm splitting into four (a 
quartet), with a ratio of 1:3:3:1 (figure 5b).  
 
 
 
(a)           (b) 
Figure 5: (a) molecular structure of lactate; (b) 1H spectrum of lactate 
 
From the pattern of the resulting peaks we can determine which metabolites 
are being seen in a spectrum. This can be achieved by using a combination of 
the known spectra of specific individual metabolites (Figure 4). These known 
spectra can then be used to ‘fit’ to the experimental spectrum, and this can 
give information regarding which metabolites are present and in what 
abundance. All metabolite concentrations have to be calculated in reference 
to a known peak; usually water. 
 
MRS can be performed both in vivo and in vitro.  Spectra taken in vitro can be 
used to aid in the interpretation of those taken in vivo.  In the case of in vitro, 
or ex vivo, NMR, the tissue is frozen at the time of surgery using liquid 
nitrogen.  This tissue can then be transported to the spectrometer for analysis. 
The field strength used to obtain in vitro spectra can be as high as 21T 
compared to the usual 1.5T used clinical practice.  A higher magnetic field 
strength will lead to better signal-to-noise, resulting in a clearer spectrum with 
greater peak resolution.  In addition to this, leading to a spectrum with sharper 
peaks, that can be more easily assigned to metabolites.    
 
2.3 CLINICAL MRS 
2.3.1 PULSE SEQUENCES 
A spin-echo is the reappearance of the MR signal after the initial FID has 
decayed.  To generate a spin-echo signal, a 180° pulse is applied after the 
90° pulse.  Local variations in the field cause some spins to precess faster 
than others, this leads to a spread of phases at the 180° pulse. This 
refocusing pulse reverses the order, but not the direction, of the precession.  
Thus, those spins that were precessing faster are now behind, in the sense of 
phase, the lower frequency spins. After a period of time, equal to that 
between the 90° and 180° pulses, the spins realign to form an echo.  This 
process can be repeated by applying subsequent 180° pulses, creating an 
‘echo train’ of signal.  The 180° pulse does not cause all of the protons to fully 
rephase, due to the inhomogeneous magnetic field; therefore the full 
transverse magnetisation is not fully recovered.  The pulse does cause a 
proportion of the original phasing to be recovered.  Therefore, the maximum 
intensity at each pulse is limited by an exponential decay curve, this has the 
decay constant T2.  This value is always greater than T2*, since T2* has 
components from both fluctuations in the magnetic field within the body and 
also non-uniformities in the magnet itself.   
 
This can be used to obtain localised MRS data, by only exciting and 
refocusing signal within a desired volume.  The two most common methods, 
used in single-voxel spectroscopy (SVS), are stimulated echo acquisition 
mode (STEAM) [126] and point-resolved spectroscopy (PRESS) [127].  For all 
the work published here, the PRESS sequence is used. 
 
 
 
 
 
 
 
 
 
 
 
 
The PRESS sequence [127]:  
 
Figure 6: The PRESS Sequence 
The use of crusher gradients (highlighted in pink) to flank the 180º refocusing pulses will 
ensure that there is selection of the desired coherences, while destroying all others. 
 
PRESS is a double spin-echo method, where slice-selective excitation is used 
in combination with two slice-selective refocusing pulses (figure 6).  The initial 
90º pulse is followed after a time period t1 by a 180º pulse.  This is followed by 
a spin-echo at 2 t1. The second 180º pulse is applied to refocus this spin-echo 
at a delay time 2t2. This leads to a final spin-echo appearing at a time 2t1 + 
2t2, this is equal to the echo time of PRESS (TE = 2t1 + 2t2).  The first spin 
echo only contains signal from the column that is the intersection between the 
two orthogonal slices selected by the 90º pulse and the first of the 180º 
pulses.  The second spin-echo only contain signal from the intersection of the 
TE 
RF 
Gx 
Gy 
Gz 
t1 t2 t1 t2 
90º 180º 180º 
three planes selected by the three pulses, this results in the selection of the 
desired volume. Signal outside of the volume of interest is either not excited 
or not refocused; this leads to rapid dephasing of the signal by the “TE 
crusher” magnetic field gradients. This block of three pulses (90°-180°-180°) 
is successively repeated.  The repetition time (TR) refers to the time interval 
between 90° pulses and the time between the 90° pulse and signal sampling 
is referred to as the echo time (TE). 
 
2.3.2 WATER SUPPRESSION 
The metabolites of interest have much lower concentrations (mmol/l) than that 
of tissue water (1-10mmol/l).  This leads to a signal at 4.7ppm dominating the 
1H-MR spectrum.  In order to detect the metabolite signal, it is necessary to 
suppress the large signal from water [123].   
 
One method in which to achieve this is by applying sequences of short, high 
amplitude RF pulses with delays between.  This allows for frequency selective 
excitation.  These sequences are designed to allow the metabolite 
resonances to rotate into the transverse plane, thus allowing for signal 
detection, while the water is returned to the longitudinal axis, rendering it 
unobservable.  While this method is imperfect, it does perform well and allows 
for the majority of the signal from the water molecules to be removed [123]. 
 
 
 
 
2.3.3 MRS SIGNAL PRE-PROCESSING 
The FID consists of signal from a variety of sources, including those from all 
metabolites, LMM and macromolecules.  In addition to this, there will be 
components from noise and, potentially, a signal due to residual water.  
Several steps can be undertaken in order to maximize data quality and 
remove any irrelevant information. 
 
FREQUENCY ALIGNMENT 
Spectra are referenced by assigning a known chemical shift to a metabolite.  
In scanner processed spectra the spectra will be aligned to the water peak at 
4.8ppm.  This is generally stable at 4.8ppm; however it does have a sensitivity 
to temperature and pH.  The molecular location of the water can vary between 
intercellular and extracellular water, which can also lead to some line 
broadening of the water peak. 
 
In spectra processed by LCModel™ [120] there are two options on 
processing, dependent on whether the region of interest is healthy brain or 
tumour.  In the case of healthy brain, the spectrum is aligned to the NAA peak 
at 2.0ppm, which is generally stable and the largest peak in health brain in the 
region 0-4ppm.  In tumour spectra, the spectrum is aligned with a combination 
of peaks and shifted accordingly to allow for the variation seen in tumour 
spectra. 
  
 
PHASE AND LINESHAPE CORRECTION 
A water unsuppressed spectrum can be used to correct the phase of a 
spectrum, by dividing the water suppressed signal by the phase term of the 
water unsuppressed signal.  This step corrects for eddy currents, which are 
caused by imperfections in the instruments. 
 
Most quantification tools model the spectrum as a sum of lorentzian 
lineshapes.  In practice, this is not achieved in vivo due to the effects from 
eddy currents and inhomogeneities in the magnetic field.  Eddy currents 
cause a time varying magnetic field, this distorts the MR resonances.  Time 
varying magnetic fields are the same for all resonances, thus the 
unsuppressed water spectrum can be used to correct for these contributions.  
Contributions due to inhomogeneities can be removed by dividing the water 
suppressed FID by the unsuppressed envelope. 
 
RESIDUAL WATER 
In the region 1-4.2ppm residual water is not generally a problem; this is the 
region of interest for the scope of this thesis.  In regions closer to the water 
peak, there are several automated post acquisition methods, most of which 
use a single value decomposition of the FID signal [123].   
 
BASELINE CORRECTION 
Most spectra will exhibit sharp metabolite peaks superimposed upon a 
baseline of broader components, mainly arising due to contributions from 
macromolecules.  Many analysis tools use prior knowledge of these 
macromolecules to account for this signal. 
 
2.3.4 TYPES OF MRS LOCALISATION: SVS Vs MULTIVOXEL 
The 2 main approaches of collecting MRS data: SVS and multivoxel (also 
known as chemical shift imaging (CSI) or magnetic resonance spectroscopic 
imaging (MRSI)).  SVS is performed by selecting a region of interest and 
placing 1 voxel (volume of interest) in this region.  CSI is performed by placing 
a grid of voxels over the region of interest; this can be performed in 2D or 3D.   
 
In a CSI examination, a grid of voxels is placed on the area of interest.  This 
can then either be viewed as a matrix of spectra or as a colour map, with 
areas of high concentration of a selected metabolite (or ratio of metabolites) 
being graded. 
 
CSI is particularly useful in detecting spread of disease beyond the obvious 
foci; this is of particular use in diffuse tumours [112, 128]. MRS can be used in 
surgical planning to guide biopsy [70], by targeting areas of active tumour in 
adults.  It is also very useful post operatively, in the assessment of irregular 
shaped or large, heterogeneous lesions, to determine response to treatment 
and areas of recurrence [109, 110].  However, it is challenging to perform CSI 
at shorter echo times and thus the amount of information contained is limited.  
Also, long acquisition times are needed to obtain a good quality spectrum. 
 
 
2.3.5 ECHO TIMES 
In a spin-echo experiment a second RF pulse is applied after the initial 90° 
pulse, with a precession angle of 180° after a given delay time.  A spin-echo 
can then be detected, this information can be collected at different echo times 
(TEs).  In principle both the spin-echo time domain signal and the FID contain 
the same information about frequencies and intensities.  However, the delay 
time between the 2 RF pulses used in the spin-echo experiment allows 
nuclear magnetisation to be manipulated and this can be used to create 
spatial localisation. 
 
The timing of the different RF pulses used is determined by both TE and TR.  
TE is defined as being the time between the initial application of a 90° RF 
pulse and the peak of the echo. This results in a differing amount of 
metabolite information being present in the resulting spectrum.  TR is defined 
as being the time between pulse sequences as applied to a single slice.  SNR 
will be greatly improved by the collection of repeated measurements, thus TR 
results from the compromise between the desired SNR and the time for the 
taken for the experiment. 
 
Signals from different metabolites have different rates of decay; this is due to 
the T2 value being dependent on the environment protons is found in.  By 
collecting data at different echo times we obtain information from a different 
number of metabolites.  At short echo times less metabolite signals have 
decayed, leading to more information being present in the spectrum.  
However, this can be problematic due to overlapping peaks and the presence 
of signals from lipids and macromolecules.   
Longer echo times (TE>135ms) allow for a more signal intensity to decay, 
resulting in fewer peaks and, thus, a clearer spectrum (figure 7a).  However, 
this leads to the loss of potentially interesting metabolite information. 
 
Figure 7a: Example of a 1H spectrum taken at TE = 135ms 
 
Signal due to small metabolites with strong J coupling decay at longer echo 
times, due to destructive interactions between resonances with J-coupled 
induced phasing.  These include signals from Glutamate, Glutamine and myo-
inositol (mIns).  Lipids and Macromolecules can often dominate a short echo 
time spectrum, however these have short T2 decay times and are, therefore, 
not present in a long echo time spectrum. 
 
Spectroscopy at a long echo time is particularly beneficial in certain regions, 
such as, between 2 and 2.6ppm. This region contains signals from NAA, Glu, 
Gln, LMMs, as well as smaller metabolites such as GABA. Despite this 
benefit, problems can occur in the determination of NAA in a spectrum [129], 
usually, with concentrations often being overestimated.  By using a longer 
echo time Glu, Gln, much of the LMM signals and those from smaller 
metabolites have decayed and, so, this peak is clear and the concentration is 
more easily determined.  In addition to this, lactate is inverted at longer echo 
times (TE~135ms), and this can be more easily assigned.  
 
However, this benefit of easy peak assignment and quantitation is offset by 
the lack of information present in a long echo time spectrum.  Those 
metabolites which decay quickly are often of a lot of importance when it 
comes to analysing a tumour, and a short echo time spectrum could be 
beneficial.  An example of a short echo time spectrum is shown in figure 7b, 
this spectrum was taken at the same time as that in figure 7a.  Both spectra 
were of the same voxel and were taken using identical parameters with only 
the echo time varying between them.   
 
 
Figure 7b: Example of a 1H spectrum taken at TE = 30ms 
 
For example, the signals from the LMM regions have been shown to be 
important in the analysis of tumours [65, 66, 68, 72-75, 94, 110, 115]; these 
are no longer present in long echo time spectra.  In short echo time MRS, 
signals from small, strongly coupled metabolites and LMM regions can be 
detected and quantified.         
 
In some cases, using 2 echo times in the same investigation is beneficial, to 
obtain the maximum information.  For example, mIns has decayed at longer 
echo times, and this has been shown to be useful in many studies 
investigating neurological problems [35, 88, 91, 130-132] and brain tumours 
[67, 68, 71, 72, 87, 98, 102, 112, 128, 133].  However, there is some 
argument as to whether the peak at 3.6ppm is due to mIns or whether it is due 
to glycine (Gly) [128, 134]. Gly is a singlet whereas mIns is a multiplet, and 
this leads to a different appearance, that may be possible to distinguish 
between at higher field strengths due to an improvement in SNR.  This is not 
easily achievable at 1.5T, but by using 2 echo times the information about 
both metabolites can be determined and also the peak assignment can be 
verified.  However, this is often not possible in a clinical scenario, due to time 
constraints.     
 
2.3.6 FUNCTIONS OF DIFFERENT METABOLITES [123]  
NOTE: All spectra are simulated as if acquired with PRESS and a 30ms echo 
time 
N-Acetyl-Aspartate (NAA) (prominent peak from methyl group at 2.01ppm + 
smaller resonances arising from the CH2  and CH  groups corresponding to 
doublet of doublets at 2.49, 2.67, 4.38ppm; plus amide proton broad temp 
sensitive resonance at 7.82ppm) is exclusively localised to the central and 
peripheral nervous system and is a marker of neuronal density.  
 
 
 
Figure 8a: Spectra of NAA  
 
It is the largest peak seen in a spectrum of healthy brain.  It has been shown 
to vary in neurological conditions [131, 135] and be decreased in brain 
tumours [72, 73, 87, 90, 96, 97, 99, 105, 107, 110, 114]. 
 In addition to this there is some overlap NAA peaks with those arising from N-
Acetyl-Aspartyl-Glutamate (NAAG), a prevalent neurotransmitter.   
 
Choline containing metabolites (most prominent in vivo at 3.2ppm, with 
secondary peaks between 3.5 and 4.0ppm)) include GPC, PCH and free 
choline.  It is often not possible to clearly distinguish between the singlets 
around 3.2ppm at 1.5T, although some studies claim that this may be possible 
[98].   
 
 
(i)      (ii) 
Figure 8b: Spectra of (i) GPC and (ii) PCh 
 
 
These metabolites are more easily distinguished by using 31PMRS [86].  An 
analysis of the combined peak (tCho) has been correlated with cell 
proliferation and is usually elevated in tumours [66, 70-72, 74, 75, 84, 87, 90, 
93, 98-101, 128, 136].  
 
Creatine (Cr) and Phosphocreatine (PCr) (3.03ppm and 3.93ppm) are 
usually combined in spectral analysis to become total Cr (Cr henceforth), due 
to the close proximity of their peaks at 1.5T.   
 
 
Figure 8c: Spectrum of Cr 
 
 
This is present in neuronal and glial cells and is involved in energy 
metabolism.  It has been shown to be decreased in gliomas [71, 96, 98, 137].  
 
Myo-inositol (mIns) (multiplets between 3.27-3.61ppm) has a doublet of 
doublets at 3.52ppm and 2 triplets (1 at 3.61 and 1 at 3.27ppm – which are 
close enough together to form a single multiplet at 1.5T).  It has a function that 
is, as yet, unknown.  It has been shown to be altered in many tumours [27, 29, 
35, 67, 68, 71, 72, 87, 90, 98, 99, 112, 128].   
 
 
Figure 8d: Spectrum of mIns 
 
 
It has been used as a glial marker [87], and there is evidence of an 
association with gliosis.  It is elevated in gliomatosis [90, 112], has been used 
in grading astrocytomas [67, 68], has been shown to be high in 
ependymomas when compared with other cerebellar tumours [98, 99], and it 
is high in diffuse pontine gliomas [72].  In addition to mIns, scyllo-inositol 
(sIns) can occasionally be distinguished (singlet at 3.34ppm); this also varies 
in neurological problems and tumours [35, 108, 130, 132, 134].  
 
 
Figure 8e: Spectrum of sIns 
 
 
Glycine (Gly) is an amino acid and resonates as a single peak at 3.55ppm.  
This peak is often indistinguishable from mIns at low field strength.   
 
 
Figure 8f: Spectrum of Gly 
 
 
Lactate (Lac) is an end product of anaerobic glycolysis with doublet at 
1.31ppm (these peaks become inverted at an echo time of 135ms, this allows 
for clarification of assignment).  
  
 
Figure 8g: Spectrum of Lac 
 
 
There can often be some confusion over the assignment of Lac when signals 
from lipid and macromolecular signals are present at short TE [75]. Lac is high 
in cysts and cystic masses [89, 94].  It has been used in the grading of 
gliomas [68, 93]  and for distinguishing between pilocytic astrocytomas and 
other cerebellar tumours [73].  
  
The peaks attributed to taurine (Tau) (2 triplets at 3.25ppm and 3.42ppm – 
the two triplets are close enough together to form a single multiplet at 1.5T) 
often merge with tCho at low field strengths, and can only be reliably 
assessed in good quality spectra.   
 
 
Figure 8h: Spectrum of Tau 
 
 
Tau has been shown to be high in medulloblastomas [71, 96, 98, 100]  and is 
also seen in pineal germinomas [71]. 
 
Lipid and macromolecular (LMM) resonances occur at various regions in a 
1H MR spectrum.  Particular areas of interest are the regions around 0.9ppm, 
1.3-1.4ppm and 2.0-2.6ppm. These can be very large and dwarf metabolite 
signals.  The signals are not always due to the tumour being analysed, they 
can be due to lipid in surrounding tissue, especially the scalp if the tumour is 
close to the skull.  Saturation bands can be placed to remove signals being 
observed from outside the voxel.  These should be used where possible to 
remove the chance of external contamination of the spectrum.  LMM 
resonances can be due to necrosis, and therefore are high in high grade 
tumours [66, 72, 74, 75, 94, 110]  and one study showed them to increase 
before progression [110]. 
 
2.4 ANALYSIS TOOLS 
There have been numerous analysis tools published for MRS pre- and post-
processing. These are generally automated with some user input dependent 
on the desired output.  Two of the most commonly used analysis tools are 
LCModel™ [120] and jMRUI [138]. 
 
LCMODEL™[120] 
The Linear Combination Model (LCModel™) is a robust tool frequently used in 
the analysis of MRS due to its flexibility and relative user-independence.  It 
comprises automated pre-processing and uses a basis set of experimental 
single metabolite and LMM spectra.  This also enables it to potentially discern 
partially overlapping spectra, such as PCh and GPC, under good conditions.  
The basis set can be either obtained on site or imported from a library of 
those from a wide range of scanners. 
 
LCModel™ gives a ‘fit’ to the spectrum of a combination of the peaks in the 
basis set; in addition to this it gives a list of the known metabolites, lipids and 
macromolecules in the spectrum.   
 
JMRUI 
The Java-based MR User Interface for the processing of in vivo MR spectra 
(jMRUI) offers considerably more user input.  This offers a broad range of pre-
processing options available for implementation by the user.  Peak-picking 
can be used to select peaks for quantitating, using tools such as AMARES 
[139].    
2.5 EXTENSIONS 
It is possible to perform MRS using any nucleus with a magnetic moment.   
The second most commonly used is 31PMRS.  31PMRS has many 
applications in vivo, including observing phospholipid metabolism.  This has 
been used to predict the rejection of liver transplants [140]  and in assessing 
the livers of diabetic patients [141].   Other uses include the assessment of 
muscle metabolism [142] and heart disease [38].  In addition to this, it has 
been used in the oncology setting both extracranially [143, 144] and 
intracranially [30, 86, 103, 113, 145-148].  It is especially useful to better 
visualise the choline region [30, 86, 103, 145, 147].  31P is also found in other 
neurometabolites such as PMEs, PDEs and PCr.  
 
2.6 CHALLENGES OF MRS 
Despite the information that MRS can provide, there are technical challenges 
that restrict and hinder the use of MRS.  The first of these can be attributed to 
the signal arising from water.  Due to its abundance in mammalian tissue, the 
water signal (resonance at circa 4.7ppm) is several orders of magnitude 
stronger than any of the metabolite signals.  This leads to much difficulty in 
the detection and quantitation of metabolite signals.   
 
An important limitation is the limited chemical shift range visible using in vivo 
MRS, this is approximately 10ppm.  Limited resolution leads to a large 
number of resonances overlapping and makes quantification difficult.  Only 
15-20 metabolites can be detected at a short TE. 
 
Correct voxel placement is vital in obtaining a valid spectrum, classification 
rates have been shown to vary depending on where the voxel was placed 
within the tumour [149].  Where the edge of the tumour was included in the 
voxel the classification rate was significantly higher.   
 
Contaminants in the spectrum can also pose a serious problem.  When a 
voxel is placed close to the edge of the brain, scalp lipid can affect the 
spectrum, giving peaks at 0.9pmm and 1.3ppm.  If unaccounted for these 
could dominate the spectrum or be mistaken for lipid signals from within the 
tumour itself.  Voxel placement near vessels and CSF also affect the spectra, 
often increasing the noise significantly and making a spectrum largely 
unreadable.  Mannitol is sometimes given to reduce intracranial pressure, 
which is common at presentation with a brain tumour.  This has a peak 
around 3.8ppm, which can be mis-assigned as a metabolite within the tumour 
[150], although if this is known this issue can be avoided. 
 
At short echo times there is the lack of distinction between peaks, due to 
spectral congestion [129-131, 133, 151-157].  Small metabolites with a weak 
signal can often become difficult to quantify in a spectrum.  These metabolites 
can potentially be of much use in assessment of tumour and other 
neurometabolic disorders, such as sIns and Tau [66, 71, 96, 98, 100, 108, 
130, 132]. These can be either mis-assigned or incorrectly quantified.  There 
are 2 regions that are of particular challenge: the region between 2 and 
2.6ppm and the tCho region around 3.2ppm.   
 
The region between 2 and 2.6ppm contains Glu, Gln, NAA and numerous 
smaller metabolites such as GABA and NAAG.  These all overlap and can be 
mis-assigned [129].  NAA is more easy to quantify at long echo times [158], 
but this is not the preferable solution as much information will be lost 
regarding the smaller metabolites.  Some sequences can be used to better 
quantitate these metabolites [154, 157] or a higher field strength can be used 
to ensure a better resolution and SNR. 
 
Although the tCho peak occurring at ~3.2ppm varies between tumours, this is 
not one metabolite alone.  The tCho peak seen at 1.5T at 3.2ppm is made up 
from contributions of PCh, GPC, choline and phosphotidylcholine.  These 
peaks can be difficult to distinguish at 1.5T, although this can potentially be 
achieved, for data obtained under good conditions, using fitting tools such as 
LCModel™ [98].  One study of posterior fossa tumours in children showed 
that GPC and PCh varied between tumours  and could be used to distinguish 
between medulloblastoma and ependymoma spectra, with higher 
concentrations of PCh being reported in medulloblastomas and higher 
concentrations of GPC in ependymomas [98].  These findings were confirmed 
by ex vivo high resolution NMR.  The observation of elevated PCh in 
medulloblastoma would be in agreement with observations made using high 
resolution NMR of neuroblastoma tissue [159], these tumours are of the same 
origin, so it would be expected for them to show similar metabolite profiles. 
 
 
Further problems can be caused by normal alterations in metabolite 
concentrations. As the brain matures, metabolite concentrations will vary [130, 
134, 160, 161].  In addition to this, metabolite concentrations can vary with the 
region of the brain being studied [134, 160, 161].  Both of these can 
potentially interfere with the interpretation of a spectrum, and can also impact 
on whether finding we see in adult tumours can be used in the assessment of 
paediatric tumours.     
 
Some metabolite changes occur very early in life (within the first year) and 
then remain approximately stable, including PCr, Cho, mIns and Glu [161].  In 
this time NAA increase in grey matter, but remains stable in white matter 
[161].  There is a high concentration of Tau in the cerebellum and in grey 
matter in infancy, which then decreases and stabilise [161].  In the basal 
ganglia, both Tau and NAA remain constant with age [161].  There is an 
increase in NAAG in the thalamus and in white matter and a decrease in Gln 
in white matter [161].   
 
Some variation has been reported later in life [130, 160].  A significant 
increase in total metabolite concentration was reported between the ages of 
25 and 31 in the orbital frontal cortex and sensor-motor cortex [160].  Both of 
these regions also exhibited a gender dependence, with women showing 
increased concentrations [160].  Other metabolites have been shown to alter 
in the normal ageing brain [130]. 
 
 
2.7 SUMMARY 
MR sequences can be manipulated in many ways in order to achieve different 
information from MRS.  Features such at echo time and field strength impact 
upon both the quality of the data obtained and also the information it is 
possible to extract from the resulting spectrum. 
 
It is more challenging to both collect and analyse data at shorter echo times, 
however these can be partially resolved by using tools such as LCModel™, or 
moving to higher field strength to ensure a higher SNR and better resolution. 
 
The additional information available in a short echo time spectrum could be 
potentially of much importance in the better understanding of childhood brain 
tumours; as such these are the spectra that will be analysed in this thesis.   
 
CHAPTER 3: METHODS 
3.1 EXPERIMENTAL PROTOCOLS 
At BCH the majority of data was collected using a 1.5T Siemens’ Symphony, 
although some spectra are acquired using a 1.5T GE Signa Excite. Single 
voxel MRS was acquired using a PRESS sequence [127] at either short (TE = 
30ms) or long (TE = 135ms) echo time.  Studies all used a relaxation time of 
1500ms. If the voxel had a 2cm side, then data was collected at both short 
and long echo times.  If the voxel had a 1.5cm side, only short echo time data 
was collected. This was done primarily to verify the quantitation of certain 
metabolites, such as NAA. Dual echo time data was also used to verify the 
assignment of certain metabolites with different decay rates which may lie 
very close to each other, an example of this is mIns and glycine (Gly).    
 
 
(a)      (b) 
Figure 9: Voxel placement for a cerebellar tumour (a) in the axial plane and (b) in the sagittal 
plane 
 
A cubic voxel was placed by the radiologist or an experienced radiographer. 
This was ideally to be placed entirely within the tumour, maximally over the 
solid tumour component.  This criteria was not always possible, as some 
tumours were smaller than the 1.5cm sided voxel, in these cases it was 
required that the tumour filled over 50% of the voxel and special consideration 
was taken over these cases when using the spectra in analysis, and it was 
usually removed from formal analysis. Voxel placement was confirmed by 
storing MR images with the voxel location recorded (figure 9). For a 1.5cm 
cubic voxel, 256 repetitions were used and for a 2.0cm cubic voxel, 128 
repetitions were used. For patients who had tumours which were large 
enough to accept a 2cm sided voxel, an additional MRS acquisition was 
performed using an echo time of 135ms. All other parameters remained 
unchanged including shimming, gain and water suppression.  In all cases, a 
water MRS acquired at the same time as the water suppressed MRS was 
used to correct for eddy currents and as a reference for metabolite 
concentrations.   
 
For studies involving data from other centres within the Childhood Cancer and 
Leukaemia Group (CCLG), MRS was performed on children from one of four 
centres: Birmingham Children’s Hospital (BCH); the Royal Marsden Hospital – 
Sutton (RMH); Queen’s Medical Centre – Nottingham (QMC); and Great 
Ormond Street Hospital (GOSH). At GOSH data was collected using a 1.5T 
Siemens’ scanner, at QMC data was either collected on either a GE or Phillips 
scanner, both 1.5T and at RMH data was collected using a 1.5T Phillips 
scanner.  
 
The acquisition protocol remained the same between centres, with 
parameters remaining largely constant.  Data was collected following the 
protocol laid out by the CCLG, although there were some marginal 
discrepancies in the echo time.  This was not a large enough variation for any 
difference to be seen within the spectrum.   
 
3.2 ANALYSIS METHODS 
3.2.1 PRE-PROCESSING AND PROCESSING 
Regardless of the analysis method employed, voxel location needed to be 
checked before an examination could be included in a study. At the time of 
MRS being performed the voxel location was saved in 3 planes if possible, 
this was not always achieved for studies performed on the GE Signa Excite at 
BCH where only 1 plane could be stored. The placement of the voxel was 
checked. Ideally, the voxel had to be placed entirely within tumour, maximally 
over the solid component. In some incidences, where the tumour was of a 
small volume, this was not achievable. In these cases, the spectrum was still 
assessed for interesting features and how well it corresponded with tumours 
of the same type, but not included in the formal analysis due to the 
contribution from ‘normal’ brain. 
 
The method used for analysing data chosen was heavily dependent on the 
intended user and the software available to them.  Spectra were processed in 
one of 2 ways: either using the software on the scanner or using tools such as 
LCModel™[120], which uses a linear combination of empirically obtained 
metabolite spectra to ‘fit’ to the experimentally obtained spectra.  LCModel™ 
has a choice of basis sets acquired at different echo times on a variety of 
scanners, thus allowing for a close match with the data to be made.  The 
metabolite concentrations are then referenced to the internal water 
concentration.  
When the classifier was designed for use by clinicians, the application of the 
method needed to be fast and simple to use, despite the underlying analysis 
being complex.  In these studies, spectra produced by the scanner software 
were selected as these were readily available without any need for additional 
software.  For studies that required a more in depth analysis of the metabolic 
differences between tumours, spectra produced by tools such as LCModel™ 
were used.  These were assessed along with the metabolite concentration 
tables produced and the quality control measurements.  In the case of 
mulitcentre data, all the raw data was sent to BCH and was processed with 
the onsite version of LCModel™, to reduce the risk of variability between 
centres. 
 
3.2.2 QUALITY CONTROL 
Before a spectrum could be included in a study some basic quality control 
measures needed to be met.   
 
SIGNAL TO NOISE RATIO (SNR)  
SNR is a measure of how high the strength of the signal under analysis in 
relation to that of the background noise. The higher this value, the less 
obtrusive this background noise is.  This was kept in the region of an 
acceptable spectrum have an SNR of at least 5 to be able to reasonably 
analyse the metabolite peaks.  This was reduced in the analysis of peaks due 
to LMM resonance; this was seen as being reasonable due to the high signal 
strength of these peaks, relative to the metabolite peaks. 
 
FULL WIDTH HALF MAXIMUM (FWHM) 
FWHM is a measure of how broad the peaks are.  If a spectrum is dominated 
by broad peaks, peaks can merge into one.  In cases with broad peaks, 
metabolite concentrations determined are not done so with high confidence.  
FWHM has to be low, and in the region of 0.015ppm, in order for a spectrum 
to be included in a study.  
 
OTHER FACTORS 
Both SNR and FWHM are quantifiable, but there are other factors that can 
deem a spectrum not fit for analysis.  If the water suppression is not sufficient, 
the region greater than 3 ppm can be difficult to interpret.  Phasing can 
sometimes be inadequate, which can lead to a spectrum that is not easily 
analyzable.  Issue such as these, and the determination of artefacts within the 
spectrum, are only determined by visual inspection of the spectrum.  This 
should be done to ensure the results from the analysis of metabolite 
concentrations are valid. 
 
 
 
 
 
3.2.3 ANALYSIS USING SPECTRA PRODUCED BY SCANNER 
SOFTWARE 
For MRS to be used in a clinical setting, the application of the tool developed 
needs to be simple to use, fast and robust. A radiologist or clinician is most 
likely to need a classifier at the time an imaging investigation being 
performed. In this case, it is most convenient to use the software provided on 
the scanners. Since a majority of the MRS investigations at BCH are 
performed on the Siemens’ Symphony, initially tools were developed using 
NUM4 processed spectra (figure 10).  
 
 
Figure 10: Example of a 1H-spectrum processed by the Siemens’ Symphony NUM4 software, 
with voxel placement images on the right hand side in all 3 planes.  Peaks marked, and 
intensities (I) given, for myo-inositol – Ins; creatine – Cr (and Cr2 for the secondary peak due 
to Cr); total choline – Cho; total NAA + NAAG – NAA; and lactate – Lac 
 
Prospective studies included data from both the Siemens’ Symphony and the 
GE Signa Excite at BCH, in addition to data from other centres in the CCLG. 
Data in prospective studies included spectra produced by software from all 3 
major scanner manufacturers. This allowed me to assess whether tools were 
robust to new data from the same scanner, but also whether the tool was 
robust to data from other sources. This is an important part of the assessment 
to determine the usage of the tool in a clinical scenario. 
 
The spectra produced by the NUM4 software, used in this study, have an 
arbitrary y-axis. This means that peaks within a spectrum can be compared 
with one another, but a comparison between different spectra is not possible 
using absolutes, since absolute values are not available. To overcome this, 
ratios were generated between peak heights/areas to allow for comparisons 
to be made. 
 
QUALITY CONTROL  
No values for SNR or FWHM were produced by the scanner software; visual 
measures had to be established.  These factors were determined by visually 
assessing a group of spectra, and from these determining at what point little 
or no information could be reliably extracted. 
 
Firstly the MRS peaks have to be sufficiently narrow for the Cr (3.0ppm) and 
tCho (3.2ppm) peaks to be visually well separated. Figure 12a shows an 
example where poor shimming has led to broad peaks, which do not therefore 
meet this criterion.  
 
Figure 11a: An example of a 1H-spectrum with broad lines.  The highlighted region shows the 
peaks arising from Cr and Cho merging into one broad peak, making it highly difficult to 
estimate the contribution from each metabolite 
 
Secondly, the tCho peak height must be at least 5 times greater than the level 
of the noise. The noise level was taken as half the height spanned by the 
noise on the spectral intensity axis. The noise was measured in the region of 
the spectrum between 0.0ppm and 0.5ppm, which is outside the range where 
metabolite peaks are seen. An example of a spectrum with unacceptably poor 
SNR is shown in figure 11b.  
 
 
 
Figure 11b: An example of a 1H-spectrum with very low SNR.  The highlighted noise region is 
shown to be far less than the acceptable 5xCho peak, metabolite peaks are difficult to 
distinguish from background noise in the spectrum 
 
Although scanner software can give values for shimming and SNR, there is no 
generally agreed definition for these parameters and an ability to assess them 
from the processed spectrum is an important part of analyzing any MRS 
investigation. Whilst the measure used for determining adequate SNR and 
FWHM are not precise, experience in their implementation should allow a 
clinician to assess the reliability of the data collected.  
 
PEAK AREAS 
The NUM4 software routinely assigns the peaks for mIns, tCho, Cr and tNAA; 
this enables a less experienced observer to easily assess a spectrum. In 
addition to labelling these peaks, the software also determines the area under 
each of these peaks by fitting them to standard curves. The areas under the 
peaks are proportional to the metabolite concentrations. The peaks shown in 
a NUM4 produced spectrum do not have a concentration reference and as 
such ratios needed to be generated to allow for comparison. Ratios could then 
be compared between spectra for the same, and different tumour types. 
However, the determination of peak areas is subject to large inaccuracies 
when peaks overlap and the estimation of the errors involved in this is difficult. 
This problem is a particular challenge in short echo time MRS, where more 
peaks are present. The most complex region, with the most difficulties was 
the region around tNAA (2.0-2.6ppm). This region contains resonances from 
Glx, LMMs and other smaller metabolites. In addition to this problem, the 
NUM4 software is designed in a way that it assumes tNAA will be the 
strongest signal. The tNAA resonance is largely decreased in tumour tissue 
and therefore is no longer the strongest resonance. To compensate for this 
the NUM4 software tended to over fit the tNAA resonance, by including 
contributions from the surrounding combined peak, thus giving a larger signal 
for tNAA than actually given. This meant that the intensity given for tNAA was 
no longer valid. 
  
PEAK HEIGHTS 
An alternative method was investigated by measuring the heights of various 
peaks in the spectrum. This is simple and fast to implement in a clinical 
setting and ratios between peak heights are easy to visualise. This method 
also allowed for additional peaks to be included in the analysis, such at Lac 
(doublet at 1.31ppm) and LMM resonances at both 0.9ppm and 1.3ppm. Peak 
heights were measured directly from the Siemens processed spectra using 
imageJTM, a standard DICOM viewer (available at http://rsb.info.nih.gov/ij/).  
 
For spectra with a flat baseline, peak heights were measured from the 
baseline to the peak tip. For spectra with an irregular baseline, a midpoint for 
the base of the peak was calculated and the peak height was taken to be from 
this point to the peak tip. Measurements were repeated 3 times to reduce 
error.  
 
3.2.4 METABOLITE CONCENTRATIONS 
LCModel™ was the preferred tool for determination of metabolite 
concentrations.  This is a tool which uses a linear combination of an 
empirically derived basis set, of metabolites and LMM resonances expected in 
the brain, in order to determine the concentration of each metabolite seen in a 
spectrum.  LCModel™ is an accurate, automatic and robust method that uses 
the frequency-domain to generate a list of metabolite concentrations (relative 
to water) along with confidence estimates. 
 
Another method assessed for analysis using metabolite concentrations was 
JMRUI.  JMRUI allows for processing of MRS in either the time- or frequency-
domain.  This method also allows for the determination of metabolite 
concentrations relative to water and allows for considerably more user-input.  
This means that this method is more time-consuming and more vulnerable to 
user-error.  Hence, LCModel™ was used for the analysis presented here, 
where the method refers to schemes derived from metabolite concentrations. 
LCModel™ gives values for both the SNR and FWHM of a spectrum; these 
values can be used to determine quantitative cut-off values for the 
assessment of data quality.  These cut-offs, however, were allowed to vary 
between studies, depending on the signals under consideration. There is a 
large difference between the strength of a signal from an LMM region and that 
of a resonance due to a metabolite in weak concentration. In studies where 
LMM resonances were the main interest, the SNR cut-off value was 
decreased and the FWHM increased.  This served to allow for more data to 
be included in these studies.  This was seen as acceptable, due to the clarity 
of the LMM resonances. To ensure that the QC criteria being implemented 
were reasonable, spectra were also checked visually by an expert 
spectroscopist.  This also allowed the assessment of quality issues not 
quantifiable, including satisfactory phasing, spectral artefacts and to ensure 
that residual water signal was not excessive. 
 
A value for the Cramer-Rao lower bounds [120] is also given for each 
metabolite concentration calculated.  This is an estimate of how well this value 
is determined. Any signal with consistently high Cramer-Rao lower bounds 
(>50%) was removed from further analysis, since these would be very poorly 
determined. 
 
LCModel™ can be used to obtain a more complete list of metabolite 
concentrations, including those due to smaller resonances, such as Tau 
(triplets at 3.25 and 3.42ppm) and sIns (3.34ppm). These concentrations are 
referenced to the concentration of water in the voxel; which removes the need 
to generate ratios between metabolites.  
 
Some MR spectral features overlap significantly at 1.5T, and for these a 
combined signal was used. This was applied to the following list of 
metabolites: 
1. glutamate and glutamine (Glx), 
2. N-Acetyl Aspartate and N-Acetyl-Aspartyl-Glutamate (tNAA), and  
3. phosphocholine and glycerophosphocholine (tCho) 
 
Generally, the Cramer-Rao bounds for the individual components of these 
metabolites are high, thus removing them from analysis. 
 
3.3 STATISTICAL METHODS FOR THE INTERPRETATION OF 
RESULTS 
The following accounts for a general overview of the statistical tests used. 
 
T-TEST 
The T-test is a statistical test which can be used where the data has a normal 
distribution and the null hypothesis is true. It is used on small samples, to 
assess whether there is a real difference between the means of two different 
groups. 
 
 
 
Z-TEST 
The Z-test uses normalised data to determine whether differences between 
either sets of data or between individual members of different groups of data 
is large enough to be significant. 
 
ANALYSIS OF VARIANCE (ANOVA) 
The simplest type of ANOVA of these is a one-way ANOVA, which is used to 
assess for the significance of differences seen between independent groups, 
by comparing the means of each group.  It is used where there are multiple 
groups. 
 
RECEIVER OPERATOR CHARACTERISTIC (ROC) CURVES  
An ROC curve is a plot of the sensitivity Vs (1-specificity) of a given binary 
classification scheme.  The larger the area under this graph, the more 
accurate the classification scheme is. 
 
PRINCIPAL COMPONENT ANALYSIS (PCA) 
A PCA transforms a list of possibly correlated variables, in the cases 
presented here this is the list of metabolite and LMM concentrations, into a 
smaller number of uncorrelated variables.  Each of these uncorrelated 
variables is called a principal component (PC).  The first of these PCs usually 
accounts for most of the variability, with each successive PC accounting for 
less.  A plot of the first 2 PCs usually allows for the visualisation of the 
variability within groups, and how well groups separate.  Along with these, 
loadings plots can be generated.  These are charts showing each of the initial 
variables used in generating the PC and how heavily each of these is 
weighted.  This allows for the assessment of which metabolite and LMM 
regions are contributing most to the separation of the groups. 
 
LINEAR DISCRIMINANT ANALYSIS (LDA) 
An LDA uses a linear combination of variables that can best separate two or 
more groups of data.  LDA is closely related to PCA, but an LDA models the 
difference between classes of data whereas a PCA does not take this into 
account.  It is, therefore, termed a supervised method.   
CHAPTER 4: CEREBELLAR TUMOURS 
4.1 INTRODUCTION 
Approximately 50% of childhood brain tumours occur in the posterior fossa 
[41], and most of these occur in the cerebellum.  There are three major 
tumour types that occur in the cerebellum: PA, medulloblastoma and 
ependymoma [41]. These all have very different clinical behaviour [41].  PAs 
generally show a benign course with a good response to surgery, these 
tumours rarely disseminate [40, 162-165].  Medulloblastoma and 
ependymoma both require further treatment beyond resection and they show 
dissemination [36, 44, 45, 166-172].  More aggressive tumours would benefit 
from an early, non-invasive diagnosis so as to allow for early treatment 
planning.   
 
For all tumours of the cerebellum, surgery is primarily the initial therapeutic 
intervention, meaning that tissue of these tumours has been extensively 
studied [56, 163, 165, 171, 173].  Since surgery is invariably performed on 
these tumours, a histopathological diagnosis is always offered, meaning that 
this patient group is ideal for testing analysis tools and classification schemes. 
 
There has been one published study analysing solely this tumour group [73, 
98].  This was performed using a long echo time [73] and used sophisticated 
pattern recognition techniques, not readily available to clinicians [73, 98].  
These studies showed that MRS can be used to distinguish between the 3 
main types of cerebellar tumour, with high accuracy.  
 
4.2 A DIAGNOSTIC SCHEME BASED ON MRS PEAK HEIGHTS 
FROM A RETROSPECTIVE ANALYSIS 
INTRODUCTION 
Successful studies utilising MRS commonly employ sophisticated data 
analysis techniques, including computerised pattern recognition [28]. This is 
not readily available to radiologists, meaning that interpretation of 
spectroscopy performed at diagnosis is often delayed. The difficulty of 
analysing MRS data remains a barrier to the widespread implementation of 
MRS in clinical practice.  
 
If this delay in interpretation of spectroscopic data could be reduced or 
removed then this may be used in conjunction with conventional MRI to aid in 
obtaining an accurate pre-surgical diagnosis. While we are reliant on 
sophisticated methods for data analysis this is not logistically feasible. This 
problem led to the development of a method for simple interpretation of 
spectroscopy at diagnosis for a well-investigated disease group, using only 
the software available on the scanner. This chapter develops an algorithm for 
paediatric brain tumour diagnosis using only the processing software currently 
available on conventional MR systems. 
 
A study by Wang et al [73] in 1995 used long echo time MRS (135/270ms) to 
assess the viability of distinguishing between tumours arising from this 
location using MRS, with promising results. This study successfully employed 
sophisticated discriminant analysis in order to differentiate the 3 main tumour 
groups and is not easily implemented at diagnosis. The longer echo time used 
also limited the amount of metabolite information extractable from the spectra 
 
A diagnostic tool was developed using data from BCH, processed by the 
Siemens’ NUM4 software, for use at the time of diagnostic imaging.  This was 
tested using a dataset accrued from MR scanners at three CCLG sites: BCH; 
QMC and RMH. This included data from Siemens’, GE and Phillips MR 
scanners. 
 
4.2.1 A DIAGNOSTIC SCHEME BASED ON MRS PEAK HEIGHTS FROM 
RETROSPECTIVE ANALYSIS 
METHODS 
The initial development of this scheme was performed using short echo time 
(TE=30ms; TR=1500ms) spectra solely from a Siemens’ Symphony at BCH, 
using NUM4 scanner software.   
 
Diagnosis was determined by standard histopathology of tumour specimens 
obtained at operation, this was verified by the local multidisciplinary team. 
Ethical approval was obtained for the study from the Local Research Ethics 
Committee and parental consent was obtained. All scans were pre-operative 
and performed before chemotherapy or radiotherapy was administered. The 
voxel had to be placed entirely within the tumour, maximally over the solid 
tumour component. The placement of the voxel was confirmed by storing MR 
images with the voxel location recorded (Figure 9).  Spectra were assessed 
using the quality control criteria outlined in chapter 3.2.3.   
Peak height ratios were generated between tCho, Cr, tNAA and mIns using 
the method outlined in chapter 3.2.3 giving six ratios.  Two-tailed t-tests were 
performed between tumour groups, those ratios showing no significance 
(P>0.05) were removed form further analysis. ROC curves were then 
produced for each of the remaining metabolite ratios for each tumour type, by 
plotting the sensitivity against the specificity. The area under the ROC curve 
(AUC) was taken to be the best measure of the accuracy of the test 
performed, these were calculated using matlab. An area of greater than 0.9 
was used to specify the metabolite ratios best able to discriminate between 
the tumour types. Scatter plots were created of the metabolite ratios that 
showed best discrimination, to check the distributions visually. Optimal cut-off 
values for each of the chosen metabolite ratios were taken to be the points at 
which the sensitivity plus specificity was at a maximum. From this data a 
simple decision tree classification scheme was built, using the cut-off values 
for the ratios that offered the best discrimination between groups. 
 
To explore the practical use of this method, and to assess user variability 
associated with measuring peak heights by hand, 20 spectra selected at 
random from the dataset were analysed by 2 radiologists and 2 scientists, 
blinded to the tumour type. These results were then compared against those 
calculated while designing this scheme. 
 
 
 
 
RESULTS 
MRI and short-echo-time MRS (TE=30ms) were performed on 31 children 
with cerebellar lesions, at the time of their initial diagnostic imaging, between 
1 January 2003 and 1 August 2006. A summary of patient details is given in 
table 1.  
Tumour Type No. Patients No. Patients Used* Mean Age No. Girls No. Boys 
PA 11 7 8.2 3 4 
Ependymoma 4 4 2.03 2 2 
Medulloblastoma 16 16 7.5 5 11 
*
number of patients whose spectra was of satisfactory quality to be used 
 
Table 1: Patient information for retrospective study of scanner produced spectra of cerebellar 
tumours 
 
Each patient had a PA (N=11), an ependymoma (N=4) or a medulloblastoma 
(N=16).  Of the 30 MRS investigations performed, data from two of the PA 
cases were excluded as the tumour size was smaller than that of a 1.5 cm 
sided cubic voxel leading to a significant level of contamination of the 
spectrum by uninvolved adjacent brain. Another spectrum, again of a PA, was 
excluded due to poor line width and poor SNR. In general, the MRS of PAs 
displayed a lower SNR than the other 2 tumour types.  
 
The only ratio to not show significance between any tumour groups was 
mIns/Cr; this was removed form further analysis.  ROC curves were 
generated for all remaining metabolite ratios, and the AUCs are given in table 
2.  
 
 
 
 
 Area Under ROC Curve (AUC) 
Ratio PA  
vs. all others 
Ependymoma 
vs. all others 
Medulloblastoma 
vs. all others 
Ependymoma  
vs. Medulloblastoma 
Cr/Cho 0.785 0.924 0.636 0.890 
NAA/Cho 0.889 0.527 0.761 0.688 
Ins/Cho 0.618 0.935 0.503 0.906 
NAA/Cr 0.964 0.810 0.594 0.789 
Ins/Cr     
Ins/NAA 0.850 0.946 0.676 0.923 
Table 2: AUC values for retrospective study of scanner produced spectra of cerebellar 
tumours.   
Values highlighted in red show those ratios offering good discrimination between specified 
disease type and other (AUC>0.85) 
 
NAA/Cr appeared to be the strongest discriminator between PA and other 
tumours other ratios offer moderate distinction on both P-values and AUCs. 
Cr/Cho, mIns/Cho and mIns/NAA all act as strong discriminators between 
ependymoma and other tumours. From this table it can be seen that there is 
no single ratio that can successfully separate all 3 groups. However, using a 
combination of ratios in a 2-stage classifier proved to be more successful.  
 
NAA/Cr can be used to determine whether a tumour is a PA or not, therefore 
this ratio can be used as stage 1. PAs are then removed from the second 
stage, which is to distinguish medulloblastoma spectra from ependymoma 
spectra. A combination of P-values and AUCs indicated that this is best 
achieved using Cr/Cho and mIns/NAA. Plots of both stages of this classifier 
can be seen in Figure 12.   
 
 
(a) NAA/Cr Vs Cr/tCho: all 3 cerebellar tumour types plotted 
Red circles – PA; green circles – ependymoma; blue circles – medulloblastoma 
 
 
(b) mIns/NAA Vs Cr/tCho: ependymoma and medulloblastoma 
Red circles – ependymoma; blue circles – medulloblastoma 
 
Figure 12: 2 step classification scheme for cerebellar tumours based on peak height ratio 
measurement 
 
Figure 12b indicates that a combination of both low Cr/tCho and low 
mIns/NAA is necessary to classify a spectrum as belonging to a 
medulloblastoma. Using this combination of ratios more comprehensively 
defines the boundaries for medulloblastoma, which is appropriate, as there is 
most data for this tumour type. In summary, the diagnostic tool consists of in 
two stages; high NAA/Cr is used to give the diagnosis of PA, and a low 
Cr/Cho and low mIns/NAA is used to classify medulloblastoma from the 
remaining ependymoma.  
 
 
Figure 13: Peak height classification scheme (version 1), based on data taken from the 3 
main tumour types of the cerebellum on the Siemens’ scanner at BCH. 
 
Based on this scheme, a new tumour may be assigned to one of the three 
tumour groups.  However, in practise, it is useful to have additional checks in 
place, using other metabolite ratios also known to be good discriminators. 
Adding these checks leads to the complete classification scheme, shown as a 
decision chart in Figure 13.  
 
In the test of user variability there was a 92.5% agreement between the 
results from the group of testers and the researcher. Since the method 
incorrectly classifies one spectrum from the peak heights determined by 
myself, the expected accuracy is 89.1%.  
 
DISCUSSION 
The peak height classifier described correctly classifies 26 out of the 27 
tumours, using short echo time single voxel MRS. The method was designed 
to aid the ongoing integration of MRS into routine clinical use. This is a simple 
and effective method which can be easily implemented by radiologists, at the 
time of the diagnostic imaging.  One of the main advantages to this scheme is 
it’s ability to be used as a guide for radiologists who are looking to gain 
experience in interpreting MRS. The scheme has a solid foundation of robust 
statistics and, therefore, a firm foundation for further data to be added and the 
scheme extended.  
 
Previous classification schemes have predominantly used long echo time 
MRS. The study by Wang et al [73] used peak area ratio’s, obtained by long 
echo time MRS, to classify childhood cerebellar tumours. They achieved a 
classification accuracy of 85%, using a linear discriminant analysis of 
NAA/Cho and Cr/Cho. The general finding of high NAA/Cho in astrocytomas 
and high Cr/Cho in ependymomas corresponds with results presented here. 
Myo-inositol was found to be an important feature in characterizing 
ependymomas and, in particular, discriminating ependymomas from 
medulloblastomas.  
The results of the current study show general agreement with findings of other 
studies. The high NAA/Cr in PAs, low Cr/Cho in medulloblastomas and high 
mIns/NAA in ependymoma agree with the findings by Panigrapy et al [71]. 
The high NAA/Cr in PAs agrees with many studies in adults which show a 
high value for this ratio in low grade, good prognosis tumours [67, 84, 97, 
105]. NAA/Cr has also been reported as being a good discriminator between 
high and low grade tumours in children [105]. The low Cr/Cho values in 
medulloblastoma is in agreement with studies that have associated this 
quantity with highly malignant tumours [66-68, 84, 97, 105]. The similar finding 
in PAs agrees with other studies of this tumour group [71, 73, 105]. This is 
surprising given the benign nature of these tumours, but this may be 
explained by a more detailed analysis of the specific choline metabolites 
which contribute to the total choline MRS signal [86, 98, 103]. 
 
(a) PA 
 
 
(b) Ependymoma 
 
(c) Medulloblastoma 
 
Figure 14: Average spectra for the three main cerebellar tumours  
 
A key feature to note in PA spectra is the presence of sharp NAA peak at 
2.0ppm (Figure 14a), along with a small or non-existent Cr peak at 3.03ppm. 
Both ependymoma (Figure 14b) and medulloblastoma (Figure 14c) spectra do 
not show a sharp peak at 2.0ppm, but rather show a broad peak between 2.0 
and 2.5ppm. Ependymoma show a particularly high peak for mIns at 3.6ppm, 
not seen in medulloblastoma. Tau is often seen in medulloblastoma spectra at 
3.35ppm, although this is not easily assigned visually due to it’s proximity to 
the tCho peak. 
 
With the advancement of technological processes, it is theoretically viable that 
it shall become possible to quantify increasing numbers of metabolites using 
MRS. This study supports the view that expansion of the metabolite profile 
improves its ability to characterize tumours. The method described in this 
section presents a scheme whereby information regarding additional useful 
metabolites can be incorporated into the algorithm in a consistent manner.  
One particular example is the peak at 3.35ppm due to taurine. This peak is 
commonly present in medulloblastomas [71, 96, 98, 100] and may aid the 
identification of these tumours.  
 
PAs showed the lowest SNRs of the tumours studied; this may be due to their 
low cellularity compared with other tumours [36]. This characteristic may be a 
useful discriminator for these tumours and demonstrates that spectra, which 
do not meet standard quality control criteria, may still possess useful 
information.  
 
An important advantage of this approach is that the same process may be 
used to incorporate further spectra into the model and hence further refine 
and improve the scheme presented. This is important, given that the current 
algorithm has been constructed using a relatively small number of cases, all 
of which were collected using a single scanner.  
 
CONCLUSIONS 
A simple peak height ratio classifier was developed as a diagnostic aid for the 
classification of childhood cerebellar tumours, with a high success rate 
determined using a retrospective analysis.  This scheme was developed using 
a small dataset, all collected from a single centre.  In order for this scheme to 
be of clinical use it needs to be robust to the addition of new data coming from 
various sources.  The next stage in the development of this classification tool 
is to test it prospectively and extend it using a larger dataset, including data 
from more than one centre. 
 
4.2.2 PROSPECTIVE EVALUATION OF PEAK HEIGHT CLASSIFIER 
INTRODUCTION 
Despite the increase in studies utilizing functional imaging in the diagnosis of 
brain tumours, few of these studies have published prospective studies 
associated with the schemes described within.  These are vital for evaluation, 
if the techniques are to be incorporated into regular clinical practice.  Single 
centre studies are subject to bias; these are usually based on data collected 
on a single MR scanner and often by the same operator.  By prospectively 
testing these schemes on, preferably, a multicentre dataset we can fully 
evaluate the method, assess how robust it is to a change of data type and 
reduce the chance that the results presented are biased.  We can also 
expand the scheme to include a larger dataset, this allows for refinement and 
expansion of scheme. 
 
The peak height classifier, presented previously, was highly successful on 
single centre data analysed retrospectively, correctly classifying 26 of 27 
spectra and having an agreement of 92.5% when using 4 blinded testers.  
However, this was restricted to a single centre (BCH) dataset acquired on a 
single scanner.  This study was expanded to include a more diverse dataset 
taken on both GE and Phillips systems, and other Siemens’ systems, at 3 
centres: BCH, Queen’s Medical Centre (QMC) and the Royal Marsden 
Hospital (RMH).  This data was collected and analysed prospectively. 
 
The peak height classifier for classifying cerebellar was published in 
September 2007; the final cut-off for inclusion of patient data was 01/08/06.  
Following this cut off date, data was accrued for further patients presenting on 
BCH, allowing a prospective analysis.  In addition to this all data accrued at 
QMC and RMH was collated and incorporated into the analysis.   
 
METHODS 
Spectra were obtained for new patients with cerebellar tumours at the time of 
diagnostic imaging at BCH, QMC or RMH using 1.5T MR scanners.  Ethical 
approval was obtained for the study from the Multicentre Research Ethics 
Committee and parental consent was obtained. 
 
Data was all collected using the same parameters to assure that data from 
different centres could be reasonably compared.  The only exception to this 
was some slight variation of echo time between centres (TE=28-35ms), but 
this was marginal and did not lead to any significant differences between 
spectra acquired.  This allowed for a direct comparison using data collected of 
various scanners, by different operators, in different centres.  Whereas the 
Siemens’ NUM4 software produced a flat baseline centred on the ppm axis, 
not all of the spectra from other software had a flat baseline due to variation in 
water suppression between scanners.  In cases where the baseline was flat, 
the peak heights were all measured from the baseline to the apex of each 
peak.  For those cases where the baseline was not flat, the peak height was 
taken to be the base of the individual peak to the apex.  
 
One new spectrum, acquired at QMC on a Phillips system, had very poor 
water suppression and in addition to this the screen capture had removed the 
lower part of the screen.  It was removed from statistical analysis as peak 
heights could not be accurately determined, although it was included in 
classification to assess whether problematic data could still be reasonable 
classified.   
 
Those new cases, that passed QC, were separated into 1 of 4 groups: PA, 
ependymoma, medulloblastoma and other.  These were assigned by 
histopathological diagnosis.  
 
Those tumours in the first 3 groups, i.e. the 3 tumour classes used in the initial 
scheme, were assessed using the classification scheme developed from the 
retrospective analysis presented in the previous section (Figure 13).  From 
this, classification rates were determined for the additional data. 
 
RESULTS 
MRI and short-echo-time MRS were performed on 36 children with cerebellar 
lesions between 16/02/05 and 01/07/08 at all 3 centres.   All of these patients 
underwent biopsy, leading to a diagnosis of 13 PA, 4 ependymoma, 14 
medulloblastoma, 2 atypical teratoid/rhyabdoid tumours (ATRT), 1 
ganglioglioma, 1 diffuse low grade astrocytoma (DA) and 1 high grade lesion 
of undetermined nature (HGT).  Of these 4 PA scanned on the Siemens’ 
Symphony at BCH failed to pass quality control, leaving a group of 9 PA for 
further consideration.  In addition, 1 of the medulloblastoma cases at RMH 
had to be removed due to incomplete data, leaving a total of 13 
medulloblastoma for further analysis.  Of the 31 cases that passed quality 
control, 26 were of one of the 3 original disease types, leaving 6 of new 
disease types not included in the original scheme.   
 
The new data, from tumours of one of the three original tumour types are 
plotted on the classification axes in Figure 15. 
 
 
(a) New cases plotted on the axes NAA/Cr Vs Cr/Cho: Red circles – pilocytic astrocytoma; 
green circles – ependymoma; blue circles – medulloblastoma 
 
(b) New ependymoma and medulloblastoma cases plotted on axes mIns/NAA Vs Cr/tCho: 
Red circles – ependymoma; blue circles – medulloblastoma 
Figure 15: New cases on the original classification axes for the peak height classification 
scheme 
 
 
 
Classification rates are summarised in table 3.   
   Classification 
Diagnosis No. 
Patients 
Correct Classification 
(%) 
PA Ependymoma Medulloblastoma 
PA 9 60 5 1 3 
ependymoma 4 50 0 2 2 
medulloblastoma 13 80 3 0 10 
Table 3: Classification Rates for prospective evaluation of classification scheme for cerebellar 
tumours, based on peak height measurement from spectra produced by MR scanner software 
 
In summary, the original peak height classifier had a correct classification rate 
65.4% on the new data, classifying 5 of the 9 PAs correctly, 2 of the 4 
ependymomas correctly and 10 of the 13 medulloblastomas correctly.   
 
DISCUSSION   
This study was performed to evaluate that the peak height classifier 
developed using peak height ratios of scanner produced spectra would be 
robust to new data of a variety of types.  Using the initial cut-off values and 
the original ratios (Figure 13) gave a moderate 65.4% classification rate of the 
new tumours.  It classified 10 of the 12 medulloblastoma spectra correctly, 5 
of the 9 PAs (1 of those misclassified was the PA from QMC with poor water 
suppression) and 2 of the 5 ependymoma spectra.   
 
One of the largest challenges in prospectively evaluating the peak height 
classifier was the inclusion of spectra produced by other scanners.  Different 
scanners offer a different amount of baseline correction and water 
suppression.  This can lead to a challenge in measuring peak heights 
accurately.  This may offer an explanation as to the relatively poor 
performance of the peak height classification scheme.  This is an inherent 
problem of measuring peak heights.  This is difficult to correct for in the 
scheme, although careful measurements made several times and averaged 
would assist in this. 
 
An additional issue with the scheme is the small number of cases in the initial 
development.  Paediatric brain tumours are relatively rare and constitute a 
wide variety of tumour types.  This leads to a small number of cases in 
individual groups, making the development of accurate classifiers 
complicated.  This was especially the issue with the ependymoma group, 
which only had 4 cases in the development of the classifier.  This was 
reflected in the mis-classification of 3 of the 5 new ependymoma cases.  One 
of the original ependymoma cases was also thought to be grade 3 rather than 
the standard grade 2 and did have a spectrum that appeared marginally 
different from the other 3 cases, which may have affected the cut-off values 
for this group.  More data is needed in each group to establish optimal ratios 
and cut-off values.  As more data is accrued it will be possible to distinguish 
between poor accuracy resulting from insufficient data and the issue 
surrounding the accurate measurement of peak heights on multicentre data. 
 
Individual centres do not receive many cases of individual tumour types, 
which shows the benefit of using a multicentre study.  The next stage of the 
development of this classifier for cerebellar was to combine the original single 
centre data with the newer cases from all centres to build a new classifier 
using the same methods that were used in the development of the original 
classification scheme. 
 
CONCLUSIONS 
The peak height classifier performed with a moderate accuracy on a more 
diverse data set acquired from a range of scanners at 3 centres.  The next 
stage in the development of a robust classification scheme was to combine 
single centre data with new multicentre data to build an updated classifier. 
 
4.2.3 UPDATING AND EXTENDING THE PEAK HEIGHT CLASSIFIER 
INTRODUCTION 
The original peak height classifier was developed using a comparatively small 
dataset.  This was especially true in the group of ependymomas, which had 
just 4 patients in.   
 
The classifier performed relatively poorly prospectively, when used to classify 
a dataset acquired from scanners at 3 centres.  This was especially true in the 
classification of ependymomas.  To assess whether this was due to the lack 
of data, a new version of the peak height classification scheme was 
developed.  The data used in the initial development of the classifier was 
combined with the new multicentre data.  This larger dataset of 58 spectra, 
including both old and new data, was then analysed retrospectively, using the 
same techniques as for the initial classifier, to create a new scheme.  
 
Previously, the classifier has only been used in the assessment of the 3 most 
common cerebellar tumours.  However, other tumours can occur here in 
addition to these.  In the analysis of this new scheme, these tumours have 
been analysed alongside the more common tumours to assess of key 
features present in MRS of these rarer tumours. 
 
METHODS 
Data was accrued on 1.5T clinical MR systems from Siemens’, GE and 
Phillips and processed using the inbuilt software on each scanner.  A simple 
flow diagram is depicted in figure 16 to show how the data goes from being 
acquired at the hospital of diagnosis through quality control and onto analysis. 
 
Figure 16: A flow diagram showing the path of data, from acquisition to analysis 
 
All the new spectra were subjected to the same quality control criteria as used 
previously (section 4.2.1), including the removal of the QMC spectrum with 
poor water suppression and an incomplete screen capture from statistical 
analysis.   
 
The complete dataset was retrospectively analysed in the same way as for 
the original classifier, to determine which ratios offered the best discrimination 
between groups.  This was done by using two-tailed t-tests to detect the ratios 
which offered the most significant difference between groups.  In addition to 
metabolites used previously, peaks associated with LMM resonances were 
measured at 1.3ppm and 0.9ppm (LMM1.3 and LMM0.9 respectively).  Ratios 
between these and tCho were generated and used in the ANOVA and further 
analysis.  Metabolite ratios offering the highest significant difference were 
used to plot ROC curves and the AUC values calculated.  Ratios offering the 
highest AUC values were used to build an updated classifier, with optimal cut-
off values being calculated as being the value where sensitivity plus specificity 
was at a maximum.  
 
Tumours that fell into the ‘other’ category were assessed for their main 
spectral characteristics.  Ratios between peaks were calculated for these 
tumours and these results were analysed using the updated classifier.  This 
allowed for an assessment as to similarities and differences with the 3 main 
tumour types, and to predict which tumour these rare cases would have been 
assigned using this scheme. 
 
RESULTS 
Of the 31 cases that passed quality control, 26 were of one of the 3 original 
disease types, leaving 5 of new disease types not included in the original 
scheme.  These 5 tumours consisted of 2 atypical teratoid/rhabdoid tumours 
(ATRTs), 1 ganglioglioma, 1 diffuse grade 2 astrocytoma (DA2) and 1 high 
grade tumour of undefined type (HGT).  These 31 new cases were then 
added to the original 27 spectra giving a total of 58 spectra, of which 53 were 
of the three groups originally classified. 
 
Results of the two-tailed t-tests between PA Vs 
ependymoma+medulloblastoma and ependymoma Vs medulloblastoma can 
be seen in table 4.   
 P-Value 
Ratio PA Vs Other Medulloblastoma Vs Ependymoma 
Cr/Cho 0.785 0.005 
NAA/Cho <0.001 0.019 
Ins/Cho 0.272 <0.001 
NAA/Cr <0.001 0.212 
Ins/Cr 0.330 0.075 
Ins/NAA <0.001 0.013 
LMM0.9/Cho 0.015 0.184 
LMM1.3/Cho 0.436 0.296 
LMM0.9/LMM1.3 0.044 0.621 
Table 4: T-Test results for re-optimising the classification scheme for cerebellar tumours 
based on spectra from the scanner software 
 
The ratios with the highest significance difference between PAs and the other 
2 tumour types were: NAA/Cho; NAA/Cr and mIns/NAA.  All of these had P-
values less than 0.001.  The ratios offering the highest significant difference 
between ependymoma and medulloblastoma spectra were Cr/Cho (P=0.005) 
and mIns/Cho (P<0.001). 
 
 
 Area Under ROC Curve (AUC) 
Ratio PA vs. all Ependymoma 
vs. all 
Medulloblastoma 
vs. all 
Ependymoma vs. 
Medulloblastoma 
Cr/Cho 0.849 0.944 0.562 0.918 
NAA/Cho 0.882 0.659 0.872 0.830 
mIns/Cho 0.677 0.985 0.608 0.978 
NAA/Cr 0.998 0.749 0.818 0.610 
mIns/Cr 0.624 0.696 0.716 0.862 
mIns/NAA 0.912 0.894 0.615 0.840 
LMM09/Cho 0.834 0.560 0.795 0.670 
LMM13/Cho 0.690 0.596 0.635 0.661 
LMM09/LMM13 0.739 0.640 0.639 0.525 
Table 5: AUC values for prospective study of scanner produced spectra of the 3 main 
cerebellar tumour types.   
Values highlighted in red show those ratios offering good discrimination between specified 
disease type and other (AUC>0.85) 
 
AUCs for PA against ependymoma+medulloblastoma (table 5) showed very 
high AUC values for NAA/Cr and mIns/NAA.  In addition to these ratios, 
Cr/Cho, NAA/Cho and LMM0.9/Cho also showed high AUC values.  AUCs for 
ependymoma against medulloblastoma (table 5) showed a very high AUC for 
mIns/Cho.  Cr/Cho and NAA/Cho both exhibit high AUC values as well.  Stage 
2 was attempted using mIns/Cho alone, with Cr/Cho and NAA/Cho as checks 
for verification of class assignment.  These ratios were used to develop a 2-
step classification scheme, as for the original scheme.    
 
 
 
(a) Step 1: NAA/Cr Vs mIns/NAA. Red circles – pilocytic astrocytoma; green circles – 
ependymoma; blue circles medulloblastoma 
 
 
 
(b) Step 2: mIns/tCho Vs Cr/tCho.  Red circles – ependymoma; blue circles – 
medulloblastoma 
 
Figure 17: All data, both from original classification scheme and additional new multicentre 
data, plotted on classification axes. 
 
Cut-off values were determined for all of these ratios giving the following 
classification scheme (Figure 18): 
 
 
Figure 18: Version 2 of the peak height classifier, based on data taken from the 3 main 
tumour types of the cerebellum on various scanners at BCH, RMH and QMC. 
 
This updated peak height classifier offered a correct classification rate of 
90.6%, correctly classifying 48 of the 53 spectra (table 6).   
   Classification 
Diagnosis No 
Patients 
Correct 
Classification 
PA Ependymoma Medulloblastoma 
PA 16 93.8% 15 1 0 
Ependymoma 8 87.5% 0 7 1 
Medulloblastoma 29 89.7% 2 1 26 
Table 6: Classification of cerebellar tumours using a multicentre dataset. 
 
Misclassifications include 1 ependymoma being classified as a 
medulloblastoma, 2 medulloblastoma being classified as a PA, 1 
medulloblastoma being classified as an ependymoma and the outlier PA 
being classified as an ependymoma.   
 
OTHER TUMOURS OF THE CEREBELLUM 
Tumours that did not fall into one of the 3 previously defined groups comprise 
a diverse group.  There were 4 tumour types in the group; each of these had 
only 1 or 2 cases.   Values for each of the ratios are shown in table 7. 
 ATRT DA2 ganglioglioma HGT 
Ratio Average StdErr Value Value Value 
Cr/Cho 0.123 0.050 1.245 0.651 0.590 
NAA/Cho 0.584 0.299 1.129 1.005 0.967 
mIns/Cho 0.386 0.293 1.299 0.499 0.872 
NAA/Cr 4.502 0.580 0.907 1.543 1.638 
mIns/NAA 0.547 0.222 1.150 0.496 0.903 
mIns/Cr 2.593 1.318 1.043 0.766 1.479 
LMM0.9/Cho 0.661 0.451 0.152 0.283 0.521 
LMM1.3/Cho 0.838 0.515 0.000 0.448 1.902 
LMM0.9/LMM1.3 1.799 1.644  0.632 0.274 
Table 7: Values for ratios in rare tumours of the cerebellum 
 
Assignments using the scheme outlined in Figure 18 are summarised in table 
8.   
  Classification 
 No Patients PA Ependymoma Medulloblastoma 
ATRT 2 1 0 1 
DA2 1 0 1 0 
ganglioglioma 1 0 0 1 
HGT 1 0 1 0 
Table 8: Classification of rare tumours of the cerebellum using revised peak height classifier 
 
There were 2 cases of ATRT in the dataset; each of these had a different 
profile.  This led to relatively large errors in the ratio values for this group.  The 
average NAA/Cr is high for this group, comparable with PA values.  This is 
caused by one of the 2 cases having a very high NAA/Cr value.  This would 
clearly be problematic clinically, since these 2 tumours carry a vastly different 
prognosis and require very different treatment strategies.  However, for the 
ATRT case, this is due to a very low Cr peak, and not a high NAA.   
 
The DA2 spectrum exhibits a high mIns peak, and thus shows high values for 
ratios containing mIns. This tumour would be classified as an ependymoma 
using the updated peak height classifier.  However, these values are still 
lower that those typically seen in ependymoma spectra.  The spectrum of the 
DA2 also shows very small LMM peaks that could be used to distinguish it 
from ependymoma. 
 
The HGT has a value for HGT close to the cut-off value for distinguishing 
between medulloblastoma and ependymoma spectra.  Since we do not know 
the nature of this tumour, no comment can be made with regards the 
spectrum, other than it appears high grade. 
 
The ganglioglioma is classified as a medulloblastoma on step 2 of the 
updated peak height classifier.  However, NAA/Cho is much higher than 
would be expected a medulloblastoma and the ratios mIns/NAA and mIns/Cr 
are lower than in medulloblastoma.   
 
DISCUSSION   
This study was performed to update and extend the original peak height 
classifier, using a larger basis set.  
 
By performing an ANOVA and recalculating AUCs for ROC curves for each 
class, new ratios were selected to give the best discrimination.  This was 
formulated into a new updated peak height classifier (Figure 18), which now 
uses 2 ratios in the first stage and 1 in the second.  NAA/Cr remained the best 
discriminator between PAs and other tumour types, but by adding information 
about mIns/NAA this was improved.   However, the cut-ff value is 
considerably lower than previously.  By including information from a second 
ratio, mIns/NAA, accuracy of classification was improved.  Only one ratio, 
mIns/Cho was now needed for the second stage.  This updated peak height 
classifier offered a classification rate of 90.6%, correctly classifying 48 of the 
53 spectra, 1 of those misclassified was the PA from QMC with poor water 
suppression.   
 
ATRT spectra both showed a strong signal for LMM at 1.3ppm, as did the 
HGT spectrum.  This would be in keeping with these tumours being of a high 
grade [66, 68, 84, 94].  The DA2 spectrum sits closely with the ependymoma 
spectra due to the presence of a high mIns peak.  The elevation of mIns is in 
keeping with observations made in diffuse gliomas [112] and grade 2 gliomas 
[67, 128].   
 
This ATRT group also showed the problems surrounding analysing groups 
with a small number of cases in, the spectra showed many differences from 
each other.  This group also showed the importance of knowing which 
metabolite of the ratio is varying.  The NAA/Cr ratio of ATRT and PAs are 
high.  However, in PAs this is due to NAA being elevated, whereas in ATRT 
this is due to Cr being decreased. 
 
Classification of small numbers of many types of different tumours is a 
challenge for any classification scheme; this is particularly difficult in a simple 
rule based classifier. However, the rarer tumours of the cerebellum have all 
shown some significant differences in their spectra from the tumours they 
would be misclassified as.  These differences are consistent with their known 
biological characteristics which is encouraging.  This again points to the need 
for the scheme to be extended with more data for a further prospective 
evaluation.   
 
4.2.4 CONCLUSIONS: DIAGNOSTIC SCHEME BASED ON MRS PEAK 
HEIGHTS  
There are highly significant differences between the mean metabolite profiles, 
and metabolite ratios, of the major tumour types of the cerebellum of children.  
However, there is considerable variability in the MRS profiles within each 
tumour type.  This means that there is no one metabolite ratio that can 
completely distinguish between these tumours.  However, a combination of 
metabolite ratios can be used to distinguish between childhood cerebellar 
tumours with a high accuracy. 
 
The prospective evaluation performed of the original peak height classifier, 
gave moderate classification accuracy of 65.4%.  To assess the factors was 
influencing the poor classification rate, a dataset combining the original and 
multicentre data was assembled and, from this, a new classifier was 
constructed.   
 
This new version of the peak height classifier correctly classified 48 of the 53 
cases in the combined dataset.  One PA with a very poor baseline and partial 
screen capture was misclassified as an ependymoma, thus highlighting the 
importance of quality control.  Of the other tumours, three medulloblastoma 
cases and one ependymoma case were misclassified.  This gave a high 
classification accuracy of 90.6%.  The high classification accuracy on the 
larger dataset implies that the inaccuracy of the original classifier on the 
prospective data was largely due to the small dataset involved rather than 
variability introduced by multiscanner data or an inherent weakness of the 
approach.  However this needs to be verified by further prospective study and 
the addition of further on data to the scheme, as it is accrued, will refine the 
cut-off values further. 
 
Another benefit from a larger cohort is the inclusion of data from rarer tumour 
types.  Classification of small numbers of many types of different tumours is a 
challenge for any classification scheme; this is particularly difficult in a simple 
rule based classifier. However, the rarer tumours of the cerebellum have all 
shown some strong differences in their spectra from the tumours they would 
be classified as using the straightforward classifier for the 3 major tumour 
types of the cerebellum.  These differences are consistent with their known 
biological characteristics. 
 
The original scheme has been put into use at BCH since its development, but 
the radiologists used in the scheme’s original testing phase.  The ease of use 
has made this simple to put forward.  A simple explanation into its usage and 
a copy of the peak height classification scheme (figure 13) is all that is 
required for this to be achieved.  An updated version of this will be supplied 
(figure 18) to replace the outdated scheme. 
 
Up to this point, analysis has been made by visually inspecting screen 
captures of spectra, as they are processed by MR scanner software.  This is a 
quick and easy method that is simple to implement in a clinical scenario.  
However, information on more metabolites, and potentially more accurate 
information on the major metabolites, can be extracted from a spectrum than 
it is possible to obtain by measuring peak heights if a more sophisticated 
method of spectral analysis is applied.  LCModel™ can be used to obtain a 
list of concentrations relative to water of a larger list of metabolites than it is 
possible to assess visually, and can potentially give more accurate 
concentrations for metabolites, such as NAA, which overlap with other 
spectral features.  More information would also aid in constructing a more 
complete picture of the metabolites present in the tumours.  As such, the next 
stage in the development of an analysis tool for cerebellar tumours was to 
construct a classifier based upon these metabolite concentrations, and to 
compare the classification rate with that of the simple peak height classifier. 
 
 
4.3 A DIAGNOSTIC SCHEME BASED ON LCMODEL™ 
METABOLITE CONCENTRATIONS 
INTRODUCTION 
A comparison of methods was performed to assess whether building a 
classifier using concentrations generated by software such as LCModel™ 
[120] is superior to a simple one based on peak height measurement.  
 
To ensure a fair comparison, data from the same patients were used in the 
development of both classifiers. The same analysis methods were used to 
decide features offering the best discrimination in both classifiers.  
 
METHODS 
MRS was acquired using a PRESS sequence with an echo time of TE 30ms, 
for all patients used in the development of the original peak height classifier. 
All raw MRS data was processed using LCModel™, to obtain a table of 
metabolite and LMM concentrations along with measures for SNR and 
FWHM. 
 
Quality control was applied using the following measures, as given by 
LCModel™:  
1. SNR had to be greater than 4   
2. FWHM had to be less than 0.150ppm  
Spectra were also checked visually to ensure phasing was satisfactory, 
residual water signal was not excessive and the spectra were free of 
artefacts. 
Initially, only the metabolites used in the peak height classifier were used in 
developing the concentrations-based classifier (mIns, tCho, Cr and tNAA).  
Ratios were calculated between these values to ensure that a direct 
comparison was being made between methods.  Analysis was performed in 
the same way as for the peak height classification scheme.  
 
Following this, all metabolites and three LMM (0.9ppm, 1.3ppm and 2.0ppm) 
concentrations were used to develop this classifier.  Ratio were not calculated 
for the analysis, rather the concentrations relative to water were used for 
analysis.  A PCA was performed using this complete basis set to assess 
variance across all data.  Following this an ANOVA was performed to 
determine the metabolites that offer the highest significant difference between 
groups. 
 
To compare the robustness of the simple peak height classifier with the more 
sophisticated LCModel™ scheme, a prospective analysis was performed 
using the scheme developed with the absolute values and the complete basis 
set.  The same data were used in studies assessing the peak height 
classification scheme and the metabolite concentration classification scheme.  
Tumours falling into one of the original three tumour groups were classified, 
spectra of rarer cerebellar tumours were assessed for which group they would 
be classified as, and for key features in their spectra. 
 
 
 
4.3.1 AN ENHANCED DIAGNOSTIC SCHEME BASED ON METABOLITE 
CONCENTRATIONS DETERMINED FROM RETROSPECTIVE ANALYSIS 
USING ONLY A LIMITED SET OF METABOLITE CONCENTRATIONS 
To begin with, a scheme was developed using ratios between four 
metabolites concentrations: mIns, tCho, Cr and tNAA.  
 
RESULTS 
All of the spectra included in the development of the initial peak height 
classifier passed quality control, using the defined parameters.   
 
Performing an ANOVA removed the ratios mIns/Cr and mIns/tNAA from 
further analysis (table 9) 
 
  AUC 
Ratio P-Value PA Vs Other Ependymoma Vs 
Other 
Medulloblastoma Vs 
Other 
Cr/tCho <0.001 0.800 0.929* 0.645 
tNAA/tCho <0.001 0.932* 0.625 0.795 
mIns/tCho <0.001 0.529 0.967* 0.591 
tNAA/Cr <0.001 0.986* 0.614 0.713 
mIns/Cr 0.340    
mIns/tNAA 0.710    
Table 9: ANOVA and AUC results for using ratios of LCModel™ derived metabolite 
concentrations in the classification of cerebellar tumours 
*Values highlighted in red show those ratios offering good discrimination between specified 
disease type and other (AUC>0.85) 
 
 
Cr/tCho, tNAA/tCho, mIns/tCho and tNAA/Cr all had P values smaller than 
0.05, and were used in ROC curve analysis. Results of this (table 9) showed 
that the AUCs were lower than for using the peak heights, with only 3 of the 
12 curves demonstrating AUCs greater than 0.9.  
The strongest discriminator between PAs and other cerebellar tumours was 
tNAA/Cr, as was found in the original peak height classifier. Cr/tCho and 
mIns/tCho both act as strong discriminators between ependymoma and the 
other 2 tumour groups. By using a combination of tNAA/Cr and mIns/tCho a 
reasonable separation can be seen between the three groups (Figure 19), 
using only one stage.  
 
 
 
Figure 19: Scatter plot showing cerebellar tumour separation on the axes tNAA/Cr Vs 
mIns/tCho using LCModel™ generated metabolite concentrations 
Blue Squares – PA; Green triangles – ependymoma; red circles medulloblastoma 
 
Cut-off values were determined by maximising sensitivity plus specificity.  The 
cut-off value for NAA/Cr was 0.35; and the value for mIns/tCho was found to 
be 3.47 (as shown by dashed lines in Figure 19). If a spectrum showed values 
for tNAA/Cr>0.35 and mIns/tCho<3.47 it was deemed to be that of a PA. For a 
spectrum to be considered a medulloblastoma, it had to exhibit tNAA/Cr<0.35 
and mIns/tCho<3.47. Spectra with values for tNAA/Cr<0.35 and 
mIns/tCho>3.47 were considered to belong to ependymoma. This results in 
the misclassification of three medulloblastoma spectra. Two medulloblastoma 
are classified as PA and one as ependymoma. This error was not reduced by 
incorporating information from other ratios. This gives a classification rate of 
88.9%, in comparison with 89.1% based on peak heights alone. 
 
4.3.2 AN ENHANCED DIAGNOSTIC SCHEME BASED ON METABOLITE 
CONCENTRATIONS DETERMINED FROM RETROSPECTIVE ANALYSIS 
USING A FULL SET OF METABOLITE CONCENTRATIONS 
To follow on from the scheme based on ratios between metabolite 
concentrations of mIns, tCho, Cr and tNAA, a more complete data set was 
used. A total of 19 metabolite and 3 LMM concentrations were used in the 
following analysis. 
 
 
 
 
 
 
 
 
 
 
 
RESULTS  
The results from the PCA are shown in Figure 20a.   
 
 
 
(a) Principal Component Analysis of LCModel™ produced metabolite and LMM 
concentrations of the 3 main tumour types of the cerebellum, principal 
components 1 (x-axes) and 2 (y-axes). 
Red circles – pilocytic astrocytoma; green circles – ependymoma; blue circles – 
medulloblastoma 
 
 
(b) Loadings plot for PC1            (c) Loadings plot for PC2 
 
Figure 20: Principal Component Analysis of metabolite and LMM concentrations for cerebellar 
tumours 
 
The PCA clearly shows good separation of the three groups, and the loadings 
plots highlight the key metabolites in achieving this separation of data (Figure 
20b and 17c).  There does appear to be one ependymoma lying separately 
from the other three, this was the grade 3 ependymoma. 
   
Results of the ANOVA are shown in table 10: 
  PA Ependymoma Medulloblastoma 
Metabolite P-Value Average  StdErr Average  StdErr Average  StdErr 
Ala 0.035 0.99 0.08 0.35 0.09 0.93 0.02 
Asp 0.130 0.27 0.03 0.00 0.00 0.43 0.03 
Cr 0.0002 0.53 0.02 4.76 0.43 3.18 0.10 
GABA 0.001 0.10 0.01 0.55 0.12 0.71 0.02 
Glc 0.096 1.21 0.07 0.63 0.14 0.65 0.04 
Gln 0.0001 1.90 0.13 4.41 0.46 1.28 0.07 
Glu 0.024 1.30 0.10 1.46 0.20 2.68 0.08 
mIns 0.0001 1.38 0.10 11.10 1.02 4.72 0.18 
Lac 0.970 2.23 0.07 2.06 0.22 2.26 0.11 
NAA 0.093 0.64 0.05 0.43 0.06 0.35 0.02 
NAAG 0.032 0.15 0.02 0.09 0.01 0.06 0.00 
sIns 0.048 0.05 0.01 0.39 0.06 0.44 0.02 
Tau 0.001 0.07 0.02 0.73 0.21 1.89 0.07 
GPC 0.061 0.94 0.05 2.18 0.20 1.68 0.06 
PCh 0.001 0.12 0.04 0.20 0.10 1.76 0.07 
Gua 0.350 1.50 0.09 1.89 0.42 2.10 0.05 
tCho 0.0002 1.06 0.03 2.38 0.28 3.44 0.08 
tNAA 0.021 0.79 0.06 0.52 0.08 0.36 0.02 
Glx 0.061 3.77 0.11 5.86 0.41 3.97 0.10 
LMM0.9 0.150 9.64 0.77 6.99 0.54 11.71 0.27 
LMM1.3 0.092 24.78 2.27 18.84 3.51 42.13 1.58 
LMM2.0 0.003 8.81 0.42 11.63 0.90 14.80 0.23 
Table 10: ANOVA results using a full LCModel™ basis set, and average values for each 
tumour type.  Metabolites in italics represent those that are not always reliably quantitated 
and have a tendency towards having larger CRLB values.  Metabolites in red show those with 
P < 0.01 (only those with low CRLB) 
 
Three of the four metabolite concentrations offering the highest P-values were 
used, in both the peak height classifier and the limited basis set LCModel™ 
analysis: mIns (p<0.0001), Cr (p=0.0002) and tCho (p=0.0002). Of these, 
mIns was the most significant (p<0.0001).  Myo-inositol was highest in 
ependymoma spectra (11.10±1.02), compared with medulloblastoma 
(4.72±0.18) and PA (1.38±0.10) spectra. Cr was lowest in PA (0.53±0.02) 
spectra, and higher in both medulloblastoma (3.18±0.10) and ependymoma 
(4.76±0.43) spectra. Total Cho was higher in the more malignant tumours, 
medulloblastoma (3.44±0.08) and ependymoma (2.38±0.28), compared with 
the PA (1.06±0.03). Other factors of significance were GABA, Gln, Tau, PCh 
and LMM2.0, all exhibiting p-values < 0.01. Ala, Glu, NAAG, sIns and tNAA 
also showed some significance, with p-values < 0.05.  Metabolites that 
repeatedly exhibit poor CRLB were excluded from further analysis despite 
showing significance; these include Gln, Glu, PCh and Ala. Average values 
for each of these metabolite concentrations for each of the 3 tumour types are 
listed in table 10.    As for the chapter 4.2, ROC curves were calculated (table 
11): 
 PA vs. all other Ependymoma vs. Medulloblastoma 
Metabolite P-Value AUC P-Value AUC 
Cr <0.0001 0.986 0.164 0.750 
mIns <0.0001 0.950 0.045 0.891 
Lac 0.977 0.607 0.755 0.516 
sIns <0.0001 0.921 0.777 0.547 
Tau <0.0001 0.929 0.062 0.813 
tCho <0.0001 0.993 0.160 0.734 
tNAA 0.054 0.793 0.395 0.656 
Glx 0.242 0.636 0.099 0.844 
LMM0.9 0.632 0.593 0.011 0.844 
LMM1.3 0.141 0.671 0.037 0.828 
LMM2.0 0.002 0.857 0.182 0.703 
Table 11: P-values and AUC values for retrospective study of LCModel processed spectra of 
cerebellar tumours. For a comparison with the chapter 4.2.1, these have been calculated for 
firstly comparing Pas with the other two tumour groups and then comparing Ependymomas 
with Medulloblastomas   
Significant values are highlighted in red 
 
A combination of Cr and tCho offered the best separation between PAs and 
the other two tumour groups (Figure 21a):  
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Figure 21a: Scatter plot of tCho Vs Cr 
Red – pilocytic astrocytoma; green – ependymoma; blue – medulloblastoma 
 
 
The cut-off for classification of a PA would be Cr < 0.94 and tCho < 1.40, this 
gives 100% correct classification of PAs in this group.   
 
Using the same methods as chapter 4.2.1, a 2-step classification scheme can 
be assessed, using figure 21a to distinguish PAs from the other two tumour 
types and a further stage to look at distinguishing ependymoma and 
medulloblastoma.  From table 11, it can be seen that only mIns offers a 
significant difference between these two groups using an AUC > 0.85 for 
significance.  However, LMM0.9 is close to significance on AUC values, and 
has a P-Value of 0.011 using a two-tailed t-test, plotting these gives (figure 
21b). 
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Figure 21b: Scatter plot of LMM0.9 vs. mIns 
Green – ependymoma; blue – medulloblastoma 
 
The cut-off for classification of a ependymoma would be mIns > 8.67 and 
LMM0.9 < 10.29, this misclassifies one ependymoma.  The PA spectra all 
exhibit low concentrations of both tCho and Cr, clustering closely together. 
PAs are generally characterised by low concentrations of all metabolites. Of 
the ependymoma spectra, three exhibit very high mIns concentrations, and a 
low LMM0.9 concentration. The medulloblastoma spectra show lower 
concentration of mIns than ependymoma spectra, and higher LMM0.9, 
although this has a larger spread.  Using the cut-off values described, only 
one spectrum would be misclassified.  This spectrum is that belonging to the 
grade 3 ependymoma spectrum, thus highlighting the issues surrounding 
using small groups with variability within them. 
 
 
(a) 
 
 
 
 
 
 
(b) 
 
 
Figure 22: Bar charts showing the average (a) metabolite and (b) LMM concentrations for 
each of the 3 major tumour types of the cerebellum, as determined from LCModel™ 
 
Looking at a bar chart showing the average concentrations for each 
metabolite and LMM region (Figures 22a and 22b), all differences can be 
seen.  Again, the concentrations of metabolites in PA spectra can be seen 
across a majority of metabolites. Cr is highest in ependymoma spectra and 
lowest in PA spectra, with a moderate value for the medulloblastoma spectra. 
PCh is highly elevated in medulloblastoma spectra compared with the other 2 
tumour types. Tau is also elevated in medulloblastoma spectra. The total NAA 
signal is moderately elevated in the PA spectra compared with the other 
tumours. Other smaller metabolites also vary between the groups.  LMM1.3 is 
elevated in medulloblastoma, when compared with PA and ependymoma 
spectra.   
 
 
 
 
 
DISCUSSION 
The most significant metabolite ratios for distinguishing between these groups 
are still the same as those used in both the peak height classifier and the 
classifier using a limited LCModel™ basis set: Cr, tCho and mIns.  Indicating 
the largest changes do occur in the metabolites offering the largest signals. 
However, using the complete basis set allows the assessment of more subtle 
changes occurring in these tumours in metabolites that are not measureable 
by hand.  
 
The ratio of mIns/tNAA was highly significant in the peak height classifier, 
which was not seen when using metabolite concentration ratios. However, two 
of the medulloblastoma spectra show very low concentrations of tNAA, thus 
leading to a large variability within the group. This was not seen using peak 
heights, since there was always a peak present at 2.0ppm, even if this was 
not wholly due to tNAA. This highlights a flaw in the peak height measurement 
technique, we cannot determine, without fitting to the spectrum, which 
metabolite is giving rise to a peak. Thus, it is likely that, at times, we will be 
assigning and measuring peaks which are not due to the metabolite expected. 
Maybe it would be more accurate to simply state the chemical shift being 
measured, and stating that the peak present at this resonance varies between 
spectra, as opposed to attempting to formally assign them using the peak 
height measurement technique. 
 
This work compliments and extends work performed by Wang et al [73] in 
1995, where ratios between concentrations were used to separate cerebellar 
tumours.  This was performed by using a combination of NAA/Cho and 
Cr/Cho, with a diagnostic accuracy of 85%. This accuracy is similar to that 
seen using the data collected at BCH.  
 
The classifier based on a limited set of metabolite concentration ratios 
successfully classified 24 out of the 27 cases, in a 1-step classification 
scheme. It classified all of the ependymoma and PA spectra correctly, but 
failed to correctly classify 3 of the medulloblastoma spectra. This means that 
its performance was inferior to the classifier based on peak height 
measurements, in which only 1 PA spectra was mis-assigned. Although, the 
expected accuracy of the peak height measurement method is 89.1%, due to 
this user variability.  The method using metabolite concentrations does not 
suffer from user variability. This would lead to the two schemes being of 
comparable accuracy.  
 
However, LCModel™ gives much more information than can be visually 
assessed in a scanner-processed spectrum, including information from 
smaller peaks not easily quantifiable “by eye”. In addition to this, ratios are not 
required when using the concentrations. The concentrations given by 
LCModel™ are already referenced to water concentration. If a comparison is 
to be made between methods of analysing a spectrum, all these 
concentrations should be used in building a classifier. 
 
Ependymoma spectra show elevated Cr and mIns signals, which have both 
been observed previously in these tumours [98, 174].  An interesting finding is 
the presence of a decreased mIns signal in the grade 3 ependymoma relative 
to the grade 2 ependymomas, allowing it to be differentiated.  However, only 
one grade 3 and three grade 2 ependymoma were available in the sample, 
meaning no conclusions can be drawn from this finding without the 
assessment of further data from both grades of ependymoma. PA spectra all 
showed decreased Cho signals, in keeping with these tumours being of a 
lower grade [67, 72, 74, 93, 97, 175]. Of the three tumour types, 
medulloblastomas showed the highest tCho, LMM0.9ppm and LMM1.3ppm, in 
keeping with these being of the highest grade [28, 29, 72, 174, 175]. 
 
Changes are also observed in metabolites with smaller signals, such as tau. 
This has previously been shown to be elevated in medulloblastoma spectra 
[71, 96, 98, 100], in keeping with observations made here, which could 
potentially be used as a characteristic of these tumours.  One 
medulloblastoma would be misclassified as an ependymoma in the scheme 
using only the main metabolites, due to a high concentration of mIns.  
However tau is elevated in this tumour meaning that misclassification could 
potentially be avoided. Knowledge of the presence of this metabolite in 
medulloblastoma spectra may be useful in the correct classification of 
tumours with some unusual features in the spectrum. 
 
The classification rate of this scheme, using only two metabolites is 96.3%. 
However, the misclassified ependymoma is thought to be grade 3 rather than 
grade 2, which is assigned to the other three cases in this study.  However, 
looking at the tau signal can question the misassignment of this as a 
medulloblastoma.  No Tau is present in this spectrum, which may assist in the 
correct classification. 
 
4.3.3 PROSPECTIVE EVALUATION – DIAGNOSTIC SCHEME BASED ON 
METABOLITE CONCENTRATIONS  
Data used in prospective testing of the peak height classification scheme was 
subjected to the same quality control criteria as for the initial development of 
the initial metabolite concentration classification scheme.  Spectra which 
passed quality control were assessed prospectively.  
 
RESULTS 
There were 26 patients in the multicentre dataset, with one of the three 
original tumour types having LCModel™, which passed the quality control 
criteria (SNR ≥4; FWHM ≤0.15ppm).  The diagnoses of these can be 
summarised: 
o 9 PA (8 from BCH and 1 from QMC) 
o 2 ependymoma (1 from BCH and 1 from QMC) 
o 15 medulloblastoma (10 from BCH, 3 from QMC and 2 from RMH) 
There was a medulloblastoma patient included in this study from RMH which 
was not used in the peak height classifier testing, due to no screen capture 
being saved.  Some of the patients included in this study failed quality control 
for the peak height classification scheme, but passed the boundaries placed 
for this analysis.  Tumours outside of the original classification scheme 
consisted of: two ATRT, one DA2, one ganglioglioma and one HGT. 
 
The scheme based on the metabolite concentrations correctly classified 
72.7%. A plot showing the all cases on the original axes is shown in Figure 
23:  
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Figure 23: All cases, new and old from all 3 contributing centres 
Red circles – old PAs; red crosses – new PAs; green circles – old ependymoma; green 
crosses – new ependymoma; blue circles – old medulloblastoma; blue crosses – new 
medulloblastoma 
 
One of the PAs was misclassified, exhibiting slightly elevated Cr compared 
with the others, although this spectrum did still exhibit a low concentration of 
tCho compared with the other tumours. Both of the two ependymoma spectra 
were misclassified as medulloblastoma, with low concentrations of mIns.  This 
was similar to that shown in the grade 3 ependymoma spectrum.  Three of the 
medulloblastoma spectra were misclassified, one of these as a PA and the 
other two as ependymoma. 
 
In summary, the original scheme had a correct classification rate 72.7% on 
the new data, which is a moderate improvement on the peak height classifier.  
 
 
OTHER TUMOUR TYPES OF THE CEREBELLUM 
Tumour types not in the original scheme fell into a variety of diagnoses.  A 
series of bar charts showing metabolite and LMM concentrations are shown in 
Figure 24.   
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Figure 24: Bar charts showing metabolite (a) and LMM (b) concentrations (relative to water) of 
rare tumours of the cerebellum compared with those found in the 3 major tumour groups of 
the cerebellum.   
 
ATRT 
There were two ATRT; both had spectra with different features.  Both ATRT 
showed a very low concentration of Cr and low/no NAA.  One had relatively 
low LMM values, while the other ATRT had very high LMM signals. 
 
DA2 
The DA2 looked very similar to ependymoma.  The spectrum showed high 
signals for Cr and mIns, which are both seen in ependymoma spectra.  
However, there was also a high signal for NAA and low LMM signals, which 
are not seen in ependymoma spectra. 
 
 
Ganglioglioma 
This showed similar concentrations to PA spectra for many metabolites, 
including mIns, tCho and LMM.  However, it had higher tNAA and Glx, which 
may be used to differentiate it. 
    
HGT 
This tumour has not been fully classified histopathologically, but it is known to 
be of an aggressive nature.  It showed high LMM signals and low NAA, but 
also a relatively low tCho signal.   
 
DISCUSSION 
Of the 26 cases tested using the scheme, six were misclassified, this is an 
improvement on the peak height classification scheme.  Amongst these were 
the two new ependymoma cases, both of which exhibit lower mIns 
concentrations, in keeping with the grade 3 ependymoma.  This highlights the 
issues surrounding using small groups, as it is uncertain which mIns 
concentration is more realistic for the ependymoma spectra, and if the grade 
does have an effect on this.  Both of the new ependymoma were labelled as 
being grade 2 ependymoma, but grading of ependymomas not always definite 
[44, 45, 47].    
 
The misclassified PA, while being misclassified outside the cut-off box, still sat 
close to this region and refinement of the cut-offs may correct for this.   
Two of the misclassified medulloblastoma were classified as being 
ependymoma and one as a PA.  Both of those classified as ependymoma 
show high values for tCho, but also show high mIns concentrations.  One of 
these two cases also shows very high tau levels and this would have 
questioned an assignment of ependymoma.  The medulloblastoma spectrum 
classified as a PA showed low tCho compared with the other cases, this 
spectrum also had broad lines and was close to the quality control limits. 
 
Looking a plot on the original axes with all data, old and new (Figure 23), 
clustering is still apparent with the three tumour types.  The PA spectra all 
cluster with low values for each of the two metabolites and the 
medulloblastoma spectra still have the highest tCho.  The ependymoma 
spectra appear to cluster in two groups, both with intermediate values for tCho 
but one cluster having much higher mIns concentrations than the other.  This 
may be to do with grading ependymoma, but this is not histologically 
confirmed. 
 
The cut-offs for these tumours groups using these two metabolites do need to 
be reoptimised and more data needs to be accrued,  Using other metabolite 
signals, such as the presence of tau in medulloblastomas, should always be 
assessed in the assigning of disease type. 
 
One of the main benefits of using a method such as determining 
concentrations using LCModel™ is allowing for a more complete picture of the 
biochemical profile of the tumour to be assessed.  This is of particular benefit 
in the assessment of the tumour types not included in the original scheme.  
There were 5 patients with tumours outside of the original classification 
scheme.  These would not be classified in the original scheme, which would 
lead to misdiagnoses.  However, the spectra of these tumour types do have 
characteristics which would make this mis-assignment less likely.  These have 
been highlighted in two bar charts showing metabolite and LMM 
concentrations (Figure 24). 
 
ATRT 
These two cases of apparently the same tumour are highly different.  There is 
little literature on this tumour type, but it is known to be highly aggressive [56].  
One of the tumours had a spectrum that appeared to be highly aggressive 
with high LMM and tCho values.  This would fit with the diagnosis, but without 
a larger series no conclusions can be made. 
 
DA2 
The spectrum of the DA2 was very similar to that on an ependymoma in 
several respects, but differed in both NAA and LMM concentrations.  The 
spectrum was very similar to other diffuse astrocytomas.  These have 
characteristic high mIns and low LMMs [72, 102, 128], and this would be in 
keeping with the given diagnosis. 
 
 
Ganglioglioma 
These tumours behave similarly to a PA and they are both low grade gliomas 
[176].  The spectra appear to be similar in many respects except for 
resonances in the region 2-2.6ppm.   
 
HGT 
The spectrum does appear to be of a high grade tumour.  In cases like this, 
where no formal diagnosis is obtained, the extra information could be vital for 
treatment planning.  There are high LMM signals, which are present in high 
grade tumours [66, 72, 74, 75, 94, 113], there is also a low NAA signal which 
is usually low or absent in higher grade lesions [66, 72, 96, 97, 107, 114].  
 
CONCLUSIONS 
Although the metabolites selected as having the largest significant differences 
between groups are the same as those used in both the peak height classifier 
and the limited metabolite basis classifier, a more detailed picture regarding 
the metabolite profiles of cerebellar tumours can be constructed using a full 
LCModel™ basis set.  Many of the weaker signals offer significant differences 
between groups.  As more data is accrued, a more complete metabolite 
profile can be constructed for each of the three tumour types, allowing for a 
better characterisation and classification of the tumours. 
 
 
 
 
 
 
 
4.4 CONCLUSIONS 
A simple method involving peak height measurement and the subsequent 
calculation of ratios between these peak heights was presented.  This had a 
high classification rate and was proven to be usable by both clinicians and 
scientists in blinded testing.  Moving to a more sophisticated method involving 
determination of metabolite concentrations using a spectral processing tool, in 
this case LCModel™, offered a reasonable improvement upon this 
classification rate.  In addition, this allowed for the assessment of many more 
metabolites, including those with weaker signals. This information is 
potentially vital in the better understanding of these tumours and can help in 
the assessment of the rarer tumours, such as ATRT, and unusual entities, 
such as the uncategorised high grade lesion.   
 
Both of these schemes have comparable success rates in classification rates 
of tumours of the cerebellum using a retrospective study group, however the 
classification scheme based upon metabolite concentrations appears to be 
more robust to the addition of new data (table 12).   
 
  LCModel™ 
Classification Accuracy Peak Height Limited metabolite 
set 
Full metabolite and LMM 
set 
Retrospective Data 89.10% 88.90% 96.3% 
Prospective Data 65.40% 61.90% 76.9% 
Table 12: Comparison of classification rates of the different schemes for classifying cerebellar 
tumours 
 
Both of these schemes have benefits in the characterisation of cerebellar 
tumours, and have their uses in different areas.  For a fast, simple diagnosis 
of tumour types the simple peak height classifier presented is preferable.  
However, for more information about a tumour and to obtain a better 
understanding of tumour biology a more sophisticated method involving 
metabolite and LMM concentrations would be preferable. 
 
The work performed using the data from cerebellar tumours showed that 
using a full data set form LCModel™ offered a good means of 
characterisation.  Although the classification rates are comparable between 
simple schemes of peak height ratios, using limited basis sets and using 
complete basis sets in the retrospective study, the scheme using the full basis 
set was more robust to the addition of new data and allows a fuller 
characterisation.  When we can link this to the underlying metabolic pathways; 
we will gain better understanding of tumour biology.  Metabolites such as tau 
offer the potential for extra confidence in diagnosis. 
 
The major benefit of using a more complete basis set was in the analysis of 
rarer tumours of the cerebellum.  It allowed a more in depth analysis of these 
tumours, which could be used to either avoid misdiagnosis or aid in the better 
understanding of these rare tumours.  LCModel™ gives values for a larger 
number of metabolites, and while these are not of huge benefit in a simple 
classification scheme, they do allow for a more in depth assessment of the 
spectrum.  This also allows more sophisticated pattern recognition methods to 
be used, which may give better classifiers. 
 
A prospective evaluation of both schemes showed them to be moderately 
robust to the addition of new data.  By adding more data over time, these 
schemes can be improved further and the cut-off values described further 
refined.  Both peak height and metabolite based classifiers were shown to be 
robust to data taken on multiple sites.  However, it should be noted that the 
prospective evaluation showed poor discrimination of ependymomas.  This 
class had very few cases in the original classifier, and the inclusion of more 
data should improve the accuracy of the classifier for this group.  This 
highlights the importance of both multicentre studies and prospective 
evaluation of schemes, especially those designed for rarer tumour types. 
 
The main challenge and limitation of the schemes presented is the 
classification of rare tumours.  In groups where there are many cases the cut-
off values can be determined and refined to allow for future cases to be 
assessed and compared in a robust manner.  For tumour types that occur 
less frequently this is more of a challenge, and these will often be 
misclassified as one of the more common tumour types.  These tumours have 
been shown to have characteristic features in their spectra, but without more 
cases to compare with no formal conclusions can be drawn.  This highlights a 
problem of using small datasets.  A larger multicentre study over a longer 
period may assist in this problem with more of these rarer cases being 
assessed. 
 
The classification accuracy compares favourably with those found using a 
more sophisticated discriminant analysis [73, 98].  One study [73], using long 
echo-time MRS, quoted a correct classification rate of 85%.  A second study, 
performed at BCH on a similar group of spectra to those used in the original 
schemes [98], showed a predictive ability of 93-95% and an accuracy of 80% 
using the first two principal components alone.  It should be noted that neither 
of these schemes were tested prospectively, so the replication of these results 
on further data has not been established. 
 
Henceforth, analysis will be performed using LCModel™ concentrations.  
Multivariate pattern recognition techniques would allow for an analysis based 
on the complete list of variables, i.e. all metabolites and LMM concentrations, 
between groups.  However, this method was not used for several reasons.  
Firstly, when performing the analysis on cerebellar tumours using LCModel™ 
concentrations the classification accuracy was not significantly improved by 
adding additional criteria beyond the two metabolite cut-off values used in the 
scheme presented.  In addition to this, the scheme using two cut-off values 
compared favourably with scheme using multivariate analysis [73, 98].  
Sophisticated pattern recognition tools are not favourable in a clinical tool, as 
there is not always the availability of tools such at matlab, required for the 
application of such methods.  Pattern recognition methods have only been 
proved to be reliable using large data sets, with large numbers in each of the 
groups for comparison.  This is rarely possible in studies performed into 
childhood brain tumours.  These tumours are rare in children and, thus, small 
numbers are present in each group and as such multivariate pattern 
recognition may not offer the best means of analysis.   
 
Presented here is a series of clinical studies, using the techniques developed 
above in a series of important clinical situations.  Cerebellar tumours are 
usually fully excised as part of their initial treatment and, so, nearly always 
have a histopathological diagnosis.  This means that this group is an ideal 
test-bed for the development of new classifiers. Other tumours are located in 
areas of the brain where surgery is more of a challenge, or at times not 
possible. In these incidences, it would be better to have a means of non-
invasive diagnosis. One of these areas is the pineal gland and surrounding 
area.  
 
 
 
 
 
CHAPTER 5: PINEAL REGION TUMOURS 
5.1 INTRODUCTION 
Pineal tumours only account for approximately 5% of childhood brain tumours. 
Despite this low incidence, they pose significant challenges in both diagnosis 
and treatment. The majority of tumours occurring in this region fall into 2 
groups: germ cell tumours (GCTs) and pineal parenchymal tumours (PPTs). 
Each of these groups is composed of a highly diverse set of tumour types, 
both in histological appearance and clinical course. Effective management 
requires an accurate diagnosis, but surgery to this region of the brain caries 
significant risks and not all tumours require a resection as part of their curative 
treatment. Non-invasive methods for diagnosing pineal tumours are 
particularly attractive and a combination of MR imaging and blood markers is 
already used to diagnose non-germinomatous secreting GCTs (SGCT). 
However, the majority of pineal tumours still require a biopsy for diagnosis, 
and new non-invasive methods for diagnosis would be a significant advance. 
Biopsies of pineal lesions commonly yield small amounts of tissue, limiting in 
vitro investigation and hampering the molecular studies required to improve 
our understanding of these tumours. Non-invasive methods which can provide 
molecular information to improve our understanding of these tumours would 
be of additional benefit. 
 
Tumours of many different histopathologies can occur in the pineal gland, 
making non-invasive diagnosis challenging. GCTs are the most common, 
accounting for 50-70% of pineal tumours in childhood [9]. For clinical 
purposes, there are three main sub-categories of GCT [9, 41, 52]: 
germinomas; SGCTs; and teratomas.  Germinomas constitute approximately 
65% of GCTs, are highly malignant and commonly secrete human placental 
lactogen (HPL). SGCTs constitute approximately 25% of GCTs, are malignant 
and secrete beta-subunit human chorionic gonadotrophin (BHCG) and/or 
alpha-fetoprotein (AFP). Teratomas constitute approximately 10% of GCTs, 
may be either mature with no-malignant elements or immature containing 
malignant elements. Approximately 20% of pineal tumours arise from 
pinealocytes and are collectively termed PPTs [53, 80, 85, 177-179]. 
Pineoblastomas (grade IV) are highly malignant embryonal tumours with a 
propensity for dissemination in young patients. Pineal parenchymal tumours 
of intermediate differentiation (PPTID) and the papillary tumour of the pineal 
region are very rare intermediate grade tumours with a variable clinical course 
[177, 178].  Pineocytomas (grade II) are slow growing tumours, with mature 
cells [80]. Astrocytomas may also occur in this region and these can be of any 
grade.  
 
Characteristic clinical and radiological features, together with raised AFP or B-
HCG in cerebrospinal fluid or blood, are sufficient for the diagnosis of SGCTs, 
without the need for biopsy. Histopathology is required for the diagnosis of all 
other pineal tumours. The pineal region is a challenging region in which to 
operate and there is an associated risk of morbidity and mortality [41]. 
Surgical resection does not form part of the curative treatment strategy for a 
number of pineal tumours and surgery could potentially be avoided altogether 
in many if a non-invasive diagnosis could be made. For example, once the 
diagnosis is made on biopsy, germinomas are commonly treated with 
chemotherapy and/or radiotherapy without resective surgery [36, 41] to give 
long term survival rates of over 90% [53, 85, 179]. They would therefore be 
ideal candidates for non-invasive diagnosis.  For other tumours, such as 
pineoblastoma, surgical resection is a key component of the treatment [85] 
and identifying such cases pre-operatively would aid in surgical planning. 
 
Some differences are visible between all tumour groups using conventional 
MRI, but these are quite subtle and not always consistent.  One example 
would be that teratomas appear to be more heterogeneous than the most 
other pineal region tumours [180].  These tumours can also have lipid present 
in them [54]. However, MRI for germinoma, pineocytoma and pineoblastoma 
are very similar, they are all reasonably homogeneous and appear bright on 
T2.  These tumours are all very different and require completely different 
management, so additional information would be highly beneficial.    
 
A number of MRS studies have been performed which have included limited 
numbers of pineal tumours. One study of MRS in childhood brain tumours 
showed pineal germinomas to have high lipids and macromolecules levels 
compared with a range of tumours outside the pineal gland [71]. Another 
study of childhood brain tumours found differences in a number of metabolite 
ratios between germinomas and a series of other tumours in a range of 
locations [72]. In a case study of a comparison of a germinoma spectrum with 
that of normal appearing white matter, the germinoma spectrum was shown to 
have elevated LMMs [115].  
 
The study presented here extends the findings in these reports by 
concentrating on MRS of the major pineal tumours and investigates the 
potential use of MRS profiles to aid their diagnosis and improve tumour 
characterisation. 
 
5.2 METHODS 
Raw data was processed using LCModel™ and Cramer-Rao bounds were 
used to remove metabolites that were poorly determined.  Quality control was 
applied using the following measures:  
3. SNR had to be greater than 3 for analysis of LMM levels and greater 
than 4 for metabolite levels 
4. FWHM had to be less than 0.200ppm for analysis of LMM levels and 
less than 0.150ppm for analysis of metabolite levels.  
LMM peaks are inherently broader than metabolite peaks allowing less 
stringent quality control criteria. 
 
For analysis, data was combined into 2 groups: GCTs and PPTs.  Two-tailed 
t-tests of significance were performed between the groups to assess for 
distinguishing features. The group of GCTs was further analysed using z-tests 
to determine whether teratomas and SGCTs can be shown to have significant 
differences from germinomas.  Z-tests were used to assess whether the 
differences seen in individual members of different groups are large enough to 
be statistically significant.  
  
 
5.3 RESULTS 
MRI and short-echo-time MRS were performed on 15 children with tumours of 
the pineal region between 01/09/03 and 31/12/07.  In addition, two children 
with germinomas in other locations of the brain, one suprasellar and one 
frontal were included in the study.  A comparison was performed with the 
pineal germinomas.  Visual inspection showed all germinoma spectra appear 
similar and additional z-tests showed pineal germinoma spectra to be 
indistinguishable from the other germinoma.  Thus, these cases were included 
in this study. All MRS were performed prior to surgery and adjuvant treatment 
with chemotherapy or radiotherapy.  There was one exception, where the 
MRS was acquired after a small biopsy, where a large fraction of the tumour 
remained. Sixteen patients proceeded to surgery, providing histological 
diagnoses of 9 germ cell tumours (7 germinomas and 2 teratomas), 5 
pineoblastomas, 1 pineocytoma and 1 PPTID. One patient had a SGCT 
diagnosed on radiological appearances and serum markers. The average age 
at diagnosis of children with GCTs was 12.0 years (germinoma 13.0 years; 
teratoma 9.1 years; SGCT 10.9 years) and for those with PPTs was 6.1 years 
(pineoblastoma 6.6 years; pineocytoma 7.1 years; PPTID 2.7 years).  
 
Of the 17 MRS studies, 2 did not meet quality control criteria required for 
quantitative analysis of metabolite concentrations; these cases had a broad 
FWHM (1 pineoblastoma and 1 germinoma). Both of these cases met the 
quality control criteria for inclusion in the LMM analysis. However, the 
germinoma also had considerable residual water in the spectrum, and needed 
to be removed from the study.   
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Figure 25: Average Spectra for (a) germinoma, (b) pineoblastoma, (c) teratoma and (d) 
example spectra for (i) PPTID and (ii) pineocytoma 
 
Mean spectra for germinoma, pineoblastoma and teratoma are shown in 
Figure 25 with the two cases not meeting quality control criteria excluded.  
Figure 25d shows the spectra for the only PPTID and pineocytoma, in the 
study group. Prominent differences can be seen between these spectra, 
particularly in the LMM regions at 0.9ppm and 1.3ppm. The MRS in GCTs is 
dominated to such an extent by LMM that the relative values of small 
metabolites, giving rise to peaks between 3.0ppm and 4.0ppm, are difficult to 
discern by visual inspection. However, a small peak is seen at 3.35ppm in the 
germinomas and is attributed to taurine. In PPTs, lipids are particularly low in 
the low and intermediate grade lesions (pineocytoma and PPTID). The 
pineoblastoma spectrum shows a high LMM peak, but the metabolite signals 
are still clearly visible. In the PPTID, the total choline peak (3.2ppm) is low 
compared with the creatine peak (3.0ppm). Taurine is prominent in the 
pineoblastomas. LCModel™ analysis was used to quantify the metabolite and 
LMM components of the individual spectra.  
 
Mean values of metabolites for each tumour type, relative to water, are given 
in table 13.  
 Germinoma SGCT Teratoma Pineoblastoma PPTID Pineocytoma 
Metabolite Average StdErr  Average StdErr Average StdErr   
Cr 1.63 0.08 1.49 0.35 0.25 1.68 0.30 5.39  
Glc 0.85 0.14 0.76 0.46 0.16 0.74 0.23 2.55  
Gua 1.71 0.16 1.64 0.59 0.42 1.59 0.34 2.74  
mIns 3.17 0.47 1.74 1.40 0.49 1.61 0.35 7.60  
sIns 0.26 0.03 0.17 0.04 0.00 0.20 0.05 0.32  
Tau 0.79 0.13 0.99 0.18 0.01 0.47 0.14 0.33  
tCho 1.44 0.10 0.73 0.31 0.01 0.79 0.17 1.24  
tNAA 1.13 0.18 1.17 0.84 0.13 0.61 0.14 1.31  
Glx 4.82 0.32 5.82 3.96 0.33 4.65 0.91 9.08  
LMM0.9 11.92 1.32 9.91 7.80 2.17 5.28 0.37 3.36 4.93 
LMM1.3 51.71 8.68 48.43 29.58 1.89 14.34 0.51 6.75 9.83 
LMM2.0 14.12 1.42 11.16 8.68 0.86 7.73 0.68 4.38 12.69 
Table 13: Average metabolite and LMM concentrations for pineal region tumours.  Where 
more than one case presented a standard error has been calculated along with the average 
concentration, for tumours with only one case in the study only the value for the concentration 
has been listed. 
 
Since only one case is available for some tumour types, a formal statistical 
analysis across all groups has not been performed. However, it is worthwhile 
noting some of the main features. GCTs are confirmed to have high LMM 
concentrations with germinomas having the highest. Germinomas also have 
the highest tCho levels and teratoma the lowest. Although taurine was 
quantitated in all tumour types, it was only identified with high confidence 
(CRLB < 25%) in a pineoblastoma and a germinoma. Taurine was highest in 
the germinomas. Teratomas show the lowest concentrations of Cr, sIns, and 
taurine. Pineoblastoma spectra show the lowest concentration of tNAA. The 
PPTID spectrum showed a very high concentration of mIns, Cr, and Glx. It 
also exhibited elevated tCho, similar to that seen in the germinoma spectra 
and a low concentration of taurine. The pineocytoma has generally low 
metabolite concentrations, in keeping with a tumour of low cellularity. 
 
Results of a two-tailed t-test between the GCTs and PPTs are presented in 
table 14.  
 
  GCT PPT 
Metabolite P-Value Average  StdErr Average StdErr 
Cr 0.275 1.29 0.09 2.42 0.39 
Glc 0.536 0.74 0.07 1.10 0.23 
Gua 0.547 1.42 0.11 1.88 0.25 
mIns 0.864 2.55 0.25 2.81 0.59 
sIns 0.763 0.19 0.02 0.22 0.03 
Tau 0.476 0.66 0.07 0.44 0.10 
tCho 0.599 1.07 0.08 0.88 0.12 
tNAA 0.400 1.06 0.09 0.75 0.12 
Glx 0.662 4.73 0.17 5.54 0.74 
LMM0.9 0.033 10.78 0.74 4.96 0.24 
LMM1.3 0.044 46.43 4.70 12.61 0.53 
LMM2.0 0.120 12.59 0.80 7.96 0.53 
Table 14: T-test results for comparison between GCTs of the pineal region and PPTs 
 
These results confirm that the LMM signals at both 0.9ppm and 1.3ppm are 
significantly higher in GCTs compared with the other tumours.  No metabolites 
were significantly different between the two groups. A scatter plot of the LMM 
levels at 0.9ppm and 1.3ppm is given in Figure 26.  
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Figure 26: Tumours grouped as either GCT or PPT and plotted on axes for LMM regions 
around 0.9ppm and 1,3ppm. 
red – GCT; blue – PPT 
 
The plot shows the distribution of LMM values across the tumours and shows 
that there is considerable variability within individual tumour groups.  Two 
germinomas had LMM levels which were as low as the non-GCT cases. One 
of these was the case where the MRS did not meet quality control criteria for 
analysis of metabolites. The other had an unusual clinical presentation with a 
long period of symptoms prior to diagnosis and a strong family history of low 
stage seminoma. The sub-analysis of the GCT group using a z-test is given in 
table 15.  
 
 
 
 
Metabolite secreting GCT teratoma 1 teratoma 2 
Glc 0.390 0.311 0.028 
sIns 0.051 <0.001 <0.001 
Tau 0.760 0.017 0.014 
Gua 0.414 0.062 0.000 
Cr 0.203 <0.001 <0.001 
mIns 0.089 0.156 0.010 
tCho 0.001 <0.001 <0.001 
tNAA 0.533 0.395 0.116 
Glx 0.918 0.289 0.033 
LMM0.9 0.267 0.013 0.373 
LMM1.3 0.439 0.122 0.180 
LMM2.0 0.198 0.113 0.028 
Table 15: P-values for the comparison of germinoma metabolite concentrations with other 
germ cell tumours of the pineal region 
 
This shows that tCho, Cr, Tau and sIns were all significantly lower in both of 
the teratomas compared with the germinomas. The SGCT had significantly 
lower tCho, sIns and mIns than the germinomas. A scatter plot of the most 
reliably quantitated metabolites, tCho and Cr is given in Figure 27.  
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Figure 27: GCTs plotted on axes tCho Vs Cr 
Circles – germinoma; empty star – secreting GCT; closed stars – teratoma 
 
The SGCT lies between the teratomas and germinomas. There were no 
significant differences detected between germinomas arising in the pineal 
gland and those in other locations. An analysis of the histopathology of the 
germinomas did not find any correlation between non-germinomatous 
elements and MRS features. 
 
5.4 DISCUSSION 
Short echo-time MRS has been used to investigate pineal tumours occurring 
in childhood. Key differences have been found between GCTs and PPTs and 
also between germinomas and teratomas. Pineal region tumours are rare 
making such studies challenging, but they represent important childhood 
diseases for which non-invasive biomarkers would be a valuable clinical tool. 
Whilst the overall numbers in the study are small, they are large compared 
with previous reports and sufficient to allow statistical analysis.  Quality control 
criteria we relaxed for looking at LMM resonances.  This was seen as 
reasonable, due to the signal strength of these peaks in relation to the noise.  
This was done to increase the number of cases for analysis, which was seen 
as important due to the small size of dataset. 
 
The most notable feature found in GCTs was the high levels of LMM. High 
LMMs in this tumour group have been noted previously both in CNS 
germinomas [71, 115] and GCTs elsewhere in the body [111]. Raised LMMs 
are a common feature in many tumours [66, 68, 69, 72-75, 94, 113, 115, 181, 
182], and are usually attributed to increased mobile lipid levels rather than 
changes in the macromolecular component [113]. High mobile lipid levels 
have been associated with malignancy in brain tumours [29, 65, 66, 74, 96].  
This is consistent with the findings in both germinoma and SGCT spectra, 
both of these are fast-growing tumours with metastatic potential.  Two of the 
germinoma spectra exhibited lower LMM concentrations.  In the case of the 
patient with a strong family history of low-stage seminoma and long period of 
symptoms prior to diagnosis, this would be consistent with MRS suggesting a 
slower growing, less aggressive tumour.  The other germinoma with low LMM 
levels was associated with a spectrum that only just met acceptable quality 
control; care should be taken in interpreting poor quality spectra even for 
LMM. Teratomas had lower LMM levels compared with germinomas and 
SGCT, in keeping with the less aggressive nature of mature teratomas [49, 
54, 177]. However, teratomas still have high LMM levels compared with non-
GCT tumours indicating that there is an additional source of LMM in these 
tumours, which is likely to be fat tissue seen on histopathology and 
conventional MR images in these tumours. The very low LMM concentrations 
in the pineocytoma and PPTID spectra are in keeping with their low grade [53, 
80, 177, 178].  
 
Another metabolite linked with tumour aggressiveness and growth is choline 
[66, 93, 101, 106, 114]. Within the group of GCTs, germinomas exhibited the 
highest concentration of tCho with lower concentrations in SGCT and the 
lowest concentrations in teratomas. This finding is in keeping with the relative 
growth patterns of these tumours. Given the lack of overlap in the tCho values 
between the tumour groups (Figure 27) tCho levels may be a useful non-
invasive discriminator between these tumours. The pineoblastomas had 
higher tCho levels than the teratomas, pineocytoma and SGCT but lower than 
the germinomas; again in keeping with their known growth pattern.  
Medulloblastoma have been reported as having very high levels of tCho, 
these are closely related to pineoblastoma, this very strong tCho signal is not 
mirrored in the pineoblastoma spectra [71, 98] indicating a different nature of 
these tumour groups.  The PPTID was associated with a spectrum showing a 
tCho concentration to be lower than the Cr peak whereas the reverse is seen 
in the pineoblastoma again reflecting the more aggressive nature of 
pineoblastomas.   
 
Taurine was convincingly identified in germinomas, in addition to 
pineoblastomas, in keeping with a previous study [71].  Primitive 
Neuroectodermal Tumours, a group that contains both medulloblastomas and 
pineoblastomas, have been shown to exhibit higher taurine levels than other 
tumours and this has been proposed as being of diagnostic value [100]. 
However, this study shows that taurine levels alone should not be used to 
discriminate between tumours of the pineal gland. Studies of primitive 
neuroectodermal tumours are usually dominated by medulloblastomas which 
are the most common subtype, thus findings are weighted to this group.  This 
would indicate a further difference between the spectra of pineoblastoma and 
medulloblastoma. The finding of Tau in germinoma would be supported by 
recent micro-RNA profiling studies that indicate that intracranial germ cell 
tumours are distinct from their extra cranial counterparts and may arise from 
endogenous CNS neural progenitor cells rather than primordial germ cells 
[183]. However, the role of taurine in brain tumours is not well understood and 
further studies are required.  
 
5.5 CONCLUSIONS 
Key differences have been identified between the spectra of GCTs and other 
tumours of the pineal region, with GCTs having significantly higher 
concentrations of LMM at both 0.9ppm and 1.3ppm. Furthermore, within the 
groups of GCTs, differences have been shown to exist between both teratoma 
and SGCT spectra and germinoma spectra.  All of these findings are 
preliminary, and further studies with significantly more data would be required 
to confirm the promising findings presented here. 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6: BRAIN STEM TUMOURS 
6.1 INTRODUCTION 
Of all brain tumours of childhood, around 10-25% occur in the brain stem 
[184, 185].  The management of brain stem tumours continues to present a 
major challenge to paediatric oncology, as it is a particularly difficult area to 
biopsy [92] and diagnosis is often made on clinical and imaging grounds 
alone. However, diagnosis of brain stem lesions using imaging alone leads to 
a misdiagnosis rate of 10-20% [185, 186].  Novel imaging methods offer a 
means of improving diagnostic accuracy and furthering our understanding of 
the biology of these important childhood tumours [72, 182].  
 
There are four main types of tumour that occur in the brain stem: tectal plate 
gliomas (TPGs), diffuse pontine gliomas (DPGs), high grade gliomas (HGGs) 
and low grade gliomas of the pons and medulla (LGGs).  TPGs and LGGs 
both share a good prognosis and, when biopsied, TPGs are invariably found 
to be low grade astrocytomas.  In contrast to this, DPGs and HGGs have a 
very poor prognosis; of these tumours DPGs are the most common lesions.  
DPGs comprise 80% of all brain stem gliomas [182] and 15-20% of all CNS 
tumours [42] in children.  These tumours have a particularly poor prognosis, 
with median survival of less than a year, and despite their prevalence there 
has been no improvement in the outcome for 30 years [42].   
 
Long echo time (TE) MRS (TE = 135-144ms) performed on the brain stem 
has previously been shown to differentiate normal surrounding tissue from 
tumour tissue [182, 187], and also indolent from aggressive lesions [187].  
However, as seen previously, many metabolite and LMM signals will be lost in 
a long echo time spectrum.  
 
Although brain stem tumours are clinically important, only small numbers 
present to any one centre each year.  This presents major challenges for the 
use of techniques such as MRS for which there is no universally agreed 
standardisation of data collection or analysis.  This work depicts a multi-centre 
study using data from the CCLG, using short echo time MRS to characterise 
childhood brain stem tumours.  Issues of protocol selection, quality control, 
data transfer, data storage and standardised data analysis were addressed 
within a well-established clinical trails infrastructure. 
 
6.2 METHODS 
Raw data was processed using LCModel™ and Cramer-Rao bounds were 
used to remove metabolites that were poorly determined.  Quality control was 
applied using the following measures:  
1. SNR had to be greater than 4 
2. FWHM had to be less than 0.150ppm  
 
Where the water unsuppressed spectrum was recorded, metabolite and lipid 
concentrations could be determined relative to water.  In the case of data that 
did not have paired water unsuppressed and water suppressed MRS, the data 
was not analysed with the rest of the dataset.  However, ratios of metabolite 
to tCho were generated for all data, and these were compared. 
 
Combined metabolite values were used for tNAA, tCho and Glx. Any signal 
with consistently high Cramer-Rao lower bounds (>50%) was removed from 
further analysis, since these would be very poorly determined. 
 
Tissue diagnosis is often not possible in brain stem lesions, in cases where 
this was the case; diagnosis was made using a centralised radiological 
review, whereby tumours were grouped into 5 diagnoses: 
o focal high grade glioma (HGG),  
o focal low grade glioma (LGG)  
o tectal plate glioma (TPG),  
o diffuse glioma contained fully within the pons (DPG), and  
o diffuse glioma centred on the pons but with a component extending 
outside (DG)   
 
TPGs and LGG were grouped into one group, henceforth known as LGG, this 
was done as TPGs are assumed to be LGGs and they behave as such.  This 
led to 4 groups being considered: HGG; LGG; DPG and DG. 
 
The variability of MRS metabolite profiles across all cases was determined 
using a PCA.  This was performed using metabolites of appropriate Cramer-
Rao lower bounds, normalised to vector length.  
 
An ANOVA was performed between LGGs, HGGs and DPG+DGs to assess 
for significant difference.  In addition to this, two-tailed t-tests were performed 
between diffuse and focal lesions, and also between focal HGGs and LGGs.  .   
Finally a comparison between diffuse gliomas confined to the pons and those 
with components outside the pons was performed, using two-tailed t-tests, to 
assess whether there were any metabolic differences between these two 
groups 
 
6.3 RESULTS 
MRI and short-echo-time MRS were performed on 32 children (15 from BCH; 
5 from GOSH, 4 from QMC and 8 from RMH) with brain stem tumours 
between 26/09/2003 and 05/10/2007.  All MRS were performed prior to 
surgery and adjuvant treatment with chemotherapy or radiotherapy.   
 
The results of the radiology review can be seen in table 16: 
 
 Total BCH QMC RMH GOSH 
Diagnosis Total In study Total In study Total In study Total In study Total In study 
DPG 14 13 10 10 2 2 2 1 1 1 
DG 5 4 1 1 1 1 2 1 1 1 
LGG
a
 6 4 2 2 1 1 2 0 1 1 
HGG
b
 5 3 3 3 0 0 0 0 2 0 
Undecided 2 0 0 NA 0 NA 2 0 0 NA 
a: includes 1 biopsied ganglioglioma and 2 biopsied pilocytic astrocytoma 
b: includes 1 aggressive tectal plate tumour 
 
Table 16: Diagnosis summary for patients in the brain stem tumour study 
 
In summary, this led to a diagnosis of 6 LGG (including 1 unbiopsied TPG and 
1 biopsied ganglioglioma); 5 HGG (3 of these were biopsy proven HGGs, the 
third was an unbiopsied TPG that appeared to be of aggressive nature on 
radiological criteria); 14 DPG and 5 DG.  There were also two tumours where 
it was considered that there was insufficient information to make an informed 
decision; these tumours were removed from further analysis.   
 Of the remaining 31 spectra, 7 were removed during quality control; these 
were all due to low SNR.  This left a total of 23 spectra, including 13 DPG and 
4 DG spectra, in addition to this 3 LGG, 3 HGG and 1 biopsied ganglioglioma 
were left remaining.  Average spectra for the 3 main tumour types are shown 
in Figure 28.   
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Figure 28: Average spectra for (a) DPG; (b) HGG and (c) LGG 
 
A PCA was performed using a full list of all metabolite and LMM 
concentrations, normalised to vector length, on the group separated into three 
subgroups – diffuse tumours (DPG +DG); DG; LGG; and HGG.  Upon 
producing a PCA for these three groups, it became apparent that five of the 
DPG+DG spectra were clustering with two HGG separate from the rest of the 
spectra.  A decision was made to separate the DPG and DG into two groups 
and a PCA was performed with the data separated into four groups: DPG; 
DG; HGG; and LGG (Figure 29).   
 
  
(a) 
 
        (b)                                                             (c)                  
Figure 29: PCA (a) for brain stem tumours collated into 4 groups: HGG – red; LGG – green; 
DPG – blue; and diffuse gliomas not localised to the pons – purple.  Loadings plots are shown 
for PC1 (b) and PC2 (c)  
 
This highlighted that it was the DG spectra that were clustering with the two 
HGG spectra.  This was primarily using PC1 alone, which was much lower in 
the DGs and HGG compared with the rest of the spectra.  PC1 is largely 
showing differences seen in the LMM signals (Figure 29b), with a lower value 
for PC1 relating to stronger LMM resonances.  This indicates that LMM 
resonances are more pronounced in DGs and HGGs in comparison with LGG 
and DPGs. These tumours also showed a low PC2 score.  A high score of 
PC2 would be strongly influenced by a strong mIns signal.  This is confirmed 
by the high scores for PC2 in the DPG spectra (Figure 29a); where this peak 
is one of the main distinguishing features of this tumour.   
 
One of the DPG patients did not have a water unsuppressed file, with which to 
reference the metabolites concentrations to.  Due to the small dataset, ratios 
to tCho were calculated for metabolites in all spectra, and analysis was 
performed using these for all data.  
 
Results of two-tailed t-tests performed between different groups are shown in 
table 17: 
 P-Values 
Ratio diffuse Vs focal DPG Vs DG HGG Vs LGG* 
Cr/tCho 0.003 0.919 0.947 
mIns/tCho 0.006 0.678 0.048 
tNAA/tCho 0.372 0.096 0.263 
Glx/tCho 0.081 0.001 0.483 
LMM0.9/tCho 0.451 0.063 0.311 
LMM1.3/tCho 0.779 0.028 0.228 
LMM2.0tCho 0.515 0.138 0.398 
*LGG group without ganglioglioma 
 
Table 17: P-Values from two-tailed t-tests between groups of brain stem tumours 
 
Table 17 shows only two ratios that differ significantly between the diffuse and 
focal groups: Cr/tCho (P = 0.003) and mIns/tCho (P = 0.006).  Performing an 
ANOVA (Table 18) between the 3 groups (LGG, HGG and DPG + DG) 
confirmed that Cr/tCho (P = 0.006) was a discriminating feature between all 
three groups.   
 
  Averages 
Ratio P-value HGG HGTPG ganglioglioma LGG DPG+DG DPG DG 
Cr/tCho 0.006 0.93 1.85 2.44 0.97 2.46 2.44 2.51 
mIns/tCho 0.059 1.46 2.12 0.13 3.28 4.38 4.53 3.89 
tNAA/tCho 0.210 0.48 0.68 1.75 1.83 1.71 1.90 1.05 
Glx/tCho 0.170 4.73 4.87 6.78 3.66 3.13 2.63 4.87 
LMM0.9/tCho 0.180 8.40 3.27 5.00 3.79 4.54 3.23 9.13 
LMM1.3/tCho 0.450 21.81 7.07 15.27 5.85 12.37 5.61 36.01 
LMM2.0tCho 0.720 10.50 5.69 9.86 6.91 7.45 5.16 15.50 
Table 18: P-Values for an ANOVA between 3 groups (HGG+HGTPG, LGG+ganglioglioma 
and DPG+DG) 
 
Although mIns/tCho was not significantly different between all three groups, it 
was still near significance (P = 0.059).  A plot of mIns/tCho Vs Cr/tCho (Figure 
30) shows the focal HGGs have very low values for both Cr/tCho (0.93±0.48) 
and mIns/Cho (1.46±0.45), with the exception of the tectal plate HGG which 
exhibited a higher value for Cr/tCho (1.85).   
 
 
Figure 30: All types of brain stem tumours in the study, from all centres, plotted on axes 
mIns/tCho Vs Cr/tCho 
Green stars – high grade glioma; red circles – low grade glioma; red star – ganglioglioma; 
blue circles – DPG; blue stars – DG 
 
The focal LGGs showed higher values for mIns/tCho (3.28±0.46) and slightly 
higher values for Cr/Cho (0.97±0.17) compared with the focal HGGs.  The 
ganglioglioma showed one of the lowest values for mIns/tCho (0.13), in 
addition to the highest value for Cr/tCho (2.44) of the focal tumours.  This 
indicated that the ganglioglioma may be metabolically different from the other 
focal tumours.  The diffuse tumours showed a large spread in both Cr/tCho 
and mIns/tCho, but showed consistently higher values for Cr/tCho (2.46±0.19) 
than the focal tumours.  The average values for both Cr/tCho and mIns/tCho 
are both higher in DPGs (2.44±0.20 and 4.53±0.61 respectively) than DGs 
(2.51±0.56 and 3.89±1.31 respectively), although this is not significant due to 
the spread. 
 
Results of two-tailed t-tests (Table 17) between the DPGs and DGs show that 
LMM1.3/tCho (P = 0.029) is significantly different between these 2 groups.  
LMM0.9/tCho is also near significance (P = 0.067) (Figure 31).  
 
 
 
Figure 31: Plot of LMM region concentrations (relative to tCho) at 0.9ppm and 1.3ppm in 
both diffuse gliomas within and extending beyond the pons 
Red circles – DPG; blue circles – DGs 
 
Both of these have higher values in the DGs (36.01±7.76 and 9.13±2.06 
respectively) compared with the DPGs (5.61±1.08 and 3.23±0.26 
respectively), confirming the observations from the PCA.  In addition to these, 
Glx/tCho (P = 0.0001) is higher in the DGs (4.87±0.33) than the DPGs 
(2.63±0.37).  NAA/tCho is close to significance (P = 0.071), being lower in 
DGs (1.05±0.33) than DPGs (1.90±0.32).   
The final set of two-tailed t-test results are shown in table 17, showing 
differences between the focal HGGs and LGGs.  Only mIns/tCho showed 
significance (P = 0.048), being higher in LGGs (3.28±0.46) than HGGs 
(1.46±0.45).  Figure 32 shows bar charts of the metabolite/tCho and 
LMM/tCho in the brain stem tumours.   
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Figure 32: Bar charts showing (a) metabolite and (b) LMM concentrations (relative to total 
Cho) for all brain stem tumour types used in the study 
 
For the sake of easy visualisation the high grade TPG is plotted as a separate 
entity from the other focal HGGs.  The plot of LMM/tCho is clearly shows the 
tendency towards higher ratios in HGGs compared with LGGs.  
 
Analysis was performed to assess whether the ratios mIns/tCho and Cr/tCho 
varied with sex, this was found to not be the case, this is in agreement with 
previous studies [184, 185]. 
 
In addition to this statistical analysis, visual inspection of the spectra, for 
unaccounted features, was performed.  Looking at the average spectrum of 
the DPGs and DGs (Figure 28a), it is clear that there is a prominent peak 
present at 2.6ppm, that is not assigned by LCModel™.   This peak is not seen 
in any of the other brain stem tumours.   
 
6.4 DISCUSSION 
MRS can provide additional information, over and above that of conventional 
MRI, on the biology of brain stem tumours by providing information on in vivo 
metabolism. 
 
The PCA results (Figure 29), showed that the main discriminant between 
HGG and other tumour types being LMM/tCho, especially those at 1.3ppm.  
This is in keeping with studies on adults and children with brain tumours 
where grade has been linked to lipid concentration [65, 72].  Despite the 
aggressive clinical behaviour of DPGs, at diagnosis they can readily be 
distinguished from HGGs of the brain stem, with the lowest LMM/tCho 
concentrations of all tumour types assessed (table 18). This finding is of 
interest as there remains debate as to the true pathological nature of DPGs, 
with biopsy studies demonstrating a spectrum of histological grades (II to IV) 
that do not correlate with prognosis [185, 188-190].  Two possible 
explanations are offered to account for these findings; firstly small size and 
sampling error of biopsies result in a down grading of heterogeneously high 
grade tumours or alternatively initial low grade lesions rapidly evolve into 
more malignant tumours. Autopsy studies tend to find a higher frequency of 
grade III and IV tumours and along with these MRS findings this may provide 
support for the idea of malignant transformation [191-193].   
 
On the PCA, the 4 DG cases appeared more closely aligned with the focal 
HGG than the DPGs. There was a clear separation in the proportion of PC1 in 
these spectra, the loadings plot of which shows this PC to be dominated by 
LMM concentrations. In addition to this, these tumours showed consistently 
higher values for both LMM1.3/tCho and LMM0.9/tCho, and lower values for 
tNAA/tCho.  This would all be in indicative of these being more aggressive 
tumours than the DPGs in this study.  This is not yet substantiated by clinical 
findings however and needs to be further assessed with a larger study group 
and follow-up with clinical outcomes and MRS. 
 
From the ANOVA results, mIns/tCho and Cr/tCho offers the best 
discrimination between all brain stem tumour types.  This shows that the 
DPG+DGs can be classified as having high Cr/tCho and high mIns/tCho, 
HGGs as having low Cr/tCho and low mIns/tCho and LGGs clustering 
between these two groups.  The exception to this is the high grade TPG, 
which is more closely aligned with the LGG group than the HGG group on 
Figure 30.  The ganglioglioma spectrum sits separately from both LGGs and 
HGGs, with a low value for mIns/tCho and a high value for Cr/tCho. 
 
TPGs are usually assumed to be low grade gliomas and are often unbiopsied. 
In this study there were two unbiopsied TPGs included.  Of these cases, one 
was classified as being typical of a low grade lesion and was included as one 
of the LGG group.  For the other, the radiological review classified it as having 
appearances of a more aggressive lesion and, due to this; it was included as 
being one of the HGG group.  This tumour was treated with radiotherapy and 
the patient is responding to treatment and remaining stable, indicating the 
tumour may have been of intermediate grade.  The metabolite profile (Figure 
32) shows that predominantly the ratio values for this tumour are in keeping 
more with it being a high grade tumour, in particular its low value for 
NAA/tCho.  However, there are some features that would be more in keeping 
with it being a low grade tumour.  It shows a high value for Cr/tCho and also 
all the LMM/tCho values are low and closer to those seen in the LGG group 
than those in the HGG group.   
 
Diffuse gliomas (including both DPGs and DGs) exhibit distinct MRS.  They all 
show prominent NAA peaks, a strong signal for mIns and a definite Cr peak.  
Most astrocytoma spectra, in children, show very little Cr and it would be 
expected that there would be little NAA present in such an aggressive tumour.  
It may be possible to explain the presence by the diffuse nature of these 
tumours.  The fact that these tumours are of a diffuse nature means that there 
will be ‘normal’ tissue entrapped within them.  We cannot separate these 2 
tissue types using MRS and, as such, we will be obtaining some signal from 
this entrapped tissue.  It is likely that the signal seen for NAA is coming from 
this entrapped tissue rather than the tumour tissue itself.  The DPG spectra all 
show very low signals for LMM regions, which may also be partially due to 
entrapped ‘normal’ tissue. Finally, all the DPG spectra seen in this study show 
an unidentified peak at 2.6ppm, which has not been seen in any other 
astrocytoma spectra of any grade in this study.  One study has presented a 
body of work supporting that this peak could be a resonance of citrate [102, 
194].  
The metabolite mIns has previously been identified as an important metabolite 
in the characterisation of  paediatric brain tumours [72] and is of particular 
interest in astrocytomas. In a study of adults, it was found that the mIns levels 
peaked at grade 2 and were the lowest in grade 4 tumours [67].  This was 
explained by looking at the change between mIns and 
phosphatidylinositol. Myo-inositol contributes to the formation of a 
phosphorylated form of phosphatidylinositol. When this breaks down, 
diacylglycerol and inositol 1,4,5, triphospate are formed.  The resulting 
diacylglycerol activates protein C kinase, which can activate proteolytic 
enzymes such as matrix metalloproteases [67]. Matrix metalloprotease-2 
(MMP-2) has been shown to partially mediate local aggression in gliomas 
[195], where it was shown that LGGs had a low expression of MMP-2, as 
expected for low grade lesions.  Both diffuse grade 2 gliomas and focal HGGs 
showed a high expression of MMP-2 in the tumour borders, but not in the 
central regions [195].  Since the focal lesions are smaller, the voxel will be 
more likely to contain some of the tumour border meaning that this 
characteristic will be more likely to be reflected in the spectroscopy.  These 
would therefore be expected to show a lower concentration of mIns.  The 
diffuse lesions are much larger and the voxel is placed centrally.  Voxels in 
these lesions contain less of the border and would, therefore, be more likely to 
show a higher value for mIns.  This all indicates that an up regulation in 
phosphatidylinositol can be indicative of a more aggressive tumour. A lower 
level of mIns would indicate that this may have occurred, and that the pool of 
mIns has decreased.    
 
There has only been one comparable study looking at high and low grade 
lesions present in children in the brain stem [187], this was performed at an 
echo time of 135ms.  They found that the Cho/Cr was largely increased in 
aggressive lesions compared with indolent lesions and control subjects.  In 
addition it was seen that NAA/Cho was decreased in all tumours when 
compared with normal controls, and this value decreased further when the 
tumour was more malignant.  Looking at Figure 32a it can be seen that this is 
true for this study in the focal lesions, but not for DPGs.  The study does not 
document whether lesions are diffuse or focal, it simply states size.  No 
comparison of mIns is available and no peak is documented at 2.6ppm. 
 
Previous studies of tumour groups in other locations in the brain commonly 
document that the Cr/Cho ratio decreases with grade [29, 72, 73, 93, 96, 106].  
Previous studies in lesions located in other locations have also shown up 
mIns as being important in distinguishing between tumour type [71, 72, 129].  
Myo-Inositol has been shown to be of particular interest in astrocytomas.  It 
has been linked with aggression and has been used in grading, being highest 
in grade two tumours and lower in high grade tumours [29, 67, 96, 196].  This 
is in agreement with the differences seen here between the DPG and HGG 
groups.  The LGG group here was comprised of pilocytic astrocytomas, which 
are very rare in adults.  These do not fit with the trend of lower mIns meaning 
a higher grade astrocytoma, but mIns has been found to be low in pilocytic 
astrocytomas in other locations [119].  Interestingly, similar MRS features to 
those seen in DPGs have  previously been noted in gliomatosis [90, 94, 112], 
another type of diffuse glioma.  This, like DPG, is aggressive despite its 
appearance of being low grade. 
 
6.5 CONCLUSIONS 
Making any firm conclusions on whether it is possible to separate the LGG 
and the HGG group using MRS alone is not possible due to the small sample 
sizes of the focal lesion spectra, although this does appear to be hopeful 
using mIns/Cho.  However, it has been shown in this study that diffuse and 
focal tumours of the brain stem can be well separated.  In addition to this, it 
has been shown that the spectra of diffuse tumours of the brain stem confined 
to the pons take on a different spectroscopic appearance to those extending 
beyond the pons.  These tumours are not currently recognised as being 
different biological entities.   
 
 
 
 
 
 
 
CHAPTER 7: PILOCYTIC ASTROCYTOMAS: 
SPECTRAL VARIATION WITH LOCATION AND 
PROGRESSION 
7.1 INTRODUCTION   
Astrocytomas account for 40-55 % of paediatric brain tumours and the 
majority of these are PAs [38]. PAs occur in various locations of the brain and 
spine, but are particularly common in both the cerebellum and the optic 
pathway [41]. The tumours are classified as WHO Grade I and have a low 
mitotic rate [39-41]. Despite their slow growth, these tumours can present a 
significant management challenge, particularly when located in areas not 
readily amenable to surgery. Furthermore, some tumours invade adjacent 
tissues and occasionally tumours present with multifocal or metastatic 
disease, behaviour which implies that they are not always as benign as their 
WHO grading suggests.  
 
The 5-year survival rate for patients with PAs is as high as 95% if a total 
resection is achieved and 85% if not [197, 198].  Generally a total excision is 
achieved in PAs in the cerebellum; hence these tumours are usually cured by 
surgery alone.  Tumours arising supratentorially are commonly sited in the 
optic pathways, hypothalamus or thalamus.  These areas are less amenable 
to surgery, and are usually not fully excised. These tumours have a more 
diverse clinical course, are more likely to progress after surgery and are 
commonly treated with adjuvant chemotherapy and/or radiotherapy [10]. It is 
uncertain whether the difference in prognosis of cerebellar and supratentorial 
tumours is due to surgical limitations or whether the tumours are inherently 
different [10].  For supratentorial tumours, complete response to adjuvant 
treatment is rare and many patients have a remitting and relapsing course 
over a period of many years, undergoing several courses of adjuvant 
treatment [10]. The decision as to whether there is disease progression, that 
requires further treatment, currently relies upon the combination of clinical 
findings, changes in visual function, and conventional MR imaging. Clinical 
findings are often unreliable in younger children; this is particularly an issue 
for testing that requires a high degree of compliance and concentration, for 
example testing visual fields or acuity.  
 
New, non-invasive imaging methods for assessing these patients would be 
particularly beneficial. Given the current difficulties in assessing PAs, non-
invasive methods that give reliable repeated measurements throughout the 
often long course of this condition are needed. Therefore, MRS has the 
potential to make a particular impact clinically in the management of these 
tumours.  
 
Previous MRS studies of childhood brain tumours have shown that PAs tend 
to have low levels of creatine and high levels of NAA when compared with 
other childhood brain tumours [71, 73]. Furthermore, these features can be 
used to distinguish cerebellar PAs from other cerebellar tumours [73, 74]. No 
difference has previously been reported between PAs in the cerebellum and 
supratentorial tumours.  
 
This study investigates the ability of MRS to characterize PAs in children. The 
variation in MRS with location is investigated and, for supratentorial PAs, pre-
treatment MRS prognostic markers are identified and the changes of 
metabolite concentrations with treatment developed.  
 
7.2 METHODS 
Raw data was processed using LCModel™ and Cramer-Rao bounds were 
used to remove metabolites that were poorly determined.  Quality control was 
applied using the following measures:  
1. SNR had to be greater than 4   
2. FWHM had to be less than 0.150ppm  
 
The variability of the pre-treatment MRS metabolite profiles across all cases 
was determined using a PCA.  This was performed using metabolites of 
appropriate Cramer-Rao lower bounds, normalised to vector length.   
 
Data was initially grouped by location, and two-tailed t-tests of significance 
were performed between spectra from supratentorial PAs and those in the 
cerebellum to assess for differences in the spectra.   
 
The patients with supratentorial lesions were grouped into ‘progressors’ and 
‘stable disease’. Progressors were defined as those in whom a clinical 
decision, based on a number of clinical factors and appearances on 
conventional MRI, had been made to give further treatment due to disease 
progression. Those with stable disease were taken to be all other patients 
provided they had been followed up for more than 6 months at the end of the 
study.  For these two groups, mean metabolite concentrations were calculated 
and two-tailed t-tests performed on pre-treatment MRS to determine factors 
associated with progression. In addition to this, patients with follow-up MRS 
studies, either on-treatment or during observation, were assessed to 
determine the presence of early metabolite changes with progression, by 
using paired t-tests.  
 
7.3 RESULTS 
MRI and short-echo-time MRS were performed on 27 children with PAs 
between 01/09/2003 and 01/04/2007, prior to any adjuvant treatment. Twelve 
patients had cerebellar and 15 supratentorial tumours. Six cases were 
excluded on quality control grounds: 2 tumours were too small to encompass 
a 1.5cm sided voxel, 3 had poor SNR and 1 had an inadequate FWHM. All 
subsequent analysis refers to the reduced cohort of 9 cerebellar and 12 
supratentorial cases. A summary of the distribution of PAs, with respect to 
location in the brain, is shown in Figure 33.  
 
 
Figure 33: Summary of PA tumour location 
 
All tumours had histopathological diagnoses established except for 4 optic 
pathway gliomas which were not biopsied, two of which were in children with 
Neurofibromatosis Type 1 (NF1). Three of the supratentorial cases had NF1. 
The mean age of the children with cerebellar tumours was 7.9 years and with 
supratentorial tumours was 4.9 years. Control MRS was recorded from brain 
distant to the tumour in children with brain tumours who had received no 
treatment other than surgery. 
 
None of the patients with a cerebellar tumour had a post operative residual 
lesion of a size amenable to MRS.  In the group of patients with supratentorial 
tumours, 7 of the 8 patients who underwent surgery had significant residual 
disease. The patient with a cerebral hemisphere tumour had a complete 
resection. Of the 11 patients with significant residual disease or having had no 
surgery, 7 proceeded to treatment with chemotherapy and 4 were initially 
observed with no adjuvant treatment. No patients had radiotherapy. Five of 
the patients had progressive disease before the end of the study follow-up 
period (01/09/2007) leaving 6 patients classified as having stable disease. 
Two of the patients did not have a follow-up MRS within the study period, 
leaving 4 “progressors” and 5 with “stable disease” in the study of treatment 
monitoring.  
 
7.3.1 DIFFERENCES IN MRS METABOLITE PROFILES BETWEEN 
CEREBELLAR AND SUPRATENTORIAL TUMOURS 
Mean MRS for cerebellar and supratentorial tumours are given in Figure 34.  
 
 
(a) 
 
(b) 
 
Figure 34: Mean spectra for PA of the (a) cerebellum and (b) supratentorial locations 
 
The mean supratentorial spectrum shows a more prominent mIns peak at 
3.65ppm. The broad component between 2.0ppm and 2.5ppm, attributed to a 
combination of Glx and LMM, is more also pronounced in the supratentorial 
compared with the cerebellar spectrum. LCModel™ was used generate 
metabolite concentrations, relative to water, average values of these are 
shown in table 19.  
  Cerebellar Supratentorial 
Metabolite P-Value Average StdErr Average StdErr 
Ala 0.731 0.95 0.16 0.87 0.15 
Cr 0.060 0.50 0.06 1.28 0.37 
mIns 0.003 1.26 0.23 3.64 0.63 
Lac 0.741 2.13 0.17 1.96 0.46 
sIns 0.096 0.04 0.03 0.11 0.03 
Tau 0.112 0.07 0.05 0.22 0.08 
Gua 0.154 1.48 0.19 1.11 0.16 
tCho 0.377 0.99 0.09 1.16 0.17 
tNAA 0.164 0.82 0.14 1.22 0.24 
Glx 0.017 3.57 0.27 5.95 0.83 
LMM0.9 0.446 8.57 1.74 7.03 0.88 
LMM1.3 0.675 18.15 3.60 22.78 10.22 
LMM2.0 0.181 7.92 1.11 10.11 1.12 
Table 19: P-values and averages for comparison between cerebellar and supratentorial PAs 
 
The supratentorial tumours had significantly greater concentrations of both 
mIns (p = 0.003) and Glx (p= 0.017) than cerebellar tumours, in agreement 
with visual differences. No other metabolites were significantly different 
between the two groups, although the cerebellar tumours tended to have 
lower creatine (p=0.06). The doublet corresponding to lactate appears, 
visually, different betweent the two locations, but this has a very high P-value.  
This is due to the large variation seen in lactate between PAs in both 
locations. 
 
No significant differences were found in the metabolite profiles of 
supratentorial tumours between patients with and without NF1. A PCA was 
performed to assess the variability of the metabolite profiles (Figure 35) and 
shows that cerebellar and supratentorial tumours tend to form separate 
groups with only one outlier. 
 
 
(a) 
 
(b) (c) 
 
Figure 35: PCA (a) for PAs by location, cerebellar – red; supratentorial – green; and frontal – 
blue. Loadings plots are shown in 36b for PC1 and 36c for PC2 
 
Control spectra were used to assess the concentrations of both mIns and in 
different locations of the brain.  The control spectra consisted of a set of 
spectra taken contralaterally to tumour site, for a group of patients who had 
only received surgical intervention.  This cohort consisted of 11 MRS taken 
from a variety of regions both infratentorially (7 cases) and supratentorially (4 
cases). Glx was significantly higher in the supratentorial regions (p = 0.02), 
but there was no significant difference in mIns levels (p = 0.60).   
 
7.3.2 PRE-TREATMENT MRS AS A PROGNOSTIC INDICATOR IN 
SUPRATENTORIAL TUMOURS 
In the cohort of 11 supratentorial tumours with follow up MRS, 5 progressed 
(mean time to progression 11 months) and 6 had stable disease throughout 
the study period (mean follow-up time 30 months).  The patients who 
progressed had a significantly lower p-value for mIns (p=0.04) on their pre-
treatment MRS (table 20).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 20: P-Value and averages for determination of progression of supratentorial PAs from 
pre-treatment MRS 
 
They also tended to have lower Glx (p=0.08) and tNAA (p=0.07).  
 
 
Figure 36: Scatter plot showing both variation in mIns and Glx by location and also by 
progression in supratentorial PAs. 
cerebellar – red circles; temporo-parietal – green circles; stable supratentorial – blue circles; 
and progressive supratentorial – blue stars. 
  Response/Stable Progression 
Metabolite P-Value Average StdErr Average StdErr 
Ala  0.336 1.00 0.25 0.69 0.17 
Cr 0.160 2.33 0.74 0.86 0.61 
mIns 0.036 5.09 0.86 2.53 0.56 
Lac 0.756 1.80 0.56 2.16 0.98 
sIns 0.115 0.17 0.06 0.06 0.03 
Tau 0.059 0.30 0.12 0.02 0.02 
Gua 0.908 1.30 0.28 1.34 0.28 
tCho 0.235 1.46 0.20 0.99 0.30 
tNAA 0.071 2.09 0.58 0.74 0.23 
Glx 0.085 7.46 1.14 4.60 0.94 
LMM0.9 0.267 5.29 0.79 7.37 1.51 
LMM1.3 0.178 8.53 1.87 17.31 5.29 
LMM2.0 0.945 8.91 0.80 8.99 0.77 
From the scatter plot of pre-treatment Glx versus mIns Figure 36, it is shown 
that supratentorial tumours cluster into 2 groups, those with low values of Glx 
and mIns tend to progress and those with higher values of these metabolites 
tend to have stable disease.  One patient with stable disease had low mIns 
and Glx. This patient had an optic chiasm tumour treated with surgery 
followed by chemotherapy (vincristine and carboplatin) for 18 months and was 
3 months off treatment at the end of the study period.  One patient, with a 
completely resected temporo-parietal tumour had been followed up for less 
than 6 months at the end of the study.   
   
7.3.3 SUPRATENTORIAL TUMOURS: TREATMENT MONITORING AND 
EARLY PREDICTORS OF PROGRESSION 
Nine of the 11 patients with supratentorial tumours followed up for at least 6 
months had follow-up scans with MRS of acceptable quality. Four of these 
patients progressed and five had stable disease. Paired t-tests were 
performed on the metabolite values between the pre-treatment and first on-
treatment MRS for each patient to assess any significant changes between 
the two MRS.  No significant changes were found in the metabolite profiles 
between the two MRS in the patients with stable disease.  However, in 
patients who later progressed, there was a significant decrease in mIns, (p= 
0.03).  The median time between the initial and subsequent MRS was 2.1 
months in the progressor group, with a median time to progression of 12.2 
months.  
 
 
7.4 DISCUSSION 
Key differences in MR spectra have been identified between PAs arising in 
supratentorial and cerebellar regions. Moreover, low levels of mIns are 
significantly associated with adverse clinical behaviour in supratentorial 
tumours.  
 
Two metabolites, mIns and Glx, are significantly higher in the supratentorial 
compared to cerebellar tumours. In controls, no significant difference was 
found in mIns levels in non-involved brain between these two regions, and 
one previous study actually found mIns to be higher in normal cerebellum 
than other brain locations [161]. Higher mIns levels in the supratentorial 
tumours are therefore likely to arise from tumour derived tissue.  In controls, 
Glx levels were higher in supratentorial non-involved brain, than the 
cerebellum.  However, since the tumours studied by MRS were not diffusely 
infiltrative, it is unlikely that the differences in Glx levels arise from normal 
tissue entrapped within the tumour. A PCA performed using MRS metabolite 
profiles showed that the cerebellar and supratentorial tumours form two 
distinct groups with only one outlier who subsequently progressed. This 
finding implies that supratentorial tumours are biologically distinct from their 
cerebellar counterparts. Clear parallels exist here with another glial series 
tumour, ependymoma, which show key differences in chromosomal 
abnormalities and gene expression patterns depending on the location [199]. 
Qualitative review of conventional MR images revealed no difference in major 
imaging characteristics between the tumours in the different locations 
including their cystic nature. 
All but one of the supratentorial tumours were located in deep structures and, 
as expected, these patients presented significant management problems. The 
use of complex treatment strategies involving various combinations of 
surgery, chemotherapy and active observation was undertaken in this group 
of patients emphasizing the importance of developing non-invasive prognostic 
markers to aid clinical decision making. In turn, information from MR spectra 
could be used in the context of multi-disciplinary review regarding the optimal 
management of these tumours. In this study significantly lower levels of mIns, 
and a tendency to lower Glx and tNAA, were found in the group of tumours 
that progressed. The higher values of mIns in those with stable disease are in 
keeping with studies on adults with astrocytomas where higher mIns is seen 
in the lower grade, better prognosis tumours [67, 96]. High levels of NAA have 
been associated with a good prognosis in a number of studies of brain 
tumours [107]. The cerebellar tumours had mIns, Glx and NAA values more 
akin to the supratentorial ‘progressors’ rather than those with stable disease. 
Most of the cerebellar cases underwent complete surgical resection leaving 
minimal residual disease post surgery. None of these tumours recurred, 
consistent with reports on the outcomes of cerebellar PAs from other studies. 
This finding implies that extent of surgical resection is a key determinant of 
prognosis, as supported in the literature [41, 200]. Levels of mIns were also 
found to decrease significantly between the first and subsequent MRS in the 
group of supratentorial tumours that progressed. Since the median time 
between the two scans was only 2 months compared with a time to 
progression of 12 months, these patients could potentially have had earlier 
intervention for their disease progression. 
Previous studies of MRS in brain tumours have identified tCho as a useful 
biomarker of tumour aggressiveness across a range of tumour types [74], but 
this was not shown in the current study of PAs. A potential explanation may 
be found in the relative proportions of the choline containing metabolites, 
which give rise to the tCho value. Studies of low grade astrocytomas, in vivo 
[86, 98] and in tissue [98], have indicated that glycerophosphocholine is the 
dominant choline containing metabolite in PAs [98], whereas phosphocholine 
has been demonstrated to be the main biomarker of tumour aggressiveness 
[201]. Lipid levels have also been demonstrated to be makers of tumour 
malignancy [74], being a measure of necrosis and apoptosis. However, PAs 
have lipid levels comparable to those found in higher grade tumours [98]. The 
origin of MRS detectable lipid in PAs is uncertain and requires further 
investigation.  
 
Whilst mIns has previously been identified as an important metabolite in the 
characterisation of brain tumours in both children [71, 72] and adults [67], 
there has been relatively little work to explain this finding. In the study of 
Castillo et al [67], variations in mIns levels were explained in terms of the 
protein kinase C pathway. Myo-Inositol contributes to the formation of a 
phosphorylated form of phosphatidylinositol which is broken down to form 
diacylglycerol and inositol 1,4,5, triphospate.  The resulting diacylglycerol 
activates protein kinase C and a cascade of proteolytic enzymes including 
matrix metalloproteases [67, 202].  Matrix metalloprotease-2 has been shown 
to mediate local aggression in cerebral gliomas and treatment of a glioma cell 
line with a metalloprotease inhibitor resulted in a 90% reduction in invasion 
[202].  Further work is warranted to establish whether these pathways are 
upregulated in PAs with low levels of mIns and explore their potential as 
targets for novel agents.  
 
A previous study has shown differences in genetic profiles of PAs between 
various locations in the brain [203], Glx was found to be higher in 
supratentorial regions when compared with cerebellar concentrations . 
However, tumours from all key brain regions were not included in the study 
and in particular, of the 10 supratentorial tumours; none were labelled as 
being in the suprasellar region. This illustrates the difficulty of investigating 
PAs using tissue since many tumours are not biopsied or have limited tissue 
taken. Tissue markers of prognosis have also been investigated and a 
retrospective study found the MIB-1 index to be a predictor of initial tumour 
progression in PAs [204]. Tissue is rarely available at relapse, limiting the use 
of tissue based methods in managing the often long clinical course of these 
patients. Non-invasive methods have the potential to provide both information 
on the biology of the tumour and be used at multiple time points. 
 
Whilst MRS is a powerful non-invasive method for the characterization of 
brain tumours, currently there are important limitations on the size of tumour 
amenable to the technique. In this study, it was necessary to exclude tumours 
which could not encompass a 1.5cm sided cube. Only two tumours did not 
meet this criterion at diagnosis, but three other highly cystic tumours had only 
a small solid component and did not meet the MRS quality control criterion for 
signal to noise ratio since the signal comes almost entirely from the solid 
component. All of these tumours had a favourable outcome. With longer scan 
times or improved technology such as higher magnetic field strength, smaller 
tumours could be studied.  
 
7.5 CONCLUSIONS 
Key differences have been identified in the MRS metabolite profiles between 
cerebellar and supratentorial PAs with cerebellar tumours having significantly 
lower mIns and Glx. Low values of mIns on the initial MRS and decreasing 
mIns on the subsequent MRS were found to be associated with later disease 
progression in supratentorial tumours. MRS is a potentially useful additional 
investigation in assessment of PAs and gives further insight into the diversity 
of these important childhood tumours.  
CHAPTER 8: CONCLUSIONS 
 
Short echo time MRS has been shown to be effective in the characterisation 
of childhood brain tumours.  Metabolites that would be difficult to quantitate in 
a long echo time spectrum have been proven to be of high importance in the 
analysis of these tumours.  These include mIns in all studies (chapters 4-7), 
LMM in the analysis of GCTs (chapter 5), Glx in brain stem tumours and PAs 
(chapters 6 and 7) and tau in medulloblastomas (chapter 4.3).  With modern 
spectral fitting tools such as LCModel™ it is easier to interpret the larger 
amount of data seen in a short echo time spectrum.  If possible, it is still 
advisable to obtain MRS at both long and short echo time for verification 
purposes. 
 
This work was started using a well studied and understood data set of 
cerebellar tumours, all of which have biopsies and thus a histopathological 
diagnosis.  This was done to confirm the best method of analysing these 
tumours.  This was also used as confirmation that short echo time MRS was 
useful for characterising childhood brain tumours and that metabolites only 
seen at short echo times, such as mIns, were important in this 
characterisation.  The conclusions from this work were that the method of 
analysis has to be tailored to the user and the question being posed.  For a 
simple, fast classifier for use by clinicians a simple peak height ratio method 
with well defined cut-off values is more appropriate to something involving 
advanced processing and statistical analysis (chapter 4.2).  These schemes 
are also robust to new data of various types as was proven by a prospective 
study (chapter 4.2.2).  The prospective analysis also highlighted the need for 
larger data sets to determine and refine cut-off values for classification 
schemes. 
 
A more sophisticated analysis, using LCModel™ determined concentrations, 
also remained robust to new data (chapter 4.3.2).  The classification rates of 
both a small single centre data set and a larger multicentre data set were 
comparable with those seen in the simple scheme using peak heights.  
However, the larger amount of metabolite information was beneficial in the 
better understanding of the biology of rarer tumours (chapters 5-7). 
 
Cerebellar tumours have been previously well studied and papers have been 
published on both the biology and MRS results.  This test-bed data set was 
used to determine the best analysis technique for use in later studies.  
Although schemes using both peak heights and LCModel™ metabolites 
concentrations showed comparable accuracy, using both retrospective and 
prospective data, it was decided that LCModel™ metabolite concentrations 
offered the best means of characterising these tumours.  LCModel™ offered 
information about more metabolites in a spectrum than is possible to measure 
using peak height ratios.  More metabolite information leads a more complete 
metabolite profile of the tumour and this is useful in characterising tumours.  
This is especially useful in the rarer tumour types in areas that are more 
difficult to access surgically.   
 
Cerebellar tumours are a well studied group, and made for a solid test-bed.  
However, techniques such as MRS are of greater use in tumours that are less 
readily amenable to surgical biopsy.  Studies were performed on two such 
groups of tumours: pineal region tumours (chapter 5) and brain stem tumours 
(chapter 6).  In both of these groups it is vital to obtain as much information 
non-invasively about the nature of the tumour as is possible.  The studies on 
data sets of both pineal region tumours (chapter 5) and brain stem tumours 
(chapter 6) showed that short echo time MRS could be successfully used to 
characterise these difficult tumour groups, and with more data could become 
and important aid to diagnosis.  The scheme developed for the diagnosis of 
brain stem tumours (chapter 6) included information from smaller metabolites, 
such as mIns.  The scheme developed for the differentiation between tumours 
of the pineal region (chapter 5) included information from Lipid and 
Macromolecular resonances.  Both of these schemes included data not easily 
interpretable from long echo time MRS, thus highlighting the benefit of 
performing short echo time MRS for the characterisation of these tumour 
types.   
 
A further use for short echo time MRS was shown in chapter 7, in the 
determination of differences between tumours within a disease class that are 
not visible on conventional histopathology.  PAs act differently depending on 
the location within the brain, yet the histopathology of these tumours does not 
vary significantly between regions.  However, differences were seen using 
short echo time MRS between PAs arising in the cerebellum and those 
occurring supratentorially.  Supratentorial PAs have a poorer prognosis that 
those in the cerebellum.  A preliminary study using a small group of 
supratentorial PAs showed the potential of short echo time MRS was used to 
predict the prognosis for these tumours.  MRS was also used to monitor 
response to treatment with high success in this small group. 
 
The most important problem found in the studies presented here is the small 
number of patients within individual study groups.  To reduce this, there is a 
huge need for large multicentre studies, which may introduce the need for an 
agreed protocol for data collection between centres.  
 
Data quality is a considerable issue with any brain MRS.  Location has a large 
impact on the quality of data, as some areas are more difficult to shim over.  
This is particularly problematic for lesions close to an air-tissue or bone-tissue 
interface.  Tumours near the skull have addition problems from contamination 
of signals from outside the voxel from scalp lipid.  This problem can be 
partially overcome by using saturation bands surrounding the voxel.  All 
spectra need to be visually inspected to ensure there are no external 
contaminates. 
  
Signals from metabolites can be lost in the noise of a spectrum.  This problem 
can either be rectified by obtaining more acquisitions or moving to higher field 
strength.  The former leads to problems of increasing acquisition times, which 
can often be intolerable.  More and more institutions are moving to higher field 
strength, and while the increases are not those predicted by theory, there are 
significant improvements seen in spectral quality. 
An additional limitation is the lack of availability of sophisticated processing 
tools and pattern recognition software in the clinical setting.  This limits the 
usability of schemes such as those presented, to those using peak height 
measurement and ratio comparisons.   
 
In conclusion, short echo time MRS has been shown to be a powerful tool for 
the characterisation of brain tumours in children.  Simple methods, which 
could be readily applied in a clinical setting have been developed, and in 
some cases tested, in the areas of diagnosis, prognosis and treatment 
monitoring.  Further multicentre studies are required to improve and evaluate 
the techniques in clinical use. 
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